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Abstract 
This thesis compares statistical methods for addressing selection bias in cost-
effectiveness analyses (CEA) that use observational data.  The thesis has four 
objectives: (1) to critically appraise currently recommended statistical methods, (2) to 
consider alternative statistical methods for CEA, (3) to compare propensity score (PS) 
approaches and Genetic Matching (GM) for estimating subgroup-effects in CEA, and 
(4) to compare methods that combine regression with PS approaches, for CEA. 
I developed a new checklist for critically appraising statistical methods for addressing 
selection bias in CEA, and applied it in a systematic review of published CEA. Most 
studies used regression or matching methods, and did not assess their underlying 
assumptions, such as the correct specification of the PS or the endpoint regression 
model. 
I identified methods that can make less restrictive assumptions: GM, a multivariate 
matching method that can directly balance covariates, double-robust (DR) methods, 
regression-adjusted matching, and machine learning estimation of the PS and the 
endpoint regression. I compared these methods across a range of typical CEA 
circumstances, using simulations and case studies. 
In the first case study, where cost-effectiveness estimates for subgroups were of interest, 
I found that the cost-effectiveness results differed according to the statistical approach. 
The accompanying simulation study found that GM was relatively robust to the 
misspecification of the PS, and provided the least biased and most precise estimates of 
cost-effectiveness for each subgroup. 
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The second simulation study considered DR methods and regression-adjusted matching 
for estimating overall cost-effectiveness and found that regression-adjusted matching 
was relatively robust to misspecification of the PS and the regression model. The third 
study extended these approaches with machine learning estimation of the PS and the 
endpoint regression, and found that bias due to misspecification could be further 
reduced. 
This thesis concludes that those approaches that relax the assumption that the statistical 
model for addressing selection bias is correctly specified, can give more accurate and 
precise estimates of cost-effectiveness than previously recommended methods. Findings 
from this thesis can improve the quality of CEA that use patient-level observational 
data, to help future studies provide a sounder basis for policy making.  
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Chapter 1 - Introduction 
1.1 Economic evaluation to inform health policy 
An important objective of health care systems is the allocation of scarce resources in 
order to maximise health gain (Gray et al., 2010). Health economic evaluation can 
address this optimisation problem,  by comparing alternative options in terms of their 
costs and consequences (Drummond et al., 2005). Health economic evaluation is 
increasingly used for centralised decision making worldwide (NICE, 2008, IQWIG, 
2009, PBAC, 2008, CADTH, 2006). 
Economic evaluation can rely on various sources of evidence, depending on the 
decision context. For example the Australian  Pharmaceutical Benefits Advisory 
Committee requires the appraisal of new pharmaceuticals and vaccines (PBAC, 2008). 
As randomised controlled trials (RCTs) are generally mandated in the drug development 
process (Glick et al., 2001), RCT evidence for such evaluations is widely available. In 
other settings, for example in the NHS in England and Wales, economic evaluation is 
used for a wider range of technologies, including medical devices, surgical procedures, 
or the development of public health guidelines. Here, RCT evidence might be 
insufficient or lacking and has to be complemented with data from non-randomised 
studies (NRS) (NICE, 2008, NICE, 2009). 
There would appear to be a consensus across methodological guidelines on several 
aspects of the study design of economic evaluations (Hjelmgren et al., 2001). These 
include the use of cost-effectiveness analysis (CEA), with health outcomes measured as 
quality adjusted life years (QALYs) (Dolan, 2000). A further general requirement is a 
time horizon that incorporates all relevant benefits and costs of the interventions under 
comparison (Kuntz and Weinstein, 2001). Decision analytical models provide a 
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framework for synthesising different sources of evidence (Caro et al., 2012), and 
analysts are encouraged to consider and report the uncertainty that surrounds any 
recommendation in regards to the relative cost-effectiveness of the alternatives under 
consideration (Briggs et al., 2012).  
The incorporation of individual patient data (IPD) in decision models has been 
recommended by methodological guidelines (Briggs et al., 2006, Briggs et al., 2012, 
Philips et al., 2006). Using IPD can help studies fully account for parameter uncertainty, 
by estimating the standard errors and correlations between model parameters. IPD can 
also help analysts address heterogeneity, by allowing input parameters to differ for 
patient subgroups (Cooper et al., 2007, Koerkamp et al., 2010).  With the availability of 
IPD, a range of further challenges can be addressed, such as censoring (Willan et al., 
2005), missing data (Noble et al., 2012) and confounding (Thompson et al., 2010).  
Methodological guidance on the analysis of IPD in CEA has been through significant 
development, mostly in the context of cost and effectiveness data from RCTs (Glick et 
al., 2001). While RCT data is generally the preferred evidence for deriving the 
effectiveness of an intervention (NICE, 2008), it has been recognised that CEA based 
on a single study rarely provides a sufficient basis for decision making (Sculpher et al., 
2006). For example, a protocol driven, multinational phase III trial might not reflect real 
world treatment patterns and resource use in a particular country; an RCT might not 
measure the relevant endpoints or include all the relevant comparators, while the time 
horizon can be too short to capture long-term costs and health benefits (Briggs et al., 
2006). Hence the synthesis of data from different sources is required, including RCTs, 
NRS, epidemiological databases or patient registries (NICE, 2008).  
Observational studies often provide a relevant data source for input parameters in a 
decision model. In some cases, observational data provides the main source of evidence 
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for CEA (Polsky and Basu, 2006, Manca and Austin, 2008).   With observational 
studies, a general methodological challenge is handling selection bias due confounding, 
i.e. differences in prognostic factors between treatment groups of interest (Fung et al., 
2011, Pizer, 2009, Rubin, 2010, Tunis et al., 2010, Polsky and Basu, 2006). When IPD 
from observational studies are available, appropriate statistical methods can be used to 
reduce selection bias. Current methodological guidance on economic evaluation warns 
of potential biases from using estimates based on observational studies (Philips et al., 
2006, NICE, 2008). Currently there is no detailed guidance on the appropriate statistical 
analysis of observational data for CEA (Kearns et al., 2012), which was raised as a 
priority in a recent review on priorities for methodological research in health technology 
assessments (HTA) used by NICE (Longworth et al., 2009).  
1.2 Observational data in CEA 
In this thesis I define observational data as data from studies that do not have random 
allocation to alternative treatments (Deeks, 2003), which includes cohort studies, case-
control studies, surveys, registries, administrative records or census data. Observational 
data can be used to estimate a wide range of parameters in CEA (Drummond, 1998, 
Deeks, 2003), including clinical endpoints, prevalence of side effects, health-related 
quality of life (HRQoL) measures, and long-term costs. While some economic 
evaluations do not use decision models and may rely heavily on RCT data, even here 
they may still use observational data, for example to obtain unit costs and HRQoL 
tariffs (Glick et al., 2007). When evidence is synthesised in decision analytical models 
(Briggs et al., 2006, NICE, 2008), observational data can be used to inform model 
parameters by making use of published external information, for example for transition 
probabilities. A more flexible use of observational data may be feasible where patient-
level observational data are available. Here, for example, it may be possible to calibrate 
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estimates of long-term outcomes for the patient characteristics of the treatment groups 
of interest, accounting for patient heterogeneity. If the patient-level observational data 
include information on the treatments of interest, incremental cost and effectiveness 
parameters can be calculated. This can be done either by complementing parameters 
derived from RCT data, or in some settings parameters may be estimated exclusively 
from observational data. Examples for incremental effectiveness parameters are relative 
risk of mortality or clinical events, HRQoL differences, or incremental QALYs. These 
parameters can be then used in a decision-analytical model when extrapolating RCT 
data, for example. 
 In many cases, particularly in evaluations of medical technologies other than 
pharmaceuticals (e.g. health services and public health interventions), there may be no 
RCT data available and both incremental cost and effectiveness parameters are 
calculated based on IPD from a single observational study (Polsky and Basu, 2006, 
Manca and Austin, 2008). Here, additional aggregate information (e.g. HRQoL) may or 
may not be used.  
The focus of this thesis is on CEA that uses patient-level observational data for 
estimating incremental cost and effectiveness parameters. Unless specified otherwise, 
by referring to observational data, this thesis will refer to patient-level observational 
data. Contributions of the thesis to the more general use of observational data in CEA 
will be noted in section 5 of this chapter (conceptual framework), and in the discussion 
of the thesis (chapter 7). 
16 
 
1.3 Statistical methods in CEA that use patient-level observational 
data 
Statistical methods for CEA that use IPD predominantly from RCTs have seen 
considerable development in the last decade (Willan and Briggs, 2006, Glick et al., 
2007, Gray et al., 2010). It has been recommended that regression methods adjust for 
covariate imbalances between treatment groups and estimate subgroup-specific 
treatment effects (Hoch et al., 2002, Willan et al., 2004, Nixon and Thompson, 2005), 
while maintaining the correlation between cost and effectiveness endpoints.  Statistical 
methods have been proposed to address further challenges, such as: hierarchical data in 
multicentre CEA (Grieve et al., 2007, Manca et al., 2007), missing data (Noble et al., 
2012), non-compliance to randomised treatment (Hughes et al., 2001) and censoring  
(Willan et al., 2002, Willan et al., 2005). Guidelines (NICE, 2008, Philips et al., 2006) 
and quality assessment tools (Doshi et al., 2006, Gomes et al., 2011) emphasise the use 
of appropriate methods to analyse patient-level data, mostly in the context of RCT data. 
Less attention has been given to methods development in CEA that use patient-level 
observational data. Here, the general concern is that the treatment groups under 
evaluation can be imbalanced in observed and unobserved characteristics, which might 
be prognostic for the cost and effectiveness endpoints. Unadjusted comparisons of cost 
and effectiveness outcomes are then prone to selection bias, which in epidemiology is 
referred to as bias due to confounding (Greenland et al., 1999), and in econometrics as 
bias due to endogeneity (Imbens and Wooldridge, 2009a). 
Selection bias can be reduced if appropriate statistical methods are applied (Jones, 2007, 
Polsky and Basu, 2006, Pizer, 2009, Rubin, 2010). The estimation of treatment effects 
using observational data has been at the centre of methodological research in the last 
decade in the general causal inference literature, including the fields of statistics (Pearl, 
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2009, Rubin, 2006), econometrics (Imbens and Wooldridge, 2009a), the social sciences 
(Morgan and Winship, 2007) and medical statistics (Austin, 2008, Shah et al., 2005, 
Stuart, 2010), but has received relatively little attention in CEA (Polsky and Basu, 2006, 
Sekhon and Grieve, 2011, Manca and Austin, 2008, Mitra and Indurkhya, 2005). 
There are specific complexities of IPD used for CEA that statistical methods must 
acknowledge.  Firstly, correlations between parameters, such as the incremental costs 
and effectiveness need to be estimated (O'Hagan and Stevens, 2001). Secondly, the 
distributions of cost (Mihaylova et al., 2010, Basu et al., 2011, Manning et al., 2005) 
and effectiveness endpoints  (Basu and Manca, 2011) are likely to be irregular (non 
normal), and relationships between covariates and endpoints can be nonlinear (Basu et 
al., 2011). Thirdly, decision makers may want estimates of cost-effectiveness for 
particular patient subgroups (Sculpher, 2008). These issues have been considered in 
methods proposed for statistical analysis of IPD, but mainly in the context of studies 
that use RCT data (Willan and Briggs, 2006, Glick et al., 2007).   
 The aim of this PhD is to help fill in these gaps of methodological literature in CEA by 
considering a range of statistical methods that can reduce selection bias when estimating 
parameters for CEA that use observational data. 
1.4 Aims and objectives of the thesis 
This thesis considers alternative statistical methods for addressing selection bias in CEA 
that use patient-level observational data.  The thesis has four main objectives:  
1. To develop and apply a new checklist for assessing the underlying assumptions 
made by statistical methods for addressing selection bias in CEA, that use 
patient-level observational data;  
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2. To consider which statistical methods from the general causal inference 
literature may be appropriate for addressing selection bias in CEA;  
3. To compare the relative performance of propensity score (PS) approaches and 
Genetic Matching (GM), a multivariate matching method for estimating 
subgroup-effects in CEA; 
4. To compare methods that combine regression with PS approaches for addressing 
selection bias when estimating incremental effectiveness and cost-effectiveness 
parameters.  
1.5 Conceptual framework of the thesis 
The four objectives of the PhD are strongly interlinked. The basis of this research is a 
conceptual literature review, which consists of a careful assessment of the 
methodological challenges that arise when addressing selection bias in CEA that use 
patient-level observational data (objective 1). Here I also review the general causal 
inference literature, to examine further promising methods for addressing selection bias 
in CEA (objective 2).  
Regression and PS methods are currently proposed to address selection bias in CEA 
(Nixon and Thompson, 2005, Polsky and Basu, 2006, Mitra and Indurkhya, 2005). The 
crucial assumption behind these methods is that all confounders can be observed 
(unconfoundedness assumption), the covariate distributions of the treatment groups 
overlap and their underlying models such as endpoint regression and PS models are 
correctly specified. It is unlikely that all these assumptions are met in CEA. For 
example, health care costs and outcomes often have irregular distributions (Jones, 2010, 
Basu and Manca, 2011), with nonlinear relationships between the confounders and the 
endpoints (Basu et al., 2011), hence it can be challenging to correctly specify regression 
models. Policy makers are often interested in cost-effectiveness results for patient 
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subgroups (Sculpher, 2008), which can necessitate specifying regression models that 
can account for heterogeneous treatment effects, or PS models that can incorporate 
heterogeneous selection into treatment.  
The first approach of investigating whether the assumptions behind the currently 
recommended statistical methods are plausible is to conduct a critical review of the 
applied CEA literature (objective 1, research paper 1). A checklist informed by the 
conceptual review can help assess whether the assumptions behind the statistical 
methods are appropriately assessed. The results of this review can highlight those 
methods that are under-utilised, or inappropriately used. These deficiencies in the 
applied literature motivated me to undertake further methodological work, to assess the 
relative performance of the methods under different circumstances faced in applied 
CEA, using case studies and simulation studies.  
I use the conceptual review to identify alternative methods that are promising, because 
they have the potential to make less restrictive assumptions than standard regression and 
PS methods (objective 2). The following methods were identified to be promising:  GM, 
a multivariate matching method that aims to balance individual covariates; and 
approaches that combine the PS and regression models, such as double-robust (DR) 
methods and regression-adjusted matching. I also consider machine learning approaches 
for estimating the PS and the endpoint regression, which can reduce misspecification 
and bias compared to using fixed parametric models. 
The conceptual review provided hypotheses on how these methods perform in realistic 
CEA settings, however previous simulation evidence may not be directly applicable in a 
CEA setting. I undertake Monte Carlo simulation studies (objective 3 and 4; research 
papers 2, 3 and 4) that extend the current CEA methods literature, by assessing the 
selected methods under settings typical of CEA.  These simulations are motivated by 
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CEA case studies, and aim to test hypotheses generated by the conceptual review, 
across different circumstances.  
The first case study (research papers 2 and 3) highlights circumstances when cost-
effectiveness for patient subgroups is of interest. The corresponding simulation study 
(research paper 2) compares methods for subgroup analysis (objective 3). Research 
papers 3 and 4 consider methods that combine the PS and endpoint regression models 
(objective 4). The second case study and corresponding simulation study (research 
paper 4) demonstrate settings where the correct specification of an effectiveness 
endpoint is challenging, and uses machine learning estimation techniques to reduce bias 
due to misspecification.  The methods are also considered in the case studies, and the 
impact of different methods on the cost-effectiveness results and estimated treatment 
effects are reported.  
This thesis considers CEA where IPD from RCTs is either unavailable, or insufficient to 
estimate either incremental costs or incremental effectiveness parameters, or both. The 
focus of the simulation studies (research papers 2, 3 and 4) is when IPD from a single 
observational study is used to calculate incremental effectiveness and cost-effectiveness 
parameters. The applied literature review (research paper 1) and the case studies 
however also consider settings where these incremental parameters are combined with 
aggregate data (research papers 2 and 3), and when input parameters for decision 
models need to be estimated using patient-level observational data (research paper 4).   
It is therefore expected that findings from the thesis will be applicable to a more general 
use of observational data in CEA.   
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1.6 Overall contribution of the thesis 
I developed a new checklist for critical appraisal of statistical methods for addressing 
selection bias in CEA that use patient-level observational data (research paper 1).  This 
checklist complements previous quality-assessment tools and methodological guidance 
(Drummond et al., 2005, Philips et al., 2006, Glick et al., 2007), which did not include 
specific criteria for the analysis of patient-level data from observational studies. 
Research paper 1 provides detailed guidance on how the underlying assumptions of the 
statistical methods can be assessed, and highlights how the choice of statistical approach 
can contribute to structural uncertainty in CEA (Bojke et al., 2009). In addition, prior to 
this work it was unknown whether applied CEA use appropriate statistical methods for 
addressing selection bias. The systematic review in research paper 1 addressed this gap, 
and found that CEA do not appropriately assess the main assumptions behind statistical 
methods. This checklist can raise awareness about these assumptions.  
Research paper 2 compares GM, a multivariate matching method, with PS matching and 
inverse probability of treatment weighting (IPTW) for estimating subgroup effects in 
CEA. GM was previously demonstrated to reduce selection bias in CEA (Sekhon and 
Grieve, 2011), but not in the context of subgroup analysis. The paper found that GM 
was relatively robust to the misspecification of the PS, and provided the lowest bias and 
root mean squared error of the estimated incremental net benefit (INB) for each 
subgroup. This paper provides the first comparison of GM with IPTW in the general 
literature.  
Research paper 3 considers methods that combine the PS with endpoint regression 
models for CEA. This paper considers DR methods and regression-adjusted matching 
for reducing selection bias for the first time in CEA. The paper found that regression-
adjusted matching was the least biased method when both the endpoint regression 
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models and the PS model were misspecified (dual misspecification). This paper 
considers the performance of regression-adjusted matching under dual misspecification 
for the first time.  
Research paper 4 extended the combined approaches presented in research paper 3, by 
considering recently proposed machine learning techniques for estimating the PS and 
the endpoint regression for estimating incremental effectiveness parameters.  This paper 
extends the previous literature which recommended regression modelling of HRQoL 
endpoints (Basu and Manca, 2011). The paper also extends the general methodological 
literature by providing the first comparison of targeted maximum likelihood estimation 
(TMLE) and bias-corrected matching (BCM). Unlike previous papers on BCM, which 
used linear regression (Abadie and Imbens, 2011, Busso et al., 2011), this paper uses 
machine learning techniques for bias correction.  The paper found that both TMLE and 
BCM could reduce bias due to misspecification, with machine-learning versus fixed 
parametric approaches. 
Overall, this thesis compares the performance of statistical methods for addressing 
selection bias under realistic circumstances for CEA. The simulation studies provide 
new evidence on the relative robustness of methods when some of their underlying 
assumptions, such as correct model specification fail. The case studies help motivate the 
simulation studies, demonstrate the appropriate use of statistical methods proposed, and 
illustrate how structural uncertainty from the choice of method can be addressed, by 
reporting results across a range of methods. The research papers provide detailed 
guidance and software codes for the implementation of the methods. It is expected that 
the findings of this thesis can add to the methodological guidance for researchers 
conducting CEA that use patient-level observational data, and help future studies 
provide a sounder basis for policy making.  
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1.7 Structure of the thesis 
The remaining chapters of the thesis are as follows. Chapter 2 first identifies the key 
challenges for statistical methods which aim to address selection bias in CEA that use 
observational data. This chapter then describes the assumptions behind previously 
recommended methods for addressing selection bias in CEA, informed by a conceptual 
review of the general causal inference literature. The chapter then reviews promising 
statistical methods from the causal inference literature, that have potential for 
addressing selection bias in CEA. Finally, chapter 2 identifies gaps in the 
methodological literature concerned with the relative performance of the methods in 
CEA.  
Chapters 3 to 6 comprise of the four research papers, each prefaced with a brief 
preamble. Research paper 1 develops a critical appraisal tool to assess the statistical 
methods for addressing selection bias in CEA that use observational data, and applies 
this checklist in a systematic review of published studies. Motivated by a CEA of a 
pharmaceutical intervention for patients with severe sepsis, research paper 2 presents a 
simulation study that compares the relative performance of GM and PS methods in 
reporting cost-effectiveness for patient subgroups. Research paper 3 evaluates the 
relative performance of statistical methods that combine the PS and regression models, 
for the cost and effectiveness endpoint in CEA. Research paper 4 extends these 
combined methods by considering the recently proposed methods, TMLE and BCM, for 
estimating incremental effectiveness parameters. The simulation study presented in this 
paper was motivated by an evaluation of the effect of alternative hip prostheses on 
patients’ HRQoL. 
Chapter 7 provides an overview of the main findings and contributions of the thesis. 
The chapter then acknowledges the limitations of the thesis, and identifies potential 
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areas for future research. This chapter concludes by highlighting the implications of the 
findings of the thesis for applied researchers and policy makers. 
1.8 Contribution of the candidate to the thesis 
The work conducted in this thesis was linked to a research grant “Methods for reducing 
selection bias in cost-effectiveness analysis”, funded by the Economic and Social 
Research Council (ESRC), and took a similar approach in using simulations and case 
studies to assess the relative merits of alternative methods for addressing selection bias 
in CEA. The focus of the ESRC project was to compare GM to PS matching. This thesis 
aimed to offer a more thorough comparison of alternative methods, and extended the 
comparison additional methods not included in the ESRC study, such as DR methods 
and regression-adjusted matching. It also looked at some of the methods in a new 
context, where cost-effectiveness for patient subgroups is of interest.  
The research questions for research papers 1 and 2 were linked to the ESRC project and 
identified by the principal investigator, Richard Grieve. In the first study, the candidate 
carried out a conceptual review, and developed a checklist and accompanying 
methodological guidance for critical appraisal of CEA that uses observational data, in 
collaboration with her supervisor, Richard Grieve. The candidate applied this checklist 
in a systematic review of studies, and interpreted the findings. A further contributor to 
this paper was a research fellow linked to the project, Zia Sadique, who verified the 
exclusion criteria of the systematic review, and conducted a second review by 
independently appraising 50% of the studies.  
For research paper 2, the candidate led the design of the simulation study, with Richard 
Grieve. The candidate wrote the simulation code, with help from post-doctoral 
researchers employed by the ESRC project, Roland Ramsahai and Rosalba Radice. 
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Roland Ramsahai helped the candidate run simulations on the LSHTM computational 
cluster.  Zia Sadique led on the analysis of the motivating case study, with the candidate 
contributing to the analysis. The candidate led on the reporting and interpretation of the 
results of the case study and the simulation studies.  For this paper, the candidate built 
on insights from another simulation study linked to the project, which aimed to compare 
GM, IPTW and PS matching for estimating subgroup-specific treatment effects on 
binary endpoints (Radice et al., 2012). For this study, aimed at a biostatistics audience, 
the candidate contributed to the design and the implementation of the simulation study 
and to the interpretation of the results, as well as to writing sections of the manuscript.  
The candidate led on the conception of the research question for research paper 3 in 
collaboration with her supervisor, Richard Grieve and an external collaborator, Jasjeet 
S. Sekhon, while visiting the Center for Causal Inference at UC Berkeley (USA, CA). 
The candidate led on the design of the simulation study, with the collaboration of 
Richard Grieve, Rosalba Radice and Jasjeet S. Sekhon.  Rosalba Radice contributed to 
the design of the simulation scenarios. The candidate wrote the code for the simulation 
study, with help from Rosalba Radice.  The candidate conducted the statistical analysis 
for the motivating case study, and interpreted the results of the paper, with Rosalba 
Radice and Richard Grieve.  
The candidate led the design of the research question for research paper 4, in 
collaboration with Richard Grieve and an external collaborator, Susan Gruber (Harvard 
School of Public Health). The candidate led on the design and implementation of the 
simulation scenarios, with help from Rosalba Radice, who also contributed to the 
implementation of the statistical methods in the motivating case study. The candidate 
led on the interpretation of the results, with Rosalba Radice, Susan Gruber, Jasjeet S. 
Sekhon and Richard Grieve.  
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For each of the research papers, the candidate wrote the first draft of the manuscripts. 
She managed each round of comments and suggestions from co-authors, in 
collaboration with Richard Grieve. All authors read and approved the final drafts of the 
research papers prior to journal submission and inclusion in this thesis. The remaining 
chapters of the thesis are the sole work of the candidate. 
  
27 
 
References 
Abadie, A. & Imbens, G. W. 2011. Bias-Corrected Matching Estimators for Average Treatment 
Effects. Journal of Business & Economic Statistics, 29, 1-11. 
Austin, P. C. 2008. A critical appraisal of propensity-score matching in the medical literature 
between 1996 and 2003. Statistics in Medicine, 27, 2037-2049. 
Basu, A. & Manca, A. 2011. Regression Estimators for Generic Health-Related Quality of Life 
and Quality-Adjusted Life Years. Med Decis Making, 2011 Oct 18. [Epub ahead of 
print]. 
Basu, A., Polsky, D. & Manning, W. 2011. Estimating treatment effects on healthcare costs 
under exogeneity: is there a ‘magic bullet’? Health Services and Outcomes Research 
Methodology, 11, 1-26. 
Bojke, L., Claxton, K., Sculpher, M. & Palmer, S. 2009. Characterizing structural uncertainty in 
decision-analytic models: a review and application of methods. Value in Health, 12, 
739-49. 
Briggs, A., Sculpher, M. & Klaxton, K. (eds.) 2006. Decision Modelling for Health Economic 
Evaluation: Oxford University Press. 
Briggs, A. H., Weinstein, M. C., Fenwick, E. A. L., Karnon, J., Sculpher, M. J. & Paltiel, A. D. 
2012. Model Parameter Estimation and Uncertainty Analysis. Medical Decision 
Making, 32, 722-732. 
Busso, M., DiNardo, J. & McCrary, J. 2011. New Evidence on the Finite Sample Properties of 
Propensity Score Reweighting and Matching Estimators. Working paper. 
CADTH. 2006. Guidelines for the Economic Evaluation of Health Tecnologies: Canada. 3rd 
Ed. [Online]. Ottawa, Canada. Available: 
http://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf. 
Caro, J. J., Briggs, A. H., Siebert, U. & Kuntz, K. M. 2012. Modeling Good Research 
Practices—Overview. Medical Decision Making, 32, 667-677. 
Cooper, N. J., Sutton, A. J., Ades, A. E., Paisley, S. & Jones, D. R. 2007. Use of evidence in 
economic decision models: practical issues and methodological challenges. Health 
Economics, 16, 1277-1286. 
Deeks, J. J. 2003. Evaluating non-randomised intervention studies [Online]. Tunbridge Wells: 
published by Gray Pub. on behalf of NCCHTA. Available: 
http://www.hta.ac.uk/execsumm/summ727.htm [Accessed 23/05/2009. 
Dolan, P. 2000. The measurement of health-related quality of life for use in resource allocation 
decisions in health care. Handbook of Health Economics. Amsterdam: North-Holland. 
Doshi, J. A., Glick, H. A. & Polsky, D. 2006. Analyses of Cost Data in Economic Evaluations 
Conducted Alongside Randomized Controlled Trials. Value in Health, 9, 334-340. 
Drummond, M., Sculpher, M., Torrance, G., O'Brien, B. & Stoddart, G. 2005. Methods for the 
Economic Evaluation of Health Care Programmes, Oxford, Oxford University Press. 
Drummond, M. F. 1998. Experimental versus observational data in the economic evaluation of 
pharmaceuticals. Medical Decision Making, 18. 
Fung, V., Brand, R. J., Newhouse, J. P. & Hsu, J. 2011. Using Medicare Data for Comparative 
Effectiveness Research: Opportunities and Challenges. Am J Manag Care, 17, 489-496. 
Glick, H., Doshi, J., Sonnad, S. & Polsky, D. 2007. Economic evaluation in clinical trials, 
Oxford, Oxford University Press. 
Glick, H., Polsky, D. & Schulman, K. 2001. Trial-based  economic evaluations: an overview of 
desgin and analysis. In: DRUMMOND, M. & MCGUIRE, A. (eds.) Economic 
evaluation in health care: Meging theory with practice. Oxford: Oxford University 
Press. 
Gomes, M., Grieve, R., Edmunds, J. & Nixon, R. 2011. Statistical methods for cost-
effectiveness analyses that use data from cluster randomised trials: a systematic review 
and checklist for critical appraisal. Medical Decision Making, 32, 209-20. 
Gray, A. M., Clarke, P. M., Wolstenholme, J. L. & Wordsworth, S. 2010. Applied Methods of 
Cost-Effectiveness Analysis in Healthcare, Oxford University Press. 
28 
 
Greenland, S., Pearl, J. & Robins, J. M. 1999. Confounding and Collapsibility in Causal 
Inference. Statist. Sci. , 14, 29-46. 
Grieve, R., SG, T., Nixon, R. M. & Cairns, J. 2007. Multilevel models for estimating 
incremental net benefits in multinational studies. Health Economics, 16, 815–26. 
Hjelmgren, J., Berggren, F. & Andersson, F. 2001. Health Economic Guidelines—Similarities, 
Differences and Some Implications. Value in Health, 4, 225-250. 
Hoch, J. S., Briggs, A. H. & Willan, A. R. 2002. Something old, something new, something 
borrowed, something blue: a framework for the marriage of health econometrics and 
cost-effectiveness analysis. Health Economics, 11, 415-430. 
Imbens, G. M. & Wooldridge, J. M. 2009a. Recent Developments in the Econometrics of 
Program Evaluation. Journal of Economic Literature, 47, 5–86. 
IQWIG. 2009. Methods for assessment of the relation of Benefits to Costs in the German 
Statutory Health Care System [Online]. Cologne, Germany. Available: 
http://www.ispor.org/peguidelines/source/Germany_AssessmentoftheRelationofBenefit
stoCosts_En.pdf. 
Jones, A. M. 2007. Identification of treatment effects in Health Economics. Health Economics, 
16, 1127-1131. 
Jones, A. M. 2010. Models For Health Care. HEDG Working Papers. HEDG, c/o Department of 
Economics, University of York. 
Kearns, B., Ara, R. & Wailoo, A. 2012. A review of the use of statistical regression models to  
inform cost-effectiveness analyses withing the NICE Technology Appraisals 
Programme [Online]. ScHARR, University of Sheffield. Available: 
http://www.nicedsu.org.uk/FINAL%20DSU%20Regressions%20report_09.10.12.pdf. 
Koerkamp, G. B., Weinstein, M. C., Stijnen, T., Heijenbrok-Kal, M. H. & Hunink, M. G. M. 
2010. Uncertainty and Patient Heterogeneity in Medical Decision Models. Medical 
Decision Making, 30, 194-205. 
Kuntz, K. M. & Weinstein, M. C. 2001. Modelling in economic evaluation. In: DRUMMOND, 
M. & MCGUIRE, A. (eds.) Economic Evaluation in Helath care. Merging theory with 
practice. Oxford: Oxford University press. 
Longworth, L., Bojke, L., Tosh, J. & Sculpher, M. 2009. MRC-NICE Scoping Project: 
Identifying the National Institute For Health And Clinical Excellence’s Methodological 
Research Priorities and an Initial Set of Priorities. In: ECONOMICS, C. F. H. (ed.). 
University of York. 
Manca, A. & Austin, P. C. 2008. Using propensity score methods to analyse individual patient-
level cost-effectiveness data from observational studies [Online]. Available: 
http://www.york.ac.uk/res/herc/documents/wp/08_20.pdf. 
Manca, A., Lambert, P., Sculpher, N. & Rice, N. 2007. Cost-effectiveness analysis using data 
from multinational trials: the use of Bayesian hierarchical modelling. Medical Decision 
Making, 471–90. 
Manning, W. G., Basu, A. & Mullahy, J. 2005. Generalized modeling approaches to risk 
adjustment of skewed outcomes data. Journal of Health Economics, 24, 465-488. 
Mihaylova, B., Briggs, A., O'Hagan, A. & Thompson, S. 2010. Review of statistical methods 
for analysing healthcare resources and costs. Health Economics, DOI: 
10.1002/hec.1653. 
Mitra, N. & Indurkhya, A. 2005. A propensity score approach to estimating the cost-
effectiveness of medical therapies from observational data. Health Economics, 14, 805-
15. 
Morgan, S. L. & Winship, C. 2007. Counterfactuals and causal inference: methods and 
principles for social research, New York, Cambridge University Press. 
NICE. 2008. Guide to the Methods of Technology Appraisal [Online]. Available: 
http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf 
[Accessed 24/10/2010. 
NICE. 2009. Methods for the development of NICE public health guidance (second edition) 
[Online]. Available: 
http://www.nice.org.uk/media/2FB/53/PHMethodsManual110509.pdf. 
29 
 
Nixon, R. M. & Thompson, S. G. 2005. Methods for incorporating covariate adjustment, 
subgroup analysis and between-centre differences into cost-effectiveness evaluations. 
Health Economics, 14, 1217-1229. 
Noble, S., Hollingworth, W. & Tilling, K. 2012. Missing data in trial-based cost-effectiveness 
analysis: the current state of play. Health Economics, 21, 187-200. 
O'Hagan, A. & Stevens, J. 2001. A framework for cost-effectiveness analysis from clinical trial 
data. Health Economics, 10, 303-15. 
PBAC. 2008. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory 
Committee [Online]. Camberra, Australia. Available: 
http://www.health.gov.au/internet/main/publishing.nsf/Content/D8EBFB77AC0E7552
CA25717D000AE40B/$File/pbac_guidelines.pdf. 
Pearl, J. 2009. Causality : models, reasoning, and inference, Cambridge, Cambridge University 
Press. 
Philips, Z., Bojke, L., Sculpher, M., Claxton, K. & Golder, S. 2006. Good practice guidelines 
for decision-analytic modelling in health technology assessment: a review and 
consolidation of quality assessment. Pharmacoeconomics, 24, 355-71. 
Pizer, S. 2009. An intuitive review of methods for observational studies of comparative 
effectiveness. Health Services and Outcomes Research Methodology, 9, 54-68. 
Polsky, D. & Basu, A. 2006. Selection Bias in Observational Data. The Elgar Companion to 
Health Economics. Edward Elgar Publishing. 
Radice, R., Grieve, R., Ramsahai, R., Kreif, N., Sadique, Z. & Sekhon, J. S. 2012. Evaluating 
treatment effectiveness in patient subgroups: a comparison of propensity score methods 
with an automated matching approach. The International Journal of Biostatistics, 8(1). 
Rubin, D. B. 2006. Matched sampling for causal effects, Cambridge, Cambridge University 
Press. 
Rubin, D. B. 2010. On the limitations of comparative effectiveness research. Statistics in 
Medicine, 29, 1991-1995. 
Sculpher, M. 2008. Subgroups and Heterogeneity in Cost-Effectiveness Analysis. 
Pharmacoeconomics, 26, 799-806. 
Sculpher, M. J., Claxton, K., Drummond, M., McCabe, C. & Mihaylova, B. 2006. Whither trial-
based economic evaluation for health care decision making? Health Economics, 15, 
677–687. 
Sekhon, J. S. & Grieve, R. D. 2011. A Matching Method for Improving Covariate Balance in 
Cost-Effectiveness Analyses. Health Economics, doi: 10.1002/hec.1748. 
Shah, B. R., Andreas, L., Janet, E. H. & Peter, C. A. 2005. Propensity score methods gave 
similar results to traditional regression modeling in observational studies: a systematic 
review. Journal of Clinical Epidemiology, 58, 550-559. 
Stuart, E. A. 2010. Matching Methods for Causal Inference: A review and a look forward. 
Statistical Science, 25. 
Thompson, S., Kaptoge, S., White, I., Wood, A., Perry, P., Danesh, J. & Collaboration, T. E. R. 
F. 2010. Statistical methods for the time-to-event analysis of individual participant data 
from multiple epidemiological studies. International Journal of Epidemiology. 
Tunis, S. R., Benner, J. & McClellan, M. 2010. Comparative effectiveness research: Policy 
context, methods development and research infrastructure. Statistics in Medicine, 29, 
1963-1976. 
Willan, A. R. & Briggs, A. H. 2006. Statistical Analysis of Cost-effectiveness Data, John Wiley 
& Sons Ltd. 
Willan, A. R., Briggs, A. H. & Hoch, J. S. 2004. Regression methods for covariate adjustment 
and subgroup analysis for non-censored cost-effectiveness data. Health Economics, 13, 
461-475. 
Willan, A. R., Lin, D. Y., Cook, R. J. & Chen, E. B. 2002. Using inverse-weighting in cost-
effectiveness analysis with censored data. Statistical Methods in Medical Research, 11, 
539-551. 
Willan, A. R., Lin, D. Y. & Manca, A. 2005. Regression methods for cost-effectiveness analysis 
with censored data. Statistics in Medicine, 24, 131-145.   
30 
 
Chapter 2 - Conceptual review of statistical methods for 
addressing selection bias in CEA that use patient-level 
observational data  
2.1 Introduction 
Statistical methods for cost-effectiveness analyses (CEA) that use individual patient 
data (IPD) from randomised controlled trials (RCTs) have been through considerable 
development in the last decade. However, statistical methods developed for the analysis 
of RCT data might not be appropriate for observational data.  In CEA that use data from 
NRS, the distribution of the baseline covariates can be highly imbalanced (Grieve et al., 
2008). Under such circumstances, estimates can be sensitive to the specification of the 
regression models, for example the inclusion or exclusion of nonlinearities in the 
covariate-endpoint relationship (Ho et al., 2007). Instead of modelling the cost and 
effectiveness endpoint, a recommended  approach in CEA is to try to achieve  covariate 
balance  using the propensity score (PS) (Manca and Austin, 2008, Mitra and 
Indurkhya, 2005). However, correctly specifying the unknown PS is also challenging 
(Dehejia and Wahba, 2002).  
This chapter aims to consider several outstanding methodological concerns that face 
CEA that use observational data. First, what are the important underlying assumptions 
made by common statistical methods for addressing selection bias in CEA?  Which 
statistical methods are most appropriate for addressing selection bias when estimates of 
cost-effectiveness are required for patient subgroups? Which methods from the general 
causal inference literature are potentially appropriate for addressing selection bias in 
CEA, and what are their relative merits under typical circumstances that arise in CEA?  
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The overall aim of this chapter is to identify gaps in the methods literature of CEA 
concerned with addressing selection bias, which the subsequent chapters of the thesis 
aim to address. The specific objectives of this chapter are: 
1. To review methodological guidance on statistical methods for addressing 
selection bias in CEA that use patient-level observational data, and to describe 
challenges that arise when using these methods. 
2. To describe the main underlying assumptions made by recommended statistical 
methods for addressing selection bias in CEA. 
3. To identify statistical methods from the general causal inference literature that 
have the potential to reduce selection bias in a CEA. 
4. To identify gaps in the methodological literature on the relative performance of 
alternative methods for addressing selection bias in CEA. 
To address these objectives, I conducted a conceptual literature review consisting of two 
parts.  First, I reviewed papers that provide methodological guidance for handling 
selection bias in CEA that use patient-level observational data.  Second, I conducted a 
targeted review of the general causal inference literature, by reviewing seminal papers 
and their reference lists, and by consulting leading researchers in the field.  
In the next section, I review the challenges statistical methods currently recommended 
for reducing selection bias in CEA need to address. Section 3 considers the main 
underlying assumptions statistical methods make in the context of CEA, based on 
methodological guidance from the general causal inference literature.  Section 4 reviews 
further promising statistical methods and their appropriateness for CEA. Section 5 
identifies gaps in the CEA methodological literature on the relative performance of the 
methods. The last section summarises the chapter and highlights areas for further 
research. 
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2.2 Statistical challenges in accounting for selection bias in CEA 
that use patient-level observational data 
When RCT data is available for the cost and effectiveness endpoints, in general, 
randomisation ensures unbiased estimates of incremental cost and effects (Gray et al., 
2010).  When the CEA uses observational data, selection bias due to the lack of balance 
between treatment groups is a potential concern. This concern applies for a wide range 
of uses of observational data. These uses include settings when the CEA is conducted 
alongside a single observational study (Manca and Austin, 2008), and the parameters of 
interest are the incremental cost and incremental effectiveness, as well as when 
observational data is used to estimate parameters for a decision model such as hazard 
ratios or  relative risks (Philips et al., 2006).     
Polsky and Basu (2006) discuss the sources of selection bias in health economic 
evaluation. Overt bias is due to differences in observed provider or patient or 
characteristics, such as diseases severity, while hidden bias is due to unobserved 
characteristics, such as patient preferences. In a case study example, the authors 
demonstrate the use of regression and PS methods that can handle overt bias, and 
instrumental variables (IV) estimation that can potentially handle both observed and 
unobserved confounding. The authors note that in the context of economic evaluation, 
finding an appropriate IV is challenging: a good instrument is strongly related to 
treatment receipt, but unrelated to the endpoints.  Moreover IV methods often estimate 
treatment effects for a narrower population than what is relevant for the original 
evaluation question (see more on IV estimation in section 3.2). My systematic review in 
research paper 1 finds that IV methods are rarely used in CEA.  
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Regression methods that can handle correlated costs and outcomes have been developed  
for covariate adjustment of RCT data, and  are also recommended for addressing the 
potential selection bias that arises when using observational data (Nixon and Thompson, 
2005). Even when using RCT data, the choice of statistical model - for example the 
error distribution chosen to model costs - has been shown to influence the estimated 
cost-effectiveness (Thompson and Nixon, 2005).  When observational data is used for 
CEA, covariate distributions between treatment groups can be highly imbalanced 
(Grieve et al., 2008). This can make regression estimates  sensitive to parametric  model 
specification (Ho et al., 2007). In CEA, regression models may be specified for the cost 
and the effectiveness endpoints, which in the case of generalised linear models (GLMs), 
for example involves specifying the functional form relationship between the covariates 
and the endpoint, and the error distributions of the endpoint.  The challenges of 
specifying regression models for resource use and cost data are widely recognised 
(Manning et al., 2005, Manning et al., 1987, Manning and Mullahy, 2001, Mihaylova et 
al., 2010, Basu and Rathouz, 2005, Jones, 2010). These are: nonlinear relationships 
between covariates and endpoints, irregular distributions and heavy tails of the 
endpoints.  Similar challenges prevail when estimating treatment effects on health 
outcomes, such as health related quality of life (HRQoL) and quality-adjusted life years 
(QALYs), which often exhibit truncated supports with spikes at 0 or 1 (Basu and 
Manca, 2011). Recommended regression techniques to handle these endpoints include 
GLMs (Barber and Thompson, 2004a), two-part models  (Buntin and Zaslavsky, 2004, 
Basu, 2011), or exponential conditional mean models (Manning et al., 2005). 
Specification tests recommended to rank competing regression models (Manning and 
Mullahy, 2001, Basu et al., 2004) can provide measures of model fit. However, failure 
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to reject a model in a specification test does not necessarily imply that the model is 
correctly specified (Horowitz, 2011). 
Instead of specifying models for the endpoints, the PS can be used to create balance 
between observed characteristics of the treatment groups (Rosenbaum  and Rubin, 
1983).  In CEA, the PS has been recommended for matching,  stratification on the PS 
and as a covariate in either univariate net benefit regression models (Mitra and 
Indurkhya, 2005, Manca and Austin, 2008) or in bivariate regression models (Manca 
and Austin, 2008). Some of these methods, such as stratification and linear regression 
on the PS are outperformed by alternative PS methods, such as inverse probability of 
treatment weighting (IPTW) (Austin, 2009c, Lunceford and Davidian, 2004).  These 
methods rely on the correct specification of the PS, which can be challenging 
(Westreich et al., 2010).  For example, just as the investigator does not know the 
specification of the relationship between covariates and endpoints, they seldom know 
how covariates influence treatment receipt. A misspecified PS, due to, for example, 
omitting nonlinear relationships between covariates and treatment assignment (Basu et 
al., 2011), can lead to biased parameter estimates. To appropriately assess the 
specification of the PS, an assessment of balance on the full distribution of the 
covariates between the treatment groups must be made (Sekhon and Grieve, 2011), 
however this is rarely performed in practice (Austin, 2008). 
These methods can be used to calculate cost-effectiveness parameters across all patients 
of interest. Decision makers are often also interested in cost-effectiveness for patient 
subgroups (Espinoza et al., 2011, Sculpher, 2008), and calculating overall estimates of 
cost-effectiveness could mask important heterogeneity between subgroups. Sources of 
heterogeneity can be characteristics of the patient (age, weight, gender, preferences, 
baseline outcomes etc.) or the health care provider (e.g. type of treatment centre) 
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(Sculpher, 2008). For example, in the CEA conducted by Mihaylova et al. (2005), cost-
effectiveness of a statin therapy differed across subgroups defined by patients’ baseline 
risk of a vascular event. In RCT-based CEA, a standard way of accounting for 
subgroup-level heterogeneity is to include covariate-by-treatment interactions in a 
regression model (Nixon and Thompson, 2005, Hoch et al., 2002, Willan et al., 2004). 
To provide unbiased cost-effectiveness estimates in an observational setting where 
subgroup effects are of interest is more challenging; the analyst needs to choose the 
correct model specification for the covariate-endpoint relationships, and the joint 
distribution of the endpoints. CEA may be sensitive to the choice of the model 
specification. 
 PS methods can potentially be used for subgroup-analysis, here they are required to 
balance baseline covariates between treatment and control groups within each subgroup. 
Just as relative costs and effectiveness can be heterogeneous across patients, in an 
observational setting it can also be expected that the mechanism of treatment 
assignment might systematically differ by patient subgroup. Balancing covariates at the 
subgroup level may prove particularly challenging: a PS approach has to recognise the 
differential treatment assignment mechanism, for example by estimating separate PS 
models for each subgroup.  
The methodological guidance on decision models in CEA emphasises the need to 
appropriately represent various sources of decision uncertainty, such as parameter 
uncertainty, methodological uncertainty and  structural uncertainty (Bojke et al., 2009). 
As Polsky and Basu (2006) illustrate, statistical methods that make different underlying 
assumptions can lead to substantially different cost-effectiveness results.  This 
uncertainty, due to the choice of statistical method can be characterised as part of 
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structural uncertainty (Jackson et al., 2011), a relatively under-researched area (Gray et 
al., 2010). Here, detailed methodological guidance is currently lacking. 
To conclude this section, the methodological literature in CEA typically considers 
regression and PS approaches for addressing selection bias. In an observational setting, 
high covariate imbalance can make estimates sensitive to the specification of the 
regression model.  PS methods can only provide reliable estimates if good balance is 
achieved after PS adjustment. Each of these methods needs to acknowledge further 
challenges which arise when cost-effectiveness estimates for subgroups are of interest. 
CEA need to acknowledge the structural uncertainty due to the choice of statistical 
method used to address selection bias. The next section considers the main assumptions 
that underlie the methods currently recommended for CEA that use observational data.  
2.3 Methodological guidance from the general causal inference 
literature  
This review had two objectives: first, to inform the development of a new quality 
appraisal tool that focuses on the appropriate assessment of assumptions for statistical 
methods currently recommended for CEA (research paper 1), and second, to identify 
alternative statistical methods and consider their assumptions in the context of 
addressing selection bias in CEA (section 4). 
I conducted a targeted review of the causal inference literature,  including articles from 
the statistics, econometrics and epidemiology literature concerned with estimating the 
effects of exposures, treatments and policies, published between 1983 and 2011 (for 
example, Rosenbaum and Rubin, 1983, Imbens and Wooldridge, 2009a, Stuart, 2010, 
Morgan and Winship, 2007). 
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2.3.1 The potential outcomes framework 
Following the causal inference literature on estimating treatment effects, I draw on the 
Neyman-Rubin potential outcomes framework (Imbens and Wooldridge, 2009a), and 
use its  concepts and  notation throughout. 
𝑌𝑖𝑘 is the observed outcome (cost if 𝑘 = 𝐶 and effectiveness if 𝑘 = 𝐸), for individual
1  
𝑖 = 1, . . . . , 𝑛, where 𝑛 is the sample size. 𝑡𝑖( 0,1) is the indicator of the observed 
treatment2.  The potential outcome of the individual that would be realised if she 
received the control is 𝑌𝑖𝑘(0), and 𝑌𝑖𝑘(1) if she received treatment. One of these 
outcomes - the actual treatment received - is observed, while the counterfactual is never 
observed.  
The causal effect of the treatment is the difference between the potential outcomes for 
an individual3: 
𝜏𝑖𝑘 = 𝑌𝑖𝑘(1) − 𝑌𝑖𝑘(0). 
The expected treatment effect across the whole population is the average treatment 
effect (ATE), given by 
𝜏𝑘 = 𝐸(𝑌𝑖𝑘(1) − 𝑌𝑖𝑘(0)). 
Another relevant estimand is the average treatment effect on the treated (ATT), here the 
expectation is taken only for those who actually received the treatment. The individual 
                                                 
1 For simplicity here I consider individuals, however treatment effects can also be calculated for different 
units such as practices and hospitals. 
2 Again, treatment is a generic term for any intervention or program. Here I consider a binary treatment 
(1= treated, 0 =control). The methods considered here can be generalised to several treatments.  
3 This review focuses on methods for analysing continuous outcomes (e.g. QALYs) and costs, where 
additive (incremental) effects are of interest. The potential outcomes framework also applies for different 
types of outcomes (e.g. count and binary data, or censored data such as survival time), where parameters 
such as odds ratios, relative risks or hazard ratios are of interest. These parameters are beyond the scope 
of this review.  
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level treatment effect (𝜏𝑖𝑘) can be heterogeneous across the patient population, for 
example by subgroups, and due to this heterogeneity, the ATE and ATT will differ from 
each other, and across subgroups. 
In the CEA context, a treatment effect of interest is the incremental net benefit, 
calculated as  
𝐼𝑁𝐵 = 𝐾 ∗ 𝜏𝐸−𝜏𝐶, 
where 𝐾 is the willingness to pay.  
 In non-randomised settings individuals can be assigned to a treatment according to 
characteristics that are observed (𝑥𝑖) and unobserved by the investigator. Under the 
assumption of  “selection on observables”, even if some of the unobserved 
characteristics influence treatment assignment, these factors are assumed not to 
influence the endpoint of interest, and not to be associated with unobserved factors 
influencing the endpoint. The mathematical counterpart of selection on observables is a 
combination of two assumptions:  the unconfoundedness assumption and the overlap 
assumption. The combination of these two assumptions is also referred to as “strong 
ignorability” (Imbens and Wooldridge, 2009a).   
2.3.2 The assumption of “no unobserved confounding” 
The assumption of no unobserved confounding (also referred to as 
“unconfoundedness”) states that, after controlling for a vector of observed covariates 
(𝑥𝑖)4, treatment assignment (𝑡𝑖) is independent of both potential outcomes: 
                                                 
4 Here I assume that the vector of observed confounders necessary for the unconfoundedness assumption 
to hold is the same for the cost and effectiveness endpoint. Research paper 2 presents a scenario where a 
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𝑡𝑖_||_ (𝑌𝑖𝑘(0), 𝑌𝑖𝑘(1)) |𝑥𝑖                     
Under this assumption, the allocation of two individuals who have similar observed 
characteristics but are in different treatment arms, can be thought of as effectively at 
random (Greenland et al., 1999). Approaches that use longitudinal data, such as panel 
data regression and “difference-in-differences”, rely on a weaker form of this 
assumption; they assume that changes over time in unobserved confounders are 
conditionally independent of treatment (Imbens and Jeffrey, 2007). 
The unconfoundedness assumption is not directly testable from the data (Imbens and 
Wooldridge, 2009a). Intuitively, it requires that the researcher has all relevant pre-
treatment covariates at his or her disposal (Rubin, 2010). To consider this assumption, 
external evidence or expert opinion of the potential influence of observed and 
unobserved baseline covariates on treatment assignment, and endpoints need to be 
considered (Rubin, 2010). Causal diagrams can be useful for defining the structure of 
such relationships (Pearl, 2001). These considerations might be complemented with 
indirect statistical tests, so called “placebo tests” which can detect violations of the 
assumption (Imbens, 2004, Jones, 2007, Abadie et al., 2010). One possible 
implementation of these tests is to split those who did not receive the treatment into two 
control groups: one that was eligible for the treatment and one that was not, and 
estimate the “treatment effect” between these two groups (Imbens and Wooldridge, 
2009a). After adjusting for the observed covariates, a nonzero estimated treatment effect 
between these groups might indicate that it is not plausible to assume 
                                                 
covariate which is a confounder for the QALY endpoint, the baseline QALY, is not associated with the 
cost endpoint.  
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unconfoundedness. However, a set of observed covariates “passing” the placebo test 
does not confirm that the unconfoundedness assumption is valid. 
Another approach is to tests the sensitivity of the treatment effect estimates to the 
impact of potential unobserved confounders, for example using Rosenbaum’s method of 
sensitivity analysis (Rosenbaum, 2002). This method can characterise the strength of 
association between the potential unobserved confounder and treatment assignment, 
which is necessary to change the conclusions regarding the estimated treatment effect.  
IV estimation is a recommended statistical approach that can account for both observed 
and unobserved confounding (Mullahy, 2011, Basu et al., 2007, Terza et al., 2008). IV 
methods assume that the instrument only influences endpoints through treatment, and is 
independent of the unobserved confounders (Hernán and Robins, 2006). This 
assumption is also untestable, however its plausibility can be assessed, for example, 
with causal diagrams informed by expert opinion and evidence from literature (Joffe 
and Mindell, 2006).  Examples of proposed instruments in health economics are, the 
distance from hospital (Basu et al., 2007), or in Mendelian randomisation studies, the 
genotype (Didelez and Sheehan, 2007). In most CEAs, however, finding a valid 
instrument is challenging (Polsky and Basu, 2006). A further challenge of IV estimation 
is that, instead of ATEs, a feasible estimand is often the local average treatment effect, 
which can differ from the ATE when individual treatment effects are heterogeneous. 
Therefore, for CEA, statistical methods that assume unconfoundedness warrant 
consideration. 
2.3.3 The overlap assumption 
The overlap assumption (also known as the assumption of positivity, or the 
”experimental treatment assignment” assumption) (Westreich and Cole, 2010)  requires 
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that for any combination of covariate values, there is a nonzero probability of being 
assigned to each treatment arm.  For a binary treatment, this requires that 
0 < 𝑝𝑟(𝑡𝑖 = 1 |𝑥𝑖) < 1).          
Intuitively this implies that no covariate or combination of covariates perfectly 
determine treatment assignment.  The overlap assumption can be assessed using the 
data, for example by inspecting histograms or density plots (continuous covariates) and 
by reporting standardised differences (categorical or continuous covariates)  (Imbens 
and Wooldridge, 2009a, Busso et al., 2011). 
Poor overlap, or structural violations of the positivity assumption, are  present when at 
certain combinations of covariates, it is impossible to observe both treated or control 
individuals (Westreich and Cole, 2010). In such cases, in order to identify the ATE for 
the whole population, statistical methods need to extrapolate. For example, if in certain 
age groups there are no treated individuals, treatment effects for these patients need to 
be extrapolated using information on younger patients.  Regression methods make this 
extrapolation automatically, and can hide overlap problems (Crump et al., 2009, Ho et 
al., 2007, Westreich and Cole, 2010). If the regression model specification is incorrect, 
this can result in biased parameter estimates. A common remedy is to estimate the 
treatment effect only for the subsamples where there is good overlap (Crump et al., 
2009). However, this approach of dropping treated and control individuals can lead to 
an estimated treatment effect for a population that differs from that of interest for the 
policy maker.  
In finite samples, even when overlap is reasonable, “practical positivity violations” 
often arise: in certain covariate strata there might be small numbers or no individuals 
from each treatment group (Westreich and Cole, 2010). This can lead to the probability 
42 
 
of treatment assignment to be close to 0 or 1, which can be problematic for methods that 
use the inverse of the PS for addressing selection bias (Kang and Schafer, 2007). This 
problem can be especially severe in reduced sample sizes of patient subgroups.  
This thesis follows the terminology of the econometrics literature (Imbens and 
Wooldridge, 2009a) and defines both structural and practical violations of the positivity 
assumption as poor overlap. 
2.4 Currently recommended methods for accounting for selection 
bias in CEA  
2.4.1 Regression methods 
A commonly used regression approach for covariate adjustment for CEA is the net 
benefit regression framework (Hoch et al., 2002). Here, the treatment effect is estimated 
on the individual net benefit endpoint, for example by using ordinary least squares 
(OLS) regression. This approach accounts for the correlation between individual costs 
and effects. However, it assumes the same, linear functional form relationship between 
the covariates and the cost and effectiveness endpoints for a fixed value of WTP, which 
may not be plausible (Nixon and Thompson, 2005).   
A more flexible approach is to model the cost and effectiveness endpoints using GLMs 
(Barber and Thompson, 2004b). The advantage of GLMs is their potential to address 
skewed endpoints and nonlinear response surfaces, where response surface describes the 
functional form relationship between the covariate and the endpoint (Rubin, 1979). 
GLMs can predict expected endpoints on the original scale of interest. Following Barber 
and Thompson (2004), GLMs for 𝑌𝑖𝑘 can be written as 
                      𝑔𝑘(𝜇𝑖,𝑘) = 𝛾𝑘𝑡𝑖 + 𝑥𝑖𝛽𝑘;     𝑌𝑖𝑘~𝐹𝑘.                                          (1)      
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Here 𝜇𝑖,𝑘 = 𝐸(𝑌𝑖,𝑘) is the expectation of 𝑌𝑖,𝑘,  𝑔𝑘 is the link function which describes 
the scale on which 𝑥𝑖 are related to 𝑌𝑖,𝑘, 𝛾𝑘 and 𝛽𝑘  are the regression coefficients, and 
𝐹𝑘 is an exponential family distribution.  If treatment effects for subgroups are of 
interest, treatment-covariate interactions in the linear predictor can account for 
heterogeneous treatment effects (Nixon and Thompson, 2005). Parameters can be 
estimated via maximum likelihood (ML), quasi ML or Bayesian methods (Basu and 
Manca, 2011). Bivariate models (Nixon and Thompson, 2005) or non-parametric 
bootstrap  (Davison and Hinkley, 1997) can be used to recognise the  joint uncertainty 
in the estimates of the incremental costs and effectiveness, for example by estimating 
confidence intervals (CIs) around the INB, or cost-effectiveness acceptability curves 
(CEACs).  
For unbiased estimation with GLMs, correct specification of the link function and linear 
predictor is needed.  For efficient estimates, the correct specification of the error 
distribution is also necessary.   With certain data typical of CEA, for example cost or 
HRQoL data with large spikes in their distributions, it is recommended that GLMs are 
extended, for example, by applying two-part models  (Buntin and Zaslavsky, 2004, 
Basu, 2011).  Further flexible approaches are semi-parametric methods such as 
extended estimating equations (Basu and Rathouz, 2005), or beta-type size distributions 
(Jones et al., 2011), which, however, are rarely used in practice (Mihaylova et al., 
2010).  A general concern is that, even a flexible parametric approach is not a substitute 
for finding the correct model specification (Manning et al., 2005).  Non-parametric 
methods such as the quintile regression and the discrete conditional density estimator 
(Gilleskie and Mroz, 2004), or machine learning algorithms can be  promising 
alternatives (Austin, 2012).   
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A general way to obtain ATEs, across a wide range of regression models, is with the 
method of recycled predictions (Basu and Rathouz, 2005), which is equivalent to the G-
computation estimator of a point treatment (Robins, 1986, Imbens and Wooldridge, 
2009a, Imbens, 2004). This method predicts the expected potential outcomes for each 
individual, under treated and control states: 
?̂?𝑘,𝑟𝑒𝑔 =
1
𝑛
∑ {?̂?𝑖,𝑘(𝑥𝑖,, 𝑡𝑖 = 1) − ?̂?𝑖,𝑘(𝑥𝑖,, 𝑡𝑖 = 0)},               
𝑛
𝑖=1                       (2) 
 where ?̂?𝑖,𝑘(. ) is the predicted mean of 𝑌𝑖,𝑘 from the GLM in equation (1),  given 𝑥𝑖, 
with 𝑡𝑖 set to 1 and then to 0 for the whole sample. Standard errors around the estimated 
ATE can be obtained using the non-parametric bootstrap.  
2.4.2 Propensity score matching 
Matching methods aim to create treated and control groups with balanced covariate 
distributions. Ideally, treated and control units can be exactly matched on their observed 
covariate values. However, with high dimensional, continuous confounders, exact 
matching is not possible. Instead, the PS can be used as a balancing score. The PS is the 
conditional probability of treatment assignment given 𝑥𝑖 (Rosenbaum  and Rubin, 
1983), 
                𝑝𝑖 = 𝑃𝑟(𝑡𝑖 = 1|𝑥𝑖). 
The estimated PS,  ?̂?𝑖, is generally obtained as a prediction from a logistic regression 
model (Westreich et al., 2010). The PS can create balance between treated and control 
comparison groups, and can be used in several ways: for matching, using the inverse of 
the PS for weighting the sample, stratifying on the PS, and including the PS as a 
covariate in regression (Rosenbaum  and Rubin, 1983). Matching and weighting – 
selected for further investigation – have been shown to dominate stratification and 
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regression in terms of accuracy (Austin, 2009b, Lunceford and Davidian, 2004, Austin, 
2009c, Austin et al., 2007).  
In PS matching, matched treated and control comparison groups can be created, using  
?̂?𝑖 as a distance metric (Rosenbaum  and Rubin, 1983). For each subject, the missing 
potential outcome, 𝑌𝑖,𝑘(0) or 𝑌𝑖,𝑘(1) is imputed, using the observed outcomes of the 
closest matches:   
?̂?𝑖,𝑘(0, 𝑥𝑖) = { 1
𝑀
𝑌𝑖,𝑘
∑ 𝑌𝑗,𝑘𝑗𝜖𝜁𝑀(𝑖)     
if  𝑡𝑖 = 0
if  𝑡𝑖 = 1
  
?̂?𝑖,𝑘(1, 𝑥𝑖) = {
1
𝑀
∑ 𝑌𝑗,𝑘𝑗𝜖𝜁𝑀(𝑖)
𝑌𝑖,𝑘     
if  𝑡𝑖 = 0
if  𝑡𝑖 = 1
  
where 𝜁𝑀(𝑖) is the set of M individuals matched to unit 𝑖. The matching estimator for 
the ATE is the mean of the estimated individual-level treatment effects: 
?̂?𝑘,𝑚𝑎𝑡𝑐ℎ =
1
𝑛
∑ {?̂?(1, 𝑥𝑖) − ?̂?(0, 𝑥𝑖)}
𝑛
𝑖=1                (3) 
The true PS is a balancing score: conditional on the PS, treatment and control groups 
are expected to have the same distribution of observed baseline characteristics. 
Matching on a correctly specified PS can therefore eliminate selection bias (Rubin and 
Thomas, 1992). However, in an observational setting, the specification of the true PS is 
generally unknown. If the PS is misspecified, for example by incorrectly omitting 
higher order terms from the  logistic model, or ignoring differences between subgroups 
in the treatment assignment mechanism, then PS matching can lead to biased estimates 
of treatment effects (Cole and Hernán, 2008). 
An appropriate check of the PS specification is whether covariate distributions between 
the treatment groups are balanced in the matched sample (Stuart, 2010). Recommended 
ways of assessing balance include calculating the standardised mean differences of 
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covariates between matched treatment groups (Rosenbaum  and Rubin, 1985, Austin, 
2009a), defined as 
𝑑 =
?̅?𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡−?̅?𝑐𝑜𝑛𝑡𝑟𝑜𝑙
√𝑠
2
𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡+ 𝑠
2
𝑐𝑜𝑛𝑡𝑟𝑜𝑙
2
,          (4) 
, where x̅ and s2 denote the covariate’s weighted means and variances by treatment 
group. It is suggested (Stuart, 2010, Diamond and Sekhon, 2012) that the balance needs 
to be assessed not only on the means, but on the full distribution of the covariates, e.g. 
by comparing empirical quantile-quantile (EQQ) plots between the treatment groups 
(Diamond and Sekhon, 2012, Basu et al., 2008, Austin, 2008, Ho et al., 2007). If the 
balance between the treatment groups is poor after matching, the analyst should try to 
improve it by re-estimating the PS  (Dehejia and Wahba, 2002, Imbens and Wooldridge, 
2009b). If treatment effects for subgroups are of interest, this process of balance checks 
should be performed for each subgroup.  This approach can, however, result in 
subjective decisions, and is rarely followed (Austin, 2008).  
There is no consensus in the methodological literature on the estimation of variance for 
matching approaches (Hill, 2008, Hill and Reiter, 2005, Abadie and Imbens, 2006b, 
Austin, 2008, Stuart, 2010). Ideally, the estimated variance of the treatment effect 
should include the variance due to the estimation of the PS, and account for the 
dependences in the data created by the matching process (Hill and Reiter, 2005, Hill, 
2008). A general suggestion is to estimate standard errors conditional on the matched 
data (Ho et al., 2007), for example using analytical standard errors from regression 
models applied on the matched data, or the non-parametric bootstrap.  In CEA, the non-
parametric bootstrap, by re-sampling individual cost and effectiveness pairs, can 
maintain the correlation between the incremental cost and effectiveness parameters 
(Sekhon and Grieve, 2011). While this approach does not account for the uncertainty 
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due to the estimated PS,  under relatively general circumstances, it expected that using 
the estimated PS instead of the true PS provides conservative variance estimates (Stuart, 
2010). Analytical variance formulas which can account for the matching process are 
subject to ongoing research (Abadie and Imbens, 2009, Abadie and Imbens, 2006a), and 
cannot be readily applied for the bivariate context of CEA. 
2.4.3 Inverse probability of treatment weighting 
A further recommended use of the estimated PS is inverse probability of treatment 
weighting (IPTW). IPTW can estimate ATEs, by reweighting the observed cost and 
effectiveness endpoints for treated and control samples. The IPT weight, 𝑤𝑖, is the 
inverse of the estimated probability of receiving the observed treatment: 
𝑤𝑖 =
𝑡𝑖
𝑝𝑖
+ 
1−𝑡𝑖
1−𝑝𝑖
                          (5) 
It is recommended that in practice the normalised IPTW estimator is implemented, 
where  weights  are divided with the sum of weights for the respective treatment group 
(Hirano and Imbens, 2001, Kang and Schafer, 2007a): 
?̂?𝑘,𝐼𝑃𝑇𝑊
∑ 𝑡𝑖𝑤𝑖𝑌𝑖,𝑘  
𝑛
𝑖=1
∑ 𝑡𝑖𝑤𝑖
𝑛
𝑖=1
−
∑ (1 − 𝑡𝑖)𝑤𝑖𝑌𝑖,𝑘  
𝑛
𝑖=1
∑ (1 − 𝑡𝑖)𝑤𝑖  
𝑛
𝑖=1
 
In CEA, IPTW has been introduced for reducing selection bias in cost analysis (Basu et 
al., 2011) and for handling censored cost (Pullenayegum and Willan, 2011) and cost-
effectiveness (Willan et al., 2002, Willan et al., 2005) data. IPTW has not previously 
been considered for addressing selection bias in CEA.  
If the PS is correctly specified, IPTW can provide consistent estimates and reach semi-
parametric efficiency (Hirano et al., 2003). This can be particularly attractive for 
subgroup analysis, where sample sizes at the subgroup level can be small.  Covariate 
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balance can be assessed following IPTW according to standardised differences (Austin, 
2009a), where the  means and standard deviations in equation (4) are weighted by the 
IPT weights.  
Misspecification of the PS, for example ignoring subgroup-specific treatment 
assignment, can cause IPTW to be biased, and it is expected to report more bias than PS 
matching. While for matching it is sufficient for the estimated PS to be a balancing 
score, for weighting, the PS needs to be the correct conditional probability of treatment 
assignment (Busso et al., 2009, Waernbaum, 2011). 
Even when the PS model is correctly specified, poor overlap can result in PS values 
close to 0 and 1, and unstable IPT weights, which can lead to estimates of ATEs that are 
biased and inefficient (Kang and Schafer, 2007a, Lee et al., 2010, Busso et al., 2011). 
Such challenges are likely to arise in CEA, where covariate imbalance can be high 
(Grieve et al., 2008), possibly resulting in poor overlap.  
After applying IPTW, uncertainty can be calculated using the sandwich estimator of a 
weighted regression of the endpoint on the treatment indicator 5 or the non-parametric 
bootstrap (Lunceford and Davidian, 2004), for example. Both approaches can maintain 
the correlation between the incremental cost and effectiveness parameters.  
2.4.4 Structural uncertainty from the choice of statistical method to address 
selection bias 
Each of the statistical approaches described above make assumptions that cannot be 
directly tested, for example the unconfoundedness assumption, or the assumption of 
                                                 
5 This weighted regression estimator, often used in applied work, corresponds the normalised IPTW 
estimator defined earlier (Busso et al., 2009). 
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correct regression model specification. This implies that no one approach is ideal, and 
the choice of statistical method for estimating cost-effectiveness parameters from 
patient-level observational data can contribute to structural uncertainty (Bojke et al., 
2009, Jackson et al., 2011). This type of structural uncertainty can be incorporated in 
CEA, by considering the impact of choosing alternative statistical methods on the 
estimated cost-effectiveness. In some cases structural uncertainty can be quantitatively 
incorporated in the analysis, for example using Bayesian model averaging for weighting 
regression models according to some measure of model adequacy (Jackson et al., 2011). 
Another approach, that can quantify the uncertainty due to possible violations of the 
unconfoundedness assumption, is calculating bounds around the estimated treatment 
effect, using Rosenbaum’s method of sensitivity analysis (Rosenbaum, 2002).  A more 
general approach is to repeat the analysis with alternative assumptions and carefully 
report and interpret their impact on the cost-effectiveness results. An example is 
provided by Polsky and Basu (2006) who report results obtained with regression, 
alongside with PS matching and IV methods.  The critical appraisal tool, developed in 
research paper 1, provides guidance on addressing structural uncertainty from the choice 
of the statistical method to address selection bias in CEA.  
2.4.5 Summary: underlying assumptions of statistical methods currently 
recommended to address selection bias in CEA 
This section reviewed the main assumptions behind statistical methods currently 
proposed for addressing selection bias in CEA. These assumptions include:  
1. Unconfoundedness. 
2. When using IV estimation, the IV only influences the endpoint through the 
treatment. 
3. Good overlap between covariate distributions of the treatment groups. 
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4. Correct specification of the endpoint regression model. 
5. Correct specification of the PS model.  
The critical appraisal tool, developed and applied in research paper 1, provides detailed 
guidance on how these assumptions can be assessed for CEA that use patient-level 
observational data, and gives guidance on how structural uncertainty from the choice of 
statistical method can be acknowledged.  
In this conceptual review, I found that in CEA, some of these assumptions are unlikely 
to hold. For example, while IV methods can potentially handle selection bias due to 
both observed and unobserved confounding, finding an appropriate IV can be 
challenging for CEA (Polsky and Basu, 2006).  While in health economics, genetic 
variation has been recently proposed as a type of valid instrument (Mullahy, 2011), its 
appropriateness for CEA has not been investigated.  This thesis therefore considers 
methods that rely on the unconfoundedness assumption. 
For these methods, including regression, PS matching and IPTW, in realistic 
circumstances of CEA, it is expected that three main challenges will prevail:   
misspecification of the endpoint regression model, misspecification of PS, and poor 
overlap.  The previous sections reviewed the expected performance of these methods 
under realistic circumstances. This is summarised in Table 2.1.   
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Table 2.1 - The expected performance of currently recommended methods, under realistic 
circumstances in CEA 
 Misspecification  
of endpoint 
regression model 
Misspecification of PS Poor overlap 
    
Regression Possible bias and 
inefficiency. 
 
Not relevant. Performance depends on 
correct specification of 
endpoint model.  
If misspecified, poor overlap 
magnifies bias. 
 
PS 
matching 
Not relevant. Possible bias and 
inefficiency. 
PS makes overlap explicitly 
testable. If weak overlap, 
treated observations 
might have to be dropped, 
alternatively bad quality 
matches, leading to bias and 
inefficiency.  
 
IPTW Not relevant.  Possible bias and 
inefficiency. More 
sensitive to 
misspecification than 
matching. 
 
Unstable IPT weights, bias 
and inefficiency.  
In the systematic review of research paper 1, I find that most applied CEA used 
regression and matching methods, including exact matching and PS matching. The 
review also revealed that the main underlying assumptions of these methods were not 
appropriately assessed.  This motivates the consideration of alternative statistical 
methods for addressing selection bias in CEA, which rely on less restrictive 
assumptions. The following sections review these methods. 
2.5 Statistical approaches identified in the general causal 
inference literature that have the potential to reduce selection 
bias in CEA  
In this section, I consider further statistical methods that, based on my conceptual 
literature review, were deemed promising for addressing selection bias in CEA. Each of 
these methods has the potential to make more plausible underlying assumptions in the 
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CEA context, than the methods currently recommended for CEA. Genetic Matching 
relaxes the assumption of the correctly specified PS model, by aiming to directly 
maximise covariate balance, using machine learning. Double-robust methods and 
regression-adjusted matching exploit information from the endpoint regression and the 
PS models, and can be unbiased even if one of these models is misspecified. I also 
consider machine learning approaches for estimating the PS and the endpoints, which 
relax the assumption of knowing the correctly specified, fixed parametric models. 
2.5.1 Genetic Matching 
Genetic Matching (GM) is a multivariate matching approach whose explicit aim is to 
optimise covariate balance (Diamond and Sekhon, 2012, Ramsahai et al., 2011, Sekhon, 
2011, Sekhon and Grieve, 2011). GM extends standard PS matching in two ways. First, 
instead of the manual process of modifying the PS and re-assessing covariate balance, 
GM harnesses an automated search algorithm that iteratively checks balance on 
observed confounders, and directs the search towards those matches that optimise 
balance (Diamond and Sekhon, 2012, Sekhon, 2011). Secondly, the GM algorithm can 
maximise covariate balance by matching on individual covariates as well as the PS.  
GM is a multivariate matching method that uses a generalised version of Mahalanobis 
distance (MD) metric.  The MD between any two column vectors (here representing the 
covariate values of a treated and a control individual) is:  
𝑀𝐷(𝑥𝑖 , 𝑥𝑗) = {(𝑥𝑖−𝑥𝑗)
𝑇
𝑆−1(𝑥𝑖−𝑥𝑗)}
1
2
 
, where S is the sample covariance matrix of 𝑥.  The distance metric for GM contains an 
extra weight 𝑊, with dimensions of a  𝑘 × 𝑥 matrix with  𝑘 free parameters in the 
diagonal, where k is the number of covariates: 
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𝐺𝑀𝐷(𝑥𝑖 , 𝑥𝑗) = {(𝑥𝑖−𝑥𝑗)
𝑇
(𝑆−1/2)
𝑇
𝑊𝑆−1/2(𝑥𝑖−𝑥𝑗)}
1
2
 
The algorithm chooses the free parameters of the  W matrix based on a loss function 
which minimises the imbalance between the covariate distributions of the matched 
treated and control groups. To measure imbalance, paired t-tests assess the equality of 
the means and Kolmogorov-Smirnov (KS) distributional tests assess covariate balance 
across the whole distribution. Using the optimal W matrix, matched pairs are selected, 
for example performing 1:1 matching, and the matching estimator can be obtained as 
described by equation (3).   
As a default, the variables that receive the highest weight in the loss function are those 
that have the worse balance at each stage of the optimisation process. However, a 
researcher might want to ensure that good balance is achieved on a subset of covariates 
designated as “high priority”.  For example, prior clinical evidence might indicate that a 
covariate is particularly prognostic for the endpoint.  GM can be tailored to prioritise  
achieving covariate balance on such high priority variables (Ramsahai et al., 2011), by 
modifying the loss function.  The ability of GM to reduce bias hence relies on the 
correct specification of the loss function.  
While it is an option to use the estimated PS in the matching process, GM does not rely 
on knowing the correct PS. Sekhon and Grieve (2011) report that when the PS is 
misspecified, GM can improve covariate balance, and reduce bias and variability in the 
cost-effectiveness estimates. For subgroup analysis, the GM algorithm can be modified 
to maximise balance for each subgroup.   
A challenge GM shares with other multivariate matching methods is that matching on a 
high dimensional covariate vector can lead to finite sample bias and loss of precision 
(Abadie and Imbens, 2006a). This can be of particular concern when reporting cost-
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effectiveness results by subgroup as sample sizes can be relatively small.  GM has not 
been considered for subgroup analysis in CEA before, nor compared to alternatives 
other than PS matching. 
2.5.2 Approaches that combine the PS with regression for the endpoints 
Some commentators raise doubts about regression approaches, where model selection 
can be influenced by its consequences for the estimated treatment effects (Rubin, 2008, 
Rubin, 2007, Ho et al., 2007). In contrast, PS methods do not require information on the 
endpoint, and can be regarded as more objective.  However, if some confounders are 
highly prognostic for the endpoint, even small imbalances that remain in these 
covariates after matching can translate into large biases in the estimated treatment 
effects. PS methods alone cannot formally take into account information on the 
confounder-endpoint relationship (Stuart, 2010). In CEA, where selection bias needs to 
be addressed for both the cost and the effectiveness endpoints, the PS might balance the 
most important confounders for one endpoint, but not for the other, leading to bias. It is 
recommended that PS and other matching methods form the design stage of an 
observational study, and are followed by regression modelling of the endpoint (Polsky 
and Basu, 2006, Rubin, 1973, Imbens and Wooldridge, 2009a, Rubin, 2007). The 
following sections describe two combined approaches: double-robust methods, and 
regression-adjusted matching. 
Double-robust methods 
Double-robust (DR) methods, proposed by Robins and colleagues (Robins et al., 1995, 
Bang and Robins, 2005, Robins et al., 2007) combine models for the PS and for the 
endpoint, with most implementations using the PS as IPT weights (Kang and Schafer, 
2007b). The distinctive property of DR estimators is that they are consistent if either 
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(but not necessarily both) the PS or the endpoint regression model is correctly specified. 
If both components are correct, the DR estimator can be a semi-parametric efficient 
estimator (Robins et al., 2007). 
 In the context of CEA, DR estimators require specifying a model for both the cost and 
the effectiveness endpoints, as well as for the PS. If treatment effect estimates for 
subgroups are required, treatment-covariate interactions can be included in the 
regression models. DR methods have been proposed for addressing censoring (Pan and 
Zeng, 2011, Bang and Tsiatis, 2000), or selection bias in cost analyses (Basu et al., 
2011), but have not been considered  for addressing selection bias in CEA. Below I 
review two DR methods that are commonly used in the causal inference literature, 
augmented IPTW (AIPTW) and weighted regression. I also describe a recently 
proposed DR method, targeted maximum likelihood estimation (TMLE). 
Commonly used DR methods  
 AIPTW (Robins et al., 1994, Basu et al., 2011) weights residuals from a regression 
model with the IPT weights. The AIPTW estimator is 
?̂?𝑘,𝐴𝐼𝑃𝑇𝑊  
∑ 𝑡𝑖𝑤𝑖(𝑌𝑖,𝑘 − ?̂?𝑖,𝑘(𝑥𝑖))  
𝑛
𝑖=1
∑ 𝑡𝑖𝑤𝑖  
𝑛
𝑖=1
−
∑ (1 − 𝑡𝑖)𝑤𝑖(𝑌𝑖,𝑘 − ?̂?𝑖,𝑘(𝑥𝑖))  
𝑛
𝑖=1
∑ (1 − 𝑡𝑖)𝑤𝑖  
𝑛
𝑖=1
+ 
1
𝑛
∑ {?̂?𝑖,𝑘(𝑥𝑖, 𝑡𝑖 = 1) − ?̂?𝑖,𝑘(𝑥𝑖, 𝑡𝑖 = 0)}
𝑛
𝑖=1 , 
where ?̂?𝑖,𝑘(. ) is the predicted endpoint from a regression model, for example from a 
GLM defined in equation (1), and 𝑤𝑖 is the IPT weight, defined in equation (5). 
An alternative is the weighted regression estimator (Freedman and Berk, 2008, Kang 
and Schafer, 2007a), which weights the endpoint regression, for example a GLM, with 
𝑤𝑖 (Freedman and Berk, 2008, Kang and Schafer, 2007a).  ATEs can be obtained using 
the method of recycled predictions, 
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?̂?𝑘,𝑤𝑟𝑒𝑔
1
𝑛
∑{?̂?𝑖,𝑘,𝑤𝑟𝑒𝑔(𝑥𝑖,, 𝑡𝑖 = 1) − ?̂?𝑖,𝑘,𝑤𝑟𝑒𝑔(𝑥𝑖,, 𝑡𝑖 = 0)},
𝑛
𝑖=1
 
where  ?̂?𝑘,𝑤𝑟𝑒𝑔(. ) is the prediction from a weighted regression. 
Due to the DR property, these methods are consistent even if one of the PS or the 
regression model are misspecified. Under circumstances of poor overlap, in theory, a 
correctly specified regression can help with extrapolation (Petersen et al., 2010), hence 
can reduce bias compared to using IPTW alone. DR methods can also  increase 
efficiency, because using the predicted  endpoint can stabilise weights (Glynn and 
Quinn, 2010).   
In realistic settings, such as when there is poor overlap and the PS and the endpoint 
models are misspecified, DR methods can provide biased and inefficient estimates of 
ATEs (Kang and Schafer, 2007a, Porter et al., 2011, Freedman and Berk, 2008, Basu et 
al., 2011).  An ongoing debate discusses the relative merits of different DR estimators 
under these circumstances (Porter et al., 2011, van der Laan and Gruber, 2010, Robins 
et al., 2007). It has been suggested that DR estimators should have a “boundedness 
property”:  they should respect the known bounds of the endpoint; so that the estimated 
parameter will always fall within the parameter space, i.e. the realistic range of values 
for that parameter (Robins et al., 2007, Rotnitzky et al., 2012). A  recently proposed DR 
method , targeted maximum likelihood estimation, can have this boundedness property 
(Gruber and van der Laan, 2010a, Gruber and van der Laan, 2012a).  
Targeted maximum likelihood estimation  
While standard maximum likelihood estimation aims to find parameter values that 
maximise the likelihood function for the whole data, targeted maximum likelihood 
estimation (TMLE) is concerned with a particular feature of the distribution such as the 
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ATE  (van der Laan and Rubin, 2006, Moore and van der Laan, 2009). Maximising a 
global likelihood function may not yield the least biased estimate of the target 
parameter, so TMLE is designed to target the initial estimate so as to reduce bias in the 
estimate of the parameter of interest. Performing TMLE involves two stages  (Gruber 
and van der Laan, 2012b). In the first stage, an initial estimate of the conditional mean 
of 𝑌𝑖 , given 𝑡𝑖 and 𝑥𝑖  , is obtained. In practice, this involves using a regression approach 
to predict the expected potential outcomes conditional on the observed confounders, 
?̂?𝑖,𝑘(𝑥𝑖, 𝑡𝑖 = 0) and ?̂?𝑖,𝑘(𝑥𝑖, 𝑡𝑖 = 1). 
In the second stage, these initial estimates of the regression functions for the potential 
outcomes are fluctuated, exploiting the information in the treatment assignment 
mechanism, using  ?̂?, the estimated PS. For the ATE, the fluctuation corresponds to 
extending the parametric regression model for 𝑌𝑖,𝑘 with “clever covariates” (ℎ), which 
are defined similarly to the IPT weights: 
ℎ0(𝑡, 𝑥) =
1 − 𝑡𝑖
1 − 𝑝𝑖
 
ℎ1(𝑡, 𝑥) =
𝑡𝑖
𝑝𝑖
 
For continuous endpoints, it is recommended (Gruber and van der Laan, 2012a, Gruber 
and van der Laan, 2010a) that known bounds of the endpoint are exploited, by rescaling  
𝑌 to between 0 and 1, to ensure that TMLE has the boundedness property. Then the 
fluctuation can be performed on the logistic scale: logistic regressions are fitted with the 
transformed endpoint on the left hand side, using the initial prediction as an offset, and 
the clever covariates as regressors. This regression can be interpreted as explaining the 
residual variability of the predicted endpoint, using information from the treatment 
assignment mechanism. The resulting targeted estimates of the expected potential 
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outcomes, ?̂?1𝑖,𝑘(𝑥𝑖, 𝑡𝑖 = 0) and ?̂?
1
𝑖,𝑘
(𝑥𝑖, 𝑡𝑖 = 1) are used in the G-computation formula 
to obtain the TMLE estimator: 
?̂?𝑘,𝑇𝑀𝐿𝐸 =
1
𝑛
∑ {μ̂1
i,k
(𝑥𝑖,, 𝑡𝑖 = 1) − μ̂
1
i,k
(𝑥𝑖,, 𝑡𝑖 = 0)},               
𝑛
𝑖=1
 
TMLE has the property of double-robustness, and if both  components are correct, it 
reaches the semi-parametric efficiency bound (van der Laan, 2010). As any DR method, 
TMLE can be biased if both the endpoint and the PS model are misspecified, and can be 
sensitive to unstable IPT weights when overlap is poor (Porter et al., 2011).  However, 
TMLE was demonstrated to report relatively  low bias compared to other DR methods 
when machine learning techniques were used to obtain the initial estimate of the 
endpoint, and to estimate the PS (Porter et al., 2011).  
TMLE has not been considered in CEA before. The method has particular appeal for 
estimating treatment effects on data where known bounds can be exploited, for example 
with common HRQoL endpoints, where distributions are bounded at small negative 
values and 1, or cost data that is typically bounded at 0.  Standard errors can be 
estimated using the influence curve (van der Laan, 2010), but also with the non-
parametric bootstrap. The latter method can be used for any DR method including 
AIPTW and weighted regression, and can maintain the correlation between the 
incremental cost and effectiveness parameters.  
Regression-adjusted matching methods 
The causal inference literature generally recommends that matching is followed by 
regression adjustment (Rubin, 1973, Rubin and Thomas, 2000, Abadie and Imbens, 
2006a). The idea is similar to regression-adjustment in randomised trials: regression is 
used to “clean up” imbalances between treatment groups after matching (Stuart, 2010). 
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Here, I review two implementations: matching as non-parametric pre-processing (Ho et 
al., 2007) and bias-corrected matching (Abadie et al., 2004, Abadie and Imbens, 2011). 
Matching as non-parametric pre-processing 
Ho et al. (2007) proposes undertaking matching - for example PS matching or GM - as 
the first step of the analysis, and then use the frequency weights from the matching to 
weight endpoint regression models, for example GLMs. Using this approach, the 
regression-adjusted matching estimator (Hill and Reiter, 2005)  of the ATEs for each 
endpoint can be obtained as:  
?̂?𝑘,𝑟𝑒𝑔−𝑚𝑎𝑡𝑐ℎ =
1
𝑛
∑{?̂?𝑖,𝑘,𝑟𝑒𝑔𝑚𝑎𝑡𝑐ℎ(𝑥𝑖,, 𝑡𝑖 = 1) − ?̂?𝑖,𝑘,𝑟𝑒𝑔𝑚𝑎𝑡𝑐ℎ(𝑥𝑖,, 𝑡𝑖 = 0)},   
𝑛
𝑖=1
 
where  ?̂?𝑖,𝑘,𝑟𝑒𝑔𝑚𝑎𝑡𝑐ℎ(. )  are the predicted potential outcomes obtained from applying 
regression models on the matched data. 
Regression-adjusted matching is expected to reduce finite sample bias and increase 
efficiency compared to matching alone (Hill and Reiter, 2005, Ho et al., 2007).  
Applying a regression model with treatment by covariate interactions can also facilitate 
hypothesis testing for differences between treatment effects among subgroups of 
interest.  This approach can reduce the sensitivity of the estimated ATEs to the 
specification of the endpoint model (Ho et al., 2007). In CEA, regression-adjustment 
has been proposed after matching in CEA, in order to reduce conditional bias and to test 
the robustness of results obtained after matching (Sekhon and Grieve, 2011). Standard 
errors and confidence intervals of cost-effectiveness estimates can be obtained 
conditional on the matched data (Ho et al., 2007). No guidance on the implementation 
of this approach has been provided for CEA, nor has its performance been compared 
with alternative methods.  
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Bias-corrected matching 
Bias-corrected matching (BCM) (Abadie et al., 2004, Abadie and Imbens, 2011) adjusts 
the imputed potential outcome with the difference in the predicted outcome that can be 
attributed  to covariate imbalances between the matched pairs. The predicted potential 
outcomes are obtained using regression models of the endpoint on covariates, stratified 
by treatment assignment. The bias-corrected predictions of the potential outcomes are: 
?̂?(0, 𝑥𝑖) = { 1
𝑀
𝑌𝑖,𝑘
∑ 𝑌𝑗,𝑘 + ?̂?𝑖,𝑘(𝑥𝑖,, 𝑡𝑖 = 0) − ?̂?𝑖,𝑘(𝑥𝑗,, 𝑡𝑖 = 0)𝑗𝜖𝜁𝑀(𝑖)     
if  𝑡𝑖 = 0
if 𝑡𝑖 = 1
  , 
?̂?(1, 𝑥𝑖) = {
1
𝑀
∑ 𝑌𝑗,𝑘 + ?̂?𝑖,𝑘(𝑥𝑖,, 𝑡𝑖 = 1) − ?̂?𝑖,𝑘(𝑥𝑗,, 𝑡𝑖 = 1)𝑗𝜖𝜁𝑀(𝑖)
𝑌𝑖,𝑘     
if  𝑡𝑖 = 0
if  𝑡𝑖 = 1
  . 
For example, for an individual 𝑖 who received control, the imputed potential outcome 
under treatment is the average outcome of its 𝑀 closest matches from the treatment 
group (indexed by 𝑗), adjusted with the difference between the predicted outcomes 
under treatment, when covariate values are set to those of its own values, 
?̂?𝑖,𝑘(𝑥𝑖,, 𝑡𝑖 = 1) and the values of the match , ?̂?𝑖,𝑘(𝑥𝑗,, 𝑡𝑖 = 1). The corresponding 
estimator, analogously to the PS matching estimator, is the mean of the estimated 
individual-level treatment effects: 
?̂?𝑘,𝐵𝐶𝑀 =
1
𝑛
∑{?̂?(1, 𝑥𝑖) − ?̂?(0, 𝑥𝑖)}
𝑛
𝑖=1
 
BCM is consistent if ?̂?𝑖,𝑘(𝑥, 0)  and ?̂?𝑖,𝑘(𝑥, 1) are consistent estimators for the potential 
outcomes (Abadie and Imbens, 2011). It has been shown that for reducing bias, the 
correct specification of the regression model is not essential, for example, for moderate 
nonlinearities in the response surface, adjustment even with a linear model can remove 
most bias (Rubin, 1973, Rubin and Thomas, 2000, Abadie and Imbens, 2011, Busso et 
al., 2011). CEA typically has highly nonlinear response surfaces, and so adjustment 
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with linear models might be insufficient. One approach would be to consider non-
parametric regression methods, such as series estimation which have been also 
recommended for bias-adjustment (Abadie and Imbens, 2011). However, such flexible 
approaches have not been considered in applied studies or simulations that implement 
BCM (Busso et al., 2011, Abadie and Imbens, 2011). In scenarios relevant to CEA, for 
example when overlap is poor, BCM has been shown to outperform reweighting 
approaches such as IPTW and DR methods (Busso et al., 2011). BCM has not been 
considered for CEA before. 
2.5.3 Machine learning estimation for the PS and the endpoint regression 
Each of the methods reviewed in the previous sections can use models for the costs and 
effectiveness endpoints, or a model for the PS.  Single methods - for example, 
regression, or PS matching - can use these models to estimate ATEs, or they can be 
combined, for example in DR methods or in regression-adjusted matching. GM extends 
PS matching, by using a machine learning algorithm to directly maximise balance.  In 
general, machine learning covers a wide range of classification and prediction 
algorithms (Westreich et al., 2010, Austin, 2012).  Unlike approaches that assume a 
fixed statistical model, for example a GLM with a log link, machine learning aims to 
extract the relationship between the endpoint and covariates through a learning 
algorithm, without choosing one specific model a priori (Lee et al., 2010). These 
approaches can be used to estimate the PS (Westreich et al., 2010), and the endpoint 
regression functions (Austin, 2012), and are reviewed in the next section.   
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Machine learning estimation of the PS 
A common approach to PS estimation is to use logistic regression models without 
interaction or higher order terms. Assumptions behind the logistic regression, for 
example the linearity of the relationship between covariates and the logit, are rarely 
assessed (Westreich et al., 2010). More flexible modelling approaches, such as series 
regression estimation (Hirano et al., 2003), and methods from the machine learning 
literature (Westreich et al., 2010), can increase the chances  of correctly specifying the 
PS.  Machine learning methods that can be used for PS modelling, include decision 
trees, neural networks, linear classifiers and boosting methods (Austin, 2012, Lee et al., 
2010, van der Laan, 2007). While these algorithms mostly choose an estimated PS 
based on the predictive performance of a model for the binary indicator of treatment 
receipt, the ultimate test of the specification is whether the PS balances the distribution 
of  potential confounders between the treatment groups (Stuart, 2010).  
This thesis considers boosted classification and regression trees (CART), which can 
reduce bias in the estimated ATE when compared to using a misspecified logistic 
regression, and also compared to alternative machine learning approaches (Lee et al., 
2010). The algorithm fits regression trees on random subsets of the data, and in each 
iteration, the data points which were incorrectly specified with the previous trees 
receive greater priority. The algorithm can be specified to stop when the best balance - 
measured as mean standardised differences or KS tests - is achieved (McCaffrey et al., 
2004, Lee et al., 2010). As well as specifying a balance measure, tuning parameters, 
such as the number of iterations, depth of interactions or shrinkage parameters need to 
be chosen.   
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Machine learning estimation of the endpoint regression function 
For estimating treatment effects, the expected potential outcomes need to be predicted 
under treated and control states, using regression functions of the endpoint. Here, 
recommended machine learning methods include bagged regression trees, random 
forests or boosted regression trees (Austin, 2012); and the “super learning” algorithm 
(van der Laan, 2007), considered for this thesis.  
Super learning uses a collection of prediction algorithms pre-selected by the user, 
potentially exploiting subject-matter knowledge of the data-generating mechanism for 
the endpoint. For example, for CEA, if a multiplicative relationship between the 
covariates and the cost endpoint is likely, a GLM with log link can be included among 
the prediction algorithms. The super learner algorithm uses cross-validation to select a 
weighted combination of estimates reported by the prediction procedures (Polley and 
van der Laan, 2010). The selected combination is proposed to be asymptotically optimal 
(van der Laan and Dudoit., 2003): if the correct model is among the candidates, the 
algorithm is expected to select it. The predicted potential outcomes can then be used in a 
regression estimator (see equation 2) or in combined methods such as TMLE (Porter et 
al., 2011) or BCM.   
There is little known about the performance of machine learning regression estimators 
when there is poor overlap between covariate distributions. It is expected that the 
increased flexibility of these methods can reduce model misspecification, as well as 
reduce bias from extrapolation with an incorrect model (Porter et al., 2011). A drawback 
of machine learning methods is computational time, especially if the non-parametric 
bootstrap is used for calculating standard errors for estimated treatment effects (Austin, 
2012).  
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2.5.4 Summary: promising methods from the causal inference literature, for 
addressing selection bias in CEA 
The objective of this section was to review promising statistical methods from the 
general causal inference literature which can be used in CEA to address selection bias, 
and to evaluate their appropriateness for CEA. Beyond the approaches recommended by 
the methods literature in CEA, such as regression, PS matching and IPTW, the 
following methods were deemed promising for CEA: GM, DR methods and regression-
adjusted matching. I also considered machine learning methods for estimating the PS 
and the endpoint regression function.  Each of these methods relies on the assumptions 
of unconfoundedness and good overlap. 
This section investigated these methods in terms of the challenges identified for CEA, 
such as the specification of the endpoint regression models and the PS, and when there 
is poor overlap.  I found that these methods can make less restrictive assumptions than 
previously proposed methods. Table 2.2 summarises the expected relative performance 
of these methods under realistic circumstances in CEA.  
GM does not require a correctly specified PS, however the analyst does need to specify 
a loss function for the machine learning algorithm. This involves selecting those 
potential confounders that the algorithm is specified to balance. This choice of 
confounders also needs to be made when PS matching or IPTW is used for creating 
balance (Stuart, 2010). GM, similarly to PS matching, can result in poor quality 
matches, hence bias and high variability if overlap is weak. Combined methods can 
mitigate the disadvantages of either PS or regression methods: DR methods can be 
unbiased if either one of the PS or regression models is correct, but can be sensitive to 
unstable weights if overlap is poor. Regression-adjusted matching can decrease the 
sensitivity of estimates to the misspecification of the regression model, due to increased 
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balance; however can be less efficient than using regression. Machine learning 
estimation methods for the PS and the endpoints, while not requiring a correctly 
specified fixed parametric model, can be sensitive to subjective choices such as the 
choice of prediction algorithms and tuning parameters. 
2.6 Identifying research gaps in the literature comparing 
alternative statistical methods for addressing selection bias in 
CEA  
In the conceptual review, I identified a range of alternative statistical methods that are 
promising in addressing selection bias in CEA.  While statistical theory offers guidance 
on how methods perform when their underlying assumptions fail, an important 
challenge for the applied researcher is to choose the least biased and most efficient  
estimator under realistic circumstances, such as not knowing the true statistical models 
that generate the endpoint and the treatment assignment.  
The results of current comparative work in the methodology literature might not 
translate directly to CEA. Therefore new simulation studies, which incorporate 
important features of CEA, such as correlated cost and effectiveness endpoints and 
nonlinear covariate-endpoint relationships, are needed. 
When cost-effectiveness for patient subgroups needs to be estimated using 
observational data, regression methods, recommended for subgroup analysis in CEA 
(Nixon and Thompson, 2005), can be sensitive to the specification of the regression 
model. Methods that use the PS to reduce selection bias are therefore of interest to 
estimate subgroup-effects. IPTW has particular appeal for subgroup analysis, where due 
to reduced sample sizes, precision can be a concern: if the PS is correctly specified, 
IPTW can provide more precise estimates of treatment effects than matching (Hirano et 
al., 2003).   
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Table 2.2 - The expected performance of proposed methods, under realistic circumstances 
in CEA 
 Misspecification 
of the endpoint1 
Misspecification of the PS1 Poor overlap 
GM Not relevant. Does not matter if loss 
function correctly specified. 
 
Treated observations 
might have to be dropped, 
or the quality of matches 
is bad, leading to bias and 
inefficiency. 
 
DR  
methods 
Consistent 
estimates if the 
PS is correct.  
Consistent estimates if the 
endpoint regression model is 
correct. 
 
 
A correctly specified 
regression can help with 
extrapolation (Petersen et 
al., 2010). 
In practice, with unstable 
weights, bias and 
inefficiency likely. 
 
Regression-
adjusted 
matching 
Matching can 
reduce sensitivity 
to model 
misspecification. 
Regression adjustment can 
correct for imbalance and 
bias due to misspecified PS. 
 
Bias and inefficiency. 
However, bias due to 
model misspecification 
can be reduced by 
increased balance after 
matching. 
 
Machine 
learning 
estimation 
of PS 
 
 
Not relevant. Reduces chance of 
misspecification. Can be 
sensitive to the choice of 
algorithm and tuning 
parameters. 
 
Can provide remedy 
against unstable IPT 
weights (Lee et al., 2010). 
Machine 
learning 
estimation 
of the 
endpoint  
Reduces chance 
of 
misspecification.  
Can be sensitive 
to the choice of 
prediction 
algorithms. 
 
Not relevant. Reduced misspecification 
can reduce bias due to 
extrapolation (Porter et 
al., 2011).  
    
Notes: 1 Misspecification is defined as functional form misspecification, for example using the incorrect 
link function or omitting higher order terms from the linear predictor. 
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However IPTW has not been considered in CEA for addressing selection bias. GM has 
been proposed for CEA (Grieve et al., 2008), and was compared to PS matching 
(Sekhon and Grieve, 2011). However GM has not been compared to IPTW in the 
general methodological literature before, and none of the PS or matching approaches 
have been considered for subgroup analysis in CEA.    
While methodological guidance in CEA propose several ways of using the PS to create 
balance (Polsky and Basu, 2006, Mitra and Indurkhya, 2005, Manca and Austin, 2008), 
these studies did not consider the combination of the PS with regression models for the 
endpoint. Previous findings on the relative merits of alternative DR methods (Kang and 
Schafer, 2007a, Porter et al., 2011) may not translate to the CEA setting, where models 
for both costs (Jones, 2010) and health outcomes (Basu and Manca, 2011) may be 
required. While regression adjustment post matching has been proposed as a sensitivity 
analysis in the CEA literature (e.g. Sekhon and Grieve, 2011), the performance of this 
method under model misspecification has not been considered in a CEA setting before.  
 The evidence on the relative performance of regression-adjusted matching and DR 
methods is limited in the general causal inference literature.  A recent working paper 
(Busso et al., 2011) compared BCM with IPTW and a DR method, across a range of 
scenarios, including poor overlap. However,  BCM has not been  compared to TMLE,  
which has been proposed to outperform alternative DR methods under circumstances of 
model misspecification and poor overlap (Porter et al., 2011, Gruber and van der Laan, 
2010b). 
Both TMLE and BCM can be coupled with machine learning estimation of the endpoint 
regression function and the PS. This can be a promising approach for estimating 
parameters for CEA, such as treatment effects on HRQoL data, where specifying the  
endpoint regression model can be challenging (Basu and Manca, 2011). There are no 
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previous studies that implement BCM with machine learning, and the simulation studies 
which consider TMLE with machine learning (Porter et al., 2011, Gruber and van der 
Laan, 2010b), did not consider typical circumstances of HRQoL data, such as spikes in 
the distribution of the endpoint.  
To conclude, a number of gaps were identified in the methodological literature of CEA 
that considers statistical methods to address selection bias: 
1. PS methods such as PS matching and IPTW have not been considered for 
estimating subgroup-effects in CEA.  
2. GM has not been compared to IPTW before in the general methodological 
literature.  
3. DR methods and regression-adjusted matching have not been considered in the 
context of CEA. 
4. TMLE and regression-adjusted matching have not been compared in the 
methodological literature. 
5. Machine learning estimation methods have not been considered for estimating 
parameters for CEA before. 
The research papers included in this thesis (chapters 3 to 6) will aim to address these 
gaps, using simulations and case studies (see Table 2.3).  
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Table 2.3 - Summary of research papers to compare alternative statistical methods for 
addressing selection bias in CEA 
 Context Main 
comparators 
Main 
challenges 
considered  
Previous 
methodological 
papers 
extended 
Gap 
addressed 
 
Research 
paper 2 
 
Subgroup 
analysis in 
CEA 
 
IPTW, PS 
matching, 
GM 
 
Misspecification 
of the PS; 
unstable IPT 
weights 
 
 
Sekhon and 
Grieve, 2011  
 
1,2 
Research 
paper 3 
CEA Common DR 
methods,  
regression-
adjusted PS 
matching  
Misspecification 
of the PS, cost 
and 
effectiveness 
endpoints;  
unstable IPT 
weights 
 
Basu et al., 
2011 
Kang and 
Schafer, 2007 
 
 
3 
Research 
paper 4  
Estimating 
incremental 
effectiveness 
TMLE, BCM, 
with PS and 
endpoint 
estimated 
using (1) 
fixed 
parametric, 
(2) machine 
learning 
methods 
Misspecification 
of PS and 
HRQoL  
endpoint; 
poor overlap 
Basu and 
Manca, 2011;  
Busso et al., 
2011; 
Porter et al., 
2011; 
Lee et al., 2010 
 
4,5 
 
2.7 Discussion 
This chapter had four interlinked objectives. First, to review methodological guidance 
on the statistical methods for addressing selection bias in CEA that use patient-level 
observational data and to describe statistical challenges that arise when using these 
methods.  Second, to describe the main underlying assumptions of statistical methods 
previously recommended for addressing selection bias in CEA. Third, to identify further 
promising statistical methods from the general causal inference. Fourth, to identify gaps 
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in the methodological literature on the relative performance of statistical methods for 
addressing selection bias in CEA.  
CEA methodological guidance recommended that regression, PS methods and IV 
estimation are considered to address selection bias.  IV methods can potentially reduce 
selection bias due to both observed and unobserved confounding, however they make 
further untestable assumptions that may be unrealistic in a CEA setting (Polsky and 
Basu, 2006). Hence methods that assume no unobserved confounding need to be 
considered for CEA. These methods make the following further assumptions: 
1. Good overlap between the covariate distributions. 
2. Correctly specifying regression models for cost and effectiveness endpoints. 
3. Correctly specifying the PS model. 
The conceptual review found that under realistic circumstances, these assumptions 
might not be plausible for methods currently recommended for CEA. For example, INB 
regression (Hoch et al., 2002) imposes a linear functional form on the relationships 
between the covariates and the net benefit endpoint. PS, when used for stratification or 
as a covariate in regression  (Manca and Austin, 2008, Mitra and Indurkhya, 2005) has 
been shown to be dominated by alternative PS approaches such as IPTW and PS 
matching (Lunceford and Davidian, 2004). These methods are not further considered for 
this thesis. 
Research paper 1 (chapter 3) uses findings from this conceptual review to give detailed 
guidance on how the plausibility of the underlying assumptions of statistical methods 
can be assessed in CEA.  As this conceptual review highlighted, any statistical method 
relies on assumptions that cannot be directly tested from the data. As the checklist 
presented in research paper 1 highlights, the uncertainty due to the choice of statistical 
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approach needs to be acknowledged as part of a structural uncertainty in the CEA. My 
systematic review appraising published CEA (research paper 1) found that most studies 
did not appropriately assess the underlying assumptions their statistical methods made. 
Motivated by this finding, this conceptual review identified alternative statistical 
approaches from the causal inference literature that can potentially make less restrictive 
assumptions than previously proposed methods.  
I found that the following alternative approaches held promise for addressing selection 
bias in CEA: GM, DR methods, regression-adjusted matching and machine learning 
estimation approaches for the PS and the endpoint regression. The relative performance 
of these methods is likely to depend on the specific circumstances of the CEA, such as 
the extent to which there is poor overlap or misspecification of the PS or the endpoints. 
There is limited evidence on the relative performance of these methods, and it is 
unknown how these methods would perform when compared to previously proposed 
methods for addressing selection bias, in typical CEA.  
This thesis aims to address these gaps with three research papers. Research paper 2 
compares PS matching, GM and IPTW, for estimating cost-effectiveness for patient 
subgroups. Research paper 3 considers the relative performance of DR methods and 
regression-adjusted matching, for CEA. Research paper 4 considers a recently proposed 
DR method, TMLE, and compares it to BCM, for estimating treatment effects on 
HRQoL data, when fixed parametric models and machine learning techniques are used 
for estimating the PS and the endpoint regression.  
This review focused on methods that can address selection bias in CEA that use patient-
level observational data to estimate incremental parameters of continuous endpoints, 
such as incremental costs or HRQoL. The methods reviewed here can be extended to 
other endpoints such as binary, count or time-to-event data, and different estimands 
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such as odds ratios (Radice et al., 2012, Moore and van der Laan, 2009) and hazard 
ratios (Thompson et al., 2010). The complexities of using these statistical methods for 
estimating alternative parameters are beyond the scope of this review.  
This conceptual review focused on methods that can estimate the effect of a time 
constant, binary treatment. Extending the methods to categorical or continuous 
treatment is possible, for example using the generalised PS (Cole and Frangakis, 2009).  
IPTW and DR methods can also be extended to handle treatment and covariates that 
vary over time (Robins et al., 2000). Such extensions have relevance in CEA which 
need to handle cross-over between treatments, or treatment starting at different time 
points for patients. More generally, these methods can be used in CEA when developing 
input parameters for decision models, for example risk equations which need to account 
for time-varying confounding (Caro et al., 2012). 
This review did not cover some further important statistical challenges in CEA which 
uses patient-level observational data. These include the appropriate analysis of missing 
data and censored endpoints such as survival times or costs. Some of the methods 
reviewed here, for example IPTW and DR methods have more general applicability to 
account for censoring (Willan et al., 2002, Willan et al., 2005, Bang and Tsiatis, 2000) 
and to estimate mean endpoints under missing data (Kang and Schafer, 2007a). 
This review concludes that current methods recommended to address selection bias in 
CEA make assumptions that may not be plausible in practice. Further promising 
statistical methods are available from the general causal inference literature, but there is 
little evidence on their relative merits across settings typically observed in CEA. The 
subsequent chapters provide insights on the relative performance of statistical methods 
that aim to tackle selection bias in CEA that use patient-level observational data, to help 
address the gaps in the methodological literature identified in this chapter. 
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Chapter 3 - Checklist for critical appraisal of statistical 
methods to address selection bias in CEA that use patient-
level observational data 
3.1 Preamble to research paper 1 
Chapter 2 reviewed the current methodological guidance on statistical methods for 
addressing selection bias in CEA, and found that recommended methods make 
important underlying assumptions that may be implausible in typical CEA. General 
checklists and methodological guidelines (Drummond et al., 2005, Glick et al., 2007) do 
not include criteria for assessing the quality of statistical methods for CEA that use 
observational data. Research paper 1 aims to fill this gap in the methodological 
literature, by developing a new checklist to critically appraise statistical methods for 
addressing selection bias in CEA that use patient-level observational data.  
The development of this checklist was informed by the conceptual review (chapter 2), 
and by insights from an expert panel. In order to help a reviewer judge whether a study 
meets the checklist criteria, and to help the analyst to appropriately apply statistical 
methods in CEA, this paper also presents detailed methodological guidance (Appendix 
3.1).  
The checklist is applied in a systematic review of the applied literature, which aims to 
identify which methods are frequently used in applied CEA, and evaluates whether the 
assumptions underlying these methods were appropriately assessed.  Findings from the 
review will inform the choice of statistical methods and simulation scenarios in the 
subsequent empirical work (research papers 2, 3 and 4).  
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Additional page for Question (3) on LSHTM cover sheet form: 
 
The research question for this paper was linked to the ESRC project and identified by 
the principal investigator, RG. I carried out a conceptual review, developed a checklist 
and accompanying methodological guidance for critical appraisal of CEA that use 
observational data, in collaboration with RG. I applied this checklist in a systematic 
review of studies, and interpreted the findings. ZS verified the exclusion criteria of the 
systematic review and conducted a second review by independently appraising 50% of 
the included studies. I wrote the first draft of the manuscript and managed each round of 
comments and suggestions from RG and ZS. All authors read and approved the final 
draft prior to journal submission and inclusion in the dissertation.  
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Abstract  
Many cost-effectiveness analyses (CEAs) use data from observational studies. 
Statistical methods can only address selection bias if they make plausible assumptions. 
No quality assessment tool is available for appraising CEAs that use observational 
studies. We developed a new critical appraisal checklist to assess statistical methods for 
addressing selection bias in CEAs that use observational data.  
The checklist criteria were informed by a conceptual review, and applied in a systematic 
review of economic evaluations. Criteria included whether the study assessed the “no 
unobserved confounding” assumption, overlap of baseline covariates between the 
treatment groups, and the specification of the regression models. The checklist also 
considered structural uncertainty from the choice of statistical approach.  
We found 81 studies that met the inclusion criteria: studies tended to use regression 
(51%), matching on individual covariates (25%) or matching on the propensity score 
(22%). Most studies (77%) did not assess the “no observed confounding”  assumption, 
and few studies (16%) fully considered structural uncertainty from the choice of 
statistical approach. 
We conclude that published CEAs do not assess the main assumptions behind statistical 
methods for addressing selection bias.  This checklist can raise awareness about the 
assumptions behind statistical methods for addressing selection bias and can 
complement existing method guidelines for CEAs. 
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Introduction 
Methodological guidance for cost-effectiveness analyses (CEAs) emphasises the use of 
pragmatic randomised controlled trials (RCTs) (Willan and Briggs, 2006, Glick et al., 
2007), but for many decision problems RCTs are unavailable or insufficient. Hence 
CEAs may use observational studies, for example to provide transition probabilities for 
decision models, or to estimate incremental costs or effectiveness. However, the non-
random selection of patients into treatment can lead to selection bias (Jones and Rice, 
2011). For CEAs where individual patient data (IPD) are available, statistical methods 
such as regression, matching or instrument variable (IV) estimation can address 
selection bias. For these methods to provide unbiased estimates, the underlying 
assumptions must be plausible.  For example, regression and matching assume that 
there is no unobserved confounding (Greenland et al., 1999), regression that the 
endpoint model is correctly specified (Ho et al., 2007), and matching that baseline 
characteristics are balanced after matching (Stuart, 2010). 
In CEA, the choice of method for addressing selection bias can lead to different 
conclusions. For example, after applying regression to adjust for baseline differences, a 
surgical intervention for breast cancer appeared cost-effective, whereas after IV 
estimation, the intervention was dominated  (Polsky and Basu, 2006) (Table 3.1). 
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Table 3.1 - Incremental cost-effectiveness results according to statistical method for 
addressing selection bias: an illustrative example from a study comparing breast 
conserving surgery to mastectomy (Polsky and Basu, 2006). 
 
Covariate adjustment Instrumental variables 
Incremental cost [USD](95%  
CI) 
14,199 (10,279 to 
18,118) 
50,997 (12,879 to 89,114) 
Incremental QALY (95%  CI) 0.12 (0.05 to  0.19) -0.29 (- 0.095 to 0.38) 
ICER (USD) (95%  CI) 
118,325 (70,040 to 
250,000) 
Dominated (150,200 to 
Dominated) 
Abbreviations: USD- US Dollars; QALY, quality adjusted life year; CI, confidence interval. 
 
Critical appraisal tools have been developed for CEAs (Drummond et al., 2005, Philips 
et al., 2006), but there is no tool for assessing the quality of CEAs that use observational 
data; it is currently unknown whether such studies adopt appropriate statistical methods.  
This paper introduces a new checklist for assessing the main assumptions made by 
statistical methods for addressing selection bias. We apply the checklist in a systematic 
review of published CEAs that use observational data.  
Method 
A critical appraisal checklist was developed for assessing whether CEAs used 
appropriate statistical methods for addressing selection bias, and to provide a tool for 
improving the quality of future studies. To inform development of the checklist, we 
undertook a conceptual review of the statistics, econometrics and epidemiology 
literatures (including work published between 1983 and 2011) to identify relevant 
statistical methods for addressing selection bias in CEAs (e.g. Rosenbaum and Rubin, 
1983, Imbens and Wooldridge, 2009a, Stuart, 2010). The approaches judged most 
relevant were regression, matching on the propensity score, matching on individual 
covariates and IV methods (Polsky and Basu, 2006, Jones and Rice, 2011). To inform 
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the development of the checklist (Table 3.2) and accompanying guidance (Appendix 
3.1), the conceptual review identified the main assumptions underlying each method. 
Provisional versions of the checklist were reviewed by a panel of health economists and 
statisticians. Three independent reviewers piloted the tool on 15 studies.  
Assumption of no unobserved confounding 
Regression and matching methods assume “no unobserved confounding”. Under this 
assumption, the allocation of two individuals, who have similar observed characteristics 
but are in different treatment arms, can be thought of as effectively at random 
(Greenland et al., 1999). So for example in the CEA described by Polsky and Basu 
(2006) (and Table 3.1), this assumption implies that after regression adjustment there 
are no differences in the distributions of unobserved confounders between treatment 
arms. Approaches that use longitudinal data such as panel data regression and 
“difference-in-differences” rely on a weaker form of this assumption; they assume that 
changes over time in unobserved confounders are conditionally independent of 
treatment (Imbens and Jeffrey, 2007). 
The assumption of no unobserved confounding cannot be tested (Imbens and 
Wooldridge, 2009a). However, as Question 1a states, studies should assess whether this 
assumption is plausible (Table 3.2).  To meet this criterion a study is required to draw 
on external evidence or expert opinion of the potential influence of observed and 
unobserved baseline covariates on treatment assignment and endpoints (Rubin, 2010). 
Causal diagrams can be useful for defining the structure of such relationships (Pearl, 
2001). 
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Table 3.2 - Checklist for critically appraising statistical methods to address selection bias, 
in estimating incremental costs, effectiveness and cost-effectiveness  
Q1a: Did the study assess the “no unobserved confounding” assumption? 
a) Yes,  for example with causal diagrams informed by external literature 
b) Partially, for example with external literature or expert opinion    
c) No   
d) Not applicable                                                                                
Q1b: Did the study assess the assumption that the IV was valid? 
a) Yes,  for example, with causal diagrams informed by external literature                
b) Partially, for example, with external literature or expert opinion    
c) No   
d) Not applicable                                                                                
Q2: Did the study assess whether the distributions of the baseline covariates overlapped 
between the treatment groups? 
a) Yes, for example, with histograms and standardised differences   
b) Partially, for example, just with standardised differences 
c) No 
d) Not applicable 
 
Q3: Did the study assess the specification of the regression model for                                                                                
        (i.) Health outcomes?  (ii.) Costs? 
     
  
a) Yes, for example, with statistical tests or plots                   
b) Partially, with qualitative arguments 
c) No 
d) Not applicable 
Q4: Was covariate balance assessed after applying a matching method? 
a) Yes, with a measure that considered imbalance 
across different aspects of the distribution 
b) Partially, for example, by assessing mean differences  
c) No    
d) Not applicable                                                                         
Q5: Did the study consider structural uncertainty arising from the choice or specification 
of the statistical method for addressing selection bias? 
a) Yes, the sensitivity of cost-effectiveness  results to the choice of method  
was quantitatively assessed  and interpreted 
b) Partially, for example, by additional statistical analysis but without 
 interpetation, or commentary  with no quantitave assessment 
c) No 
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One way of handling both observed and unobserved confounding is with IV methods 
(Basu et al., 2007, Mullahy, 2011). IV estimation assumes that the instrument only 
influences endpoints through treatment and is independent of the unobserved 
confounders (Hernán and Robins, 2006). Although this assumption is also untestable, 
studies should again assess plausibility, for example with causal diagrams informed by 
expert opinion and evidence from the literature (Joffe and Mindell, 2006) (Question 
1b). For instance in a Mendelian randomisation study where genotype is the proposed 
instrument, causal diagrams may help the assessment of whether genotype only 
influences the endpoint of interest through the treatment (Didelez and Sheehan, 2007). 
 Assumption of good overlap in the distribution of baseline covariates between 
treatment arms 
Question 2 highlights that methods that assume no unobserved confounding also 
assume that there is good overlap in the distributions of baseline covariates between the 
treatment groups (Imbens and Wooldridge, 2009a). Good overlap implies there are no 
baseline characteristics which fully predict treatment status.  With weak overlap, a 
regression model extrapolates beyond the observed covariate data, so unless the model 
is correctly specified, this will lead to biased estimates (Ho et al., 2007). Overlap can be 
assessed by inspecting histograms or density plots (continuous covariates), and by 
reporting standardised differences (categorical or continuous covariates) (Imbens and 
Wooldridge, 2009b), before statistical adjustment takes place. A remedy for weak 
overlap is to constrain the sample to the area of good overlap, but recognising that this 
alters the population of interest (Crump et al., 2009).   
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Assumption that the parametric regression model is correctly specified 
Parametric regression models can only provide unbiased and efficient parameter 
estimates if they are correctly specified.  For unbiased estimates, the model must state 
the true relationship between the covariates and the mean endpoint (Ho et al., 2007). For 
the model to provide the most precise estimates, the probability distribution of the 
endpoint or error terms must be correct. In CEAs, these two elements of correct model 
specification are challenging, especially as it is also important to recognise any 
correlation of costs with health outcomes. Flexible bivariate models have been proposed 
that allow for non-normal distributions, and can improve the precision of the estimates 
(Nixon and Thompson, 2005), but less attention has been given to specifying the correct 
relationship between the covariates and the mean endpoint (Thompson et al., 2006). 
While the true parametric model is always unknown, a study should assess the relative 
fit of alternative models, for example by using likelihood based model diagnostics or 
cross validation  (Jones, 2010, Hill and Miller, 2010). Question 3 of the checklist 
considers whether the study has evaluated the model specification appropriately.  
Assumption that a matching method has balanced the matched samples 
Matching aims to balance treatment and control groups, by creating matched samples 
with similar observed covariate distributions. The estimated propensity score (Pscore) is 
often used as a balancing score (Rosenbaum  and Rubin, 1983). As Question 4 
emphasises, matching methods can only produce unbiased estimates if matching 
balances the distributions of baseline covariates. Hence the appropriate specification test 
is whether the matched samples are balanced (Stuart, 2010). Some balance diagnostics 
such as standardised differences use a comparison of means, but these are insufficient 
for capturing imbalances elsewhere in the covariate distributions (Sekhon and Grieve, 
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2011).  In CEAs, covariates tend to be non-normal, making it important to assess 
balance on the full distributions of the covariates using graphical tools (e.g. quantile-
quantile plots) and nonparametric tests (Stuart, 2010).  
Structural uncertainty from the choice of statistical method for addressing selection 
bias 
Each of the statistical approaches described makes untestable assumptions, which 
implies that no one approach is ideal. The choice of statistical method for estimating 
cost-effectiveness parameters from IPD can therefore contribute to structural 
uncertainty, both when the CEA takes data from a single study and if the estimates are  
used in a decision-model (Jackson et al., 2011). Question 5 considers structural 
uncertainty in the context of addressing selection bias. These criteria assess whether the 
study has considered the impact of choosing alternative methods for addressing 
selection bias, for example by making alternative assumptions about unobserved 
confounders, or assuming different regression model specifications. 
Even if, for example, the study has previously judged that a regression model is 
appropriate, it is still important to assess whether the results are sensitive to alternative 
approaches. The rationale is that even amongst regression models with similar fit, 
results can still be sensitive to the choice of model (Thompson and Nixon 2005). A 
recommended approach for characterising structural uncertainty is to repeat the analysis 
with alternative structural assumptions and carefully report and interpret the impact on 
results.  One way to assess whether results are sensitive to the potential for unobserved 
confounders is to employ “Rosenbaum bounds” (Rosenbaum, 2002). Here, cost-
effectiveness results can be reported according to alternative assumptions about the 
level of unobserved confounding (see Noah et al., 2011).  
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Systematic review of published cost-effectiveness analyses  
A literature search identified published economic evaluations that used observational 
data. The databases searched were MEDLINE, EMBASE, NHS Economic Evaluations 
Database (NEED), and the Health Economic Evaluations Database (HEED) (Appendix 
3.2). Inclusion and exclusion criteria were applied in title, abstract and full text reviews. 
Papers had to be published between 2000-2011, report a full economic evaluation 
(Drummond et al, 2005) that estimated at least one incremental parameter (e.g. 
incremental costs, incremental quality adjusted life years, or an incremental surrogate 
measure such as relative risks) using  observational IPD. The studies had to employ a 
statistical method to address selection bias (Appendix 3.2).  
Title and abstract screening were conducted by one reviewer (NK); a second reviewer 
(ZS) verified exclusion criteria on a random sample of 5% of excluded studies. There 
were no disagreements on the articles excluded. The selected studies were critically 
appraised by the first reviewer. The second reviewer independently appraised a random 
sample of 50% of these papers. The inter-rater reliability of the checklist was good 
(kappa > 0.95), disagreements were resolved by a third reviewer (RG). Pre-specified 
subgroup analyses were defined according to publication year (post 2006 versus 2006 or 
earlier), the observational study’s design (prospective versus retrospective), and journal 
type (health economics or statistics versus other). 
Results 
The literature search yielded 4203 abstracts, 257 papers were selected for full text 
review with data extracted from 81 papers (Figure 3.1). The most common statistical 
method for addressing selection bias was regression (Table 3.3).  
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Figure 3.1. - Flow chart of studies included in the systematic review of published economic 
evaluations 
 
Most studies (77%) did not assess the assumption of “no unobserved confounding” 
(Table 3.4). Both studies using IV methods only partially assessed the validity of the 
instrument. A small minority of regression-based studies fully assessed model 
specification with statistical tests; others gave a partial assessment by citing 
methodological work to justify the model choice. Around half of the matching studies 
assessed covariate balance by comparing means in the matched samples.   
A minority of studies (16%) fully considered structural uncertainty. They reported and 
interpreted cost-effectiveness estimates across different methods (e.g. regression and 
matching); 35% partially assessed structural uncertainty by considering alternative 
model specifications, or by providing a “qualitative assessment” of the potential role of 
unobserved confounders. 
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Structural uncertainty was fully considered by a higher proportion of studies published 
in health economics and statistics journals (30% vs. 13%; p=0.091). For other items any 
differences between subgroups were relatively small.  
 
Table 3.3 - Characteristics of studies included in the review (n=81) 
Primary statistical method to address selection bias  
Regression  Matching on 
the Pscore 
Matching on 
covariates 
Instrumental  
variables 
 
 41 (51%)  18 (22%)   20 (25%)   2 (2%)   
 
Year of publication 
 
2000-2005 
 
2006-2011 
  
 
 36 (44%)   45 (56%)   
 
Journal type 
 
Health 
economics 
Statistics Medical Public health, health 
services. 
Other 
 16 (20%)   1 (1%)   53 (65%)   9 (11%)   2 (3%)  
 
Intervention type 
 
Health services Disease 
management 
Prevention, 
screening 
Substance abuse 
 treatment 
Other 
  11 (14%)    54 (67%)    7 (9%)    6 (7%)   3 (4%)  
 
Design of observational study 
 
Concurrent 
cohort 
Before-after Historic cohort Cross-
sectional 
Case -  
control 
Other 
 41 (51%)   2 (2%)   25 (31%)  2 (2%)  2 (2%)   9 (11%)  
 
Observational data is used to estimate… 
 
Does the CEA use a decision 
model? 
    
Incremental cost 
and effects or 
INB 
Incremental 
effects 1 
Incremental 
cost 2 
Yes No 
54 (67%) 26 (32%) 1 (1%) 12 (15%) 69 (85%) 
Notes: Pscore, propensity score; INB, incremental net benefit; IPD, individual patient data, CEA, cost-
effectiveness analysis 
1 These studies used aggregate estimates of incremental costs, for example, from external literature. 
2 This study used an aggregate estimate of incremental effectiveness from external literature. 
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Table 3.4 - Results of applying the checklist to published CEAs (n=81)  
Q1a. Was the “no unobserved confounding” assumption assessed?1 
Yes Partially 
 1/79 (1%) 
 
 17/79 (22%) 
 
 
Q2. Was the overlap of the covariate distributions between the treatment groups 
assessed?1  
Yes Partially 
 2/79 (3%) 
 
 0/79 (0%) 
 
 
Q3. For regression methods, was model specification assessed, for 
 
Health outcomes?2 Costs?2 
Yes Partially  Yes Partially 
8/41 (20%) 
 
12/41 (29%) 
 
3/23(13%) 
 
9/23 (39%) 
 
 
Q4. Was covariate balance assessed after applying a matching method? 
Yes Partially 
1/38 (3%) 20/38 (51%) 
 
 
Q5. Was structural uncertainty from the choice of statistical method considered? 
Yes Partially 
  13/81 (16%)   28/81 (35%) 
Notes: 1 Two studies used IV estimation which does not rely on the assumption of no unobserved 
confounding. For these studies Q1a and Q2 do not apply. Therefore for Q1a and Q2 the denominator was 
79.  Results for Question 1b are given in the Results section. 
2 Regression adjustment was used in 41 papers for health outcomes, 23 for costs. 
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Discussion 
This paper presents a critical appraisal tool for assessing and improving the way 
selection bias is addressed in CEAs that use observational data. The systematic review 
found that in the majority of published CEAs, the main assumptions underlying the 
statistical methods were not assessed. In particular, most studies assumed “no 
unobserved confounding” without any justification, raising concerns that the cost-
effectiveness estimates were biased. To improve practice, studies could use external 
evidence, for example from previous clinical studies to carefully consider potential 
confounders. Synthesising this information in causal diagrams can help make the 
assumption of no unobserved confounding explicit, and help assess whether this 
assumption is credible (Joffe and Mindell, 2006). 
We found that half the matching studies reported balance statistics, but only one study 
followed recent recommendations and assessed balance according to the full covariate 
distribution (Stuart, 2010). In CEAs, covariates tend to have irregular distributions, so 
using balance statistics that consider the full covariate distribution can be important in 
helping to address bias (Sekhon and Grieve, 2011).  
A promising approach for CEAs would be to combine matching with regression; this 
can address residual imbalances post matching, and findings tend to be insensitive 
to model choice (Ho et al., 2007, Abadie and Imbens, 2011). Another alternative is to 
combine weighting on the inverse probability of treatment assignment with regression 
(Robins et al., 1994). Such estimators can have double-robust properties; if either the 
model for the endpoint or for the treatment assignment is correctly specified, estimates 
are unbiased and  achieve semiparametric efficiency (Basu et al., 2008, Vansteelandt et 
al., 2011). Further work is required to test double-robust methods in CEA. 
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This paper has some limitations; as with any critical appraisal tool, study quality is 
judged according to the methods reported, and does not recognise that a study may have 
justified an assumption without reporting it.  However, the goal is to encourage studies 
to adopt better methods and report them transparently. Studies which did not apply a 
statistical method for addressing selection bias were excluded from the review, so the 
findings do not apply to all CEAs that use observational data, nor to those that relied on 
aggregate estimates from previous studies. The checklist does not cover other aspects of 
statistical analysis, for example the handling of missing or censored data. The checklist 
is therefore intended to complement rather than substitute for current methods guides 
for CEA (Drummond et al., 2005, Philips et al., 2006, Glick et al., 2007). 
Furthermore, as with any methodological guidance (Philips et al., 2006),  our checklist 
cannot prescribe which specific statistical method should be used to address selection 
bias in CEAs. The checklist’s main contribution is to raise awareness of the 
assumptions underlying alternative statistical methods.  
There has been recent interest and investment in comparative effectiveness research, 
which tends to assess cost-effectiveness without using RCTs (Sox et al., 2010). The 
findings from our paper suggest that it is vital to scrutinise the assumptions behind the 
statistical methods that purport to address selection bias. Indeed critical appraisal may 
reveal that the study design is flawed in that key underlying assumptions, for example 
that there are no unobserved confounders, cannot be justified. These insights might 
encourage future studies with more rigorous designs such as prospective cohort studies 
that collect baseline data on rich set of measured covariates (Rubin, 2010) including 
plausible instruments, or RCTs. 
In conclusion, CEAs that use observational data rarely assess the main assumptions 
behind statistical analyses for addressing selection bias. This checklist can raise 
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awareness about the major assumptions behind statistical methods for addressing 
selection bias and can complement existing method guidelines for CEAs. 
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Appendix 3.1 - Methodological guidance to the checklist 
The aim of this guidance is to help a reviewer judge whether or not the published study 
assessed the main assumptions underlying the use of the statistical method for 
addressing selection bias.  The guidance offers examples of how each criterion can be 
met, drawing on findings from the conceptual review. However, the guidance does not 
aim to be exhaustive.  The checklist and guidance are intended for studies that meet the 
same inclusion criteria stipulated for the systematic review reported in the paper 
(Appendix 3.2).  
Step 1: Identifying the primary statistical method 
The checklist focuses on the statistical method that is used to address selection bias. A 
common example is where the study attempts to address selection bias with regression 
analysis, specifying a binary variable for the treatment and additional baseline 
covariates to adjust for observed differences in patient characteristics. By contrast, a 
regression model which aims to predict costs associated with the outcome of interest 
(e.g. the costs of atrial fibrillation event versus no event, as input to a decision analytical 
model) is not considered a relevant approach for this study. 
Some questions of the checklist are applicable only for certain methods, therefore the 
primary statistical method needs to be identified and recorded. If several statistical 
methods are applied, the one which the authors rely on in the CEA is selected as 
primary method and any other method will count as part of the structural sensitivity 
analysis (Table 3.2, Question 5). 
The classification of statistical methods used in this paper, with some accompanying 
examples, is as follows: 
103 
 
1. Regression: Examples are ordinary least squares (OLS), Generalised Linear 
Models (GLMs), panel data regression, difference-in-differences methods, Cox 
survival regression or net benefit regression. 
2. Matching methods: 
-  Matching on the Pscore: for example, Pscore matching, inverse probability of 
treatment weighting (IPTW), kernel density matching, 
stratification/subclassification/blocking/interval matching, regression on the 
Pscore or full matching. 
- Matching on individual covariates: for example, exact matching, Mahalanobis 
distance matching, or Genetic Matching. 
3. Instrumental variables (IV): for example, two stage least squares, two stage 
residual inclusion or generalised method of moments. 
Step 2: Applying the checklist 
Question 1a: Did the study assess the “no unobserved confounding” assumption? 
Applicability: A statistical method relies on the assumption of no unobserved 
confounding if regression or matching methods are used as a primary analysis of the 
study. If the primary method that is used allows for unobserved confounding (e.g. IV), 
the “Not applicable” option should be selected.  
a) Yes, for example, with causal diagrams informed by external literature. 
The assumption that needs to be assessed is that all potential confounders are accounted 
for in the statistical analysis, that is, baseline covariates that are associated with the 
treatment assignment and the cost or effectiveness endpoint.  This assumption might 
also be referred to as “unconfoundedness”, “strong ignorability”, “exogeneity”, 
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“selection on observables” or “conditional independence” (Imbens and Wooldridge, 
2009a, Imbens and Wooldridge, 2009b, Jones and Rice, 2011). If a panel data 
regression or a difference-in-differences method is used, the assumption is somewhat 
weaker: instead the assumption is that there are no time-varying unobserved 
confounders correlated with treatment assignment and the endpoints (Imbens and 
Jeffrey, 2007). 
A paper is defined to have fully assessed the assumption, if the causal relationships 
between covariates (observed and hypothesised unobserved) and endpoints (both cost 
and effectiveness) were assessed on the basis of a priori scientific knowledge (e.g. 
previous clinical studies on prognostic factors), using some of the following tools: 
-  Graphical representation with causal diagrams or directed acyclic graphs (Pearl, 
2001). 
-  Mathematical description of the relationships, by structural equation models 
(Pearl, 2001). 
These considerations might be complemented with placebo tests (Jones, 2007), which 
can detect violations of the assumption.     
b) Partially, for example, with external literature/expert opinion.    
The criterion would be partially met, if, for example:  
- The authors justified the set of observed confounders used in their statistical 
methods with substantive a priori knowledge, for example of risk factors for the 
disease or mechanism of treatment assignment (Rubin, 2010), but did not use the 
tools mentioned in a). 
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- The paper justified the choice of specific covariates by commenting (for 
example, in the discussion) on the plausibility and sufficiency of the observed 
confounders. 
c) No, if none of the above applies. 
 For example, if covariate selection is based solely on statistical tests (e.g. t-test of 
equality of covariate means between treatment groups) or automated model selection 
(e.g. stepwise) procedures (Brookhart et al., 2006). A general warning about unobserved 
confounding does not fulfil the criterion.  
d) Not applicable - see applicability  
Question 1b: Did the study assess the assumption that the IV was valid?                     
Applicability: This question is applicable if instrumental variable estimation was used 
as the primary statistical analysis. Otherwise, the “Not applicable” option should be 
selected. 
The validity assumption consists of two untestable assumptions (Hernán and Robins, 
2006): (i) the instrument only influences the outcome through treatment and (ii) the 
instrument is independent of the unobserved confounders. Although these assumptions 
cannot be tested directly, they can be assessed in similar ways to the no unobserved 
confounding assumption. 
a) Yes, for example, with causal diagrams informed by external literature. 
Similarly to Question 1a, previous empirical information and expert judgment need to 
be combined to assess the assumption that the instrument has a causal effect on the 
treatment, but does not have an independent casual effect on the outcome, nor is it 
associated with unobserved confounders. The causal diagrams can use this information 
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to formulate the relationships between the treatment, the instrument, observed and 
unobserved confounders and the endpoints. The use of causal diagrams can make the IV 
assumption explicit (Joffe and Mindell, 2006). If more than one instrument is available, 
tests of overidentifying restrictions can be used in addition (Jones and Rice, 2011). 
b) Partially, for example, with external literature/expert opinion    
- The authors justified the choice of the IV with substantive a priori knowledge of 
how the instrument is associated with treatment assignment, and is conditionally 
independent of endpoints without using the  tools mentioned in a). 
- The criterion can be partly met with commentary in the discussion justifying the 
validity of the instrument, if it uses prior scientific knowledge (e.g. other studies 
justifiying the use of the same instrument) or expert opinion. 
c) No, if none of the above applies. 
d) Not applicable - see applicability. 
                                       
Question 2: Did the study assess whether the baseline covariates (e.g. age and sex) 
had distributions that overlapped between the treatment groups? 
Applicability: This question is applicable for the same studies where Q1a is applicable. 
For IV, “Not applicable” should be selected.  
a) Yes, for example with histograms and standardised differences.  
This assumption is also referred to as the “common support” assumption (Rosenbaum  
and Rubin, 1983), the “experimental treatment assignment “, or the “positivity 
assumption” (Petersen et al., 2010). It is fully assessed if one of the following steps is 
taken, and the authors make explicit that the intention is assessing overlap: 
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- Histograms or smoothed density plots of the continuous covariates are plotted 
(Imbens and Wooldridge, 2009b), and areas of weak support in the densities are 
investigated. For binary variables, standardised differences are investigated. 
- If there are many covariates, this criteria is met if the distribution of Pscore is 
inspected for both treatment groups, so as to reveal possible lack of overlap in 
the multivariate covariate distributions.  
- Quantiles of the Pscore distributions are investigated. 
b) Partially, for example, just with standardised differences. 
Inspecting standardised differences of variables with the explicit objective of assessing 
overlap partially fulfills this requirement (Imbens and Wooldridge, 2009b). 
c) No, if none of the above applies, for example if standardised differences are reported 
for the purposes of assessing balance. 
d) Not applicable - see applicability. 
 
Question 3: Did the study assess the specification of the regression model for                                                                             
(i) health outcomes and (ii) cost? 
Applicability:  This question is applicable for studies where the primary statistical 
analysis to address selection bias was regression adjustment.  If regression adjustment 
was performed only for the cost or effectiveness endpoint, only the relevant part of the 
question needs to be answered. If regression on a univariate measure of net benefit was 
used (e.g. net benefit regression) the same answers should be given to both questions. 
a) Yes, for example with statistical tests/plots. 
Several options are available to statistically assess the specification of a regression 
model, for example, 
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- For GLMs, the correct specification of the link function and the outcome 
distribution can be tested, for example, with the the Hosmer–Lemeshow, 
Pregibon’s link test, or the modified Park test (Basu et al., 2004, Jones, 2010). 
-  The fit of models estimated through a maximum likelihood method can be 
assessed using log-likelihood based fit statistics, for example, the Akaike 
Information Criterion or the Bayesian Information Criterion (Barber and 
Thompson, 2004, Jackson et al., 2011). 
- Cross-validation is a general method to assess model fit based on predictive 
abilities (Buntin and Zaslavsky, 2004, Hill and Miller, 2010). 
- If a linear model (e.g. OLS) is used, residual plots can be examined to detect 
misspecification of the functional form of the regression model or 
heteroscedastic errors (Jones, 2010). Multicollinearity in the models can also be 
assessed. 
- Lag structure of time series models can be tested.  
- If a semiparametric Cox proportional hazards model is used, the proportionality 
of the hazard can be tested (Hosmer et al., 2008). 
b) Partially, with qualitative arguments. 
If a study uses previous applied and methodological work to guide the choice of the 
regression model, the criterion can be considered partly met, for example, 
- The distribution of an outcome can imply a modeling approach, e.g. logistic 
regression for binary data, or two-part models for costs with a large number of 
zeros (Buntin and Zaslavsky, 2004). 
- There might be a consensus in the clinical literature that certain covariates have 
a nonlinear effect on the outcome, or interaction with the treatment.  
- The linear net benefit regression is used and referenced (Hoch et al., 2002). 
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c) No,  if none of the above applies. 
d) Not applicable -  see applicability. 
 
Question 4: Was covariate balance assessed after applying a matching method? 
Applicability: This question is applicable if the primary statistical method to address 
selection bias is a matching method. 
a) Yes, with a measure that considered imbalance  across different aspects of the 
distribution 
This requirement is fulfilled if covariate balanced is assessed for aspects of the covariate 
distributions beyond the mean. Examples include: 
- For continuous covariates quantile–quantile plots can be examined, which 
compare the empirical distributions of variables in the treatment and control 
groups. This can be also compared for second moments of the variables, and 
interactions (Stuart, 2010). 
- Nonparametric tests of the equality of distributions can be performed, for 
example Kolmogorov-Smirnoff tests (Diamond and Sekhon, 2012). 
- Five-number summaries (quantiles) of the distributions can be provided (Austin, 
2009a). 
- Side-by side boxplots (Austin, 2009a) are presented. 
- Higher moments (variance, skewness, kurtosis) and cross-moments (covariance) 
of covariate distributions are compared (Jones and Rice, 2011). Variance can be 
compared using variance ratios (Austin, 2009a). 
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The assessment can be performed for any matching method. For methods that create 
matched treatment and control groups, the resultant groups can be compared. For Pscore 
subclassification, the assessment can be performed by the created strata; for IPTW, 
weighted boxplots can be used to assess balance (Stuart, 2010). If the Pscore is used for 
covariate adjustment, weighted conditional standardised absolute differences can be 
computed (Austin, 2009a). 
b) Partially, for exmaple, by assessing mean differences. 
Balance is partially assessed if covariate means of matched groups are compared, using 
the following tools, for example, 
- Standardised differences (also referred to as normalised differences) are 
measures which express difference in means in units of the pooled standard 
deviation (Rosenbaum  and Rubin, 1983) and are frequently used as balance 
diagnostics (Austin, 2009a). These measures are recommended for balance 
assessment since they are invariant to sample size (Stuart, 2010) and can be 
applied across a wide range of balancing methods (matching, IPTW, 
stratification). Using graphical displays (Austin, 2009a, Stuart, 2010) makes 
standardised differences on a large number of covariates easier to interpret. 
- Comparing mean differences with for example t-tests carries some information 
on balance, therefore it is considered to partially fulfil the criterion of balance 
assessment. It is, however, not recommended because sample size can change 
during a matching process resulting in misleading tests statistics (Imbens and 
Wooldridge, 2009a). 
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c) No, if none of the above applies. For example, the c-statistic or area under the 
receiver operating characteristic curve of the Pscore model and balance assessed on the 
estimated Pscore is not regarded as informative (Austin, 2009a). 
d) Not applicable – see applicability.  
 
Question 5: Did the study consider structural uncertainty arising from the choice 
or specification of the statistical method for addressing selection bias? 
a) Yes, the authors quantitatively assessed  and interpreted the  sensitivity of cost-
effectiveness  results to the choice of method. 
This criterion is fully met if the authors conducted an additional statistical analysis 
beyond the primary method used to address selection bias, and interpreted how the 
results are altered by using the alternative method. Structural uncertainty stems from 
many sources (Jackson et al., 2011), and the particular form of structural uncertainty 
here is that pertaining to the method for handling selection bias. Even this specific form 
of structural uncertainty can take several forms. Some examples are as follows: 
- Distinct methods based on different structural assumptions are applied, and 
results are reported and compared (e.g. instrumental variables versus Pscore, 
matching versus regression (Polsky and Basu, 2006)). 
- Methods are combined to add robustness to the analysis. For example methods 
combining regression and Pscore (Robins et al., 1994), or matched data adjusted 
using regression models (Ho et al., 2007). Results of these analyses are reported, 
and compared to those obtained from just one method. 
- Different specifications of the cost and effectiveness regressions are applied, 
results are reported and compared (e.g. with and without interactions; OLS 
versus gamma GLM). 
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- Structural uncertainty in the choice of parametric model for regression can be 
quantified, for example by Bayesian model averaging (Jackson et al., 2011). 
- Assessing the sensitivity to the assumption of no unobserved confounders, by 
exploring the effect of potentially omitted confounders on the parameters of 
interest, using sensitivity analysis (Rosenbaum, 2002). 
b) Partially, for example, additional statistical analysis with no interpetation, or 
commentary with no quantitave assessment. 
The criterion is partially met if: 
-  Statistical analysis beyond the primary method was performed; however, the 
implications for cost-effectiveness results were not interpreted appropriately. 
Examples are: 
- Specification tests for regression model are conducted, but results obtained 
using different specifications are not contrasted. 
- Matched data is adjusted with a regression model. 
- Pscore is included as an additional covariate in the regression model. 
- As a sensitivity analysis, some covariates are omitted from the set of 
variables used in the statistical analysis. 
- Commentary on the implications of the method choice is provided, without 
conducting a formal analysis, for example: 
- by discussing suspected bias due to unobserved  confounders. 
- by outlining a possible instrumental variables analysis. 
c) No, if none of the above applies. For example, conducting sensitivity analysis for 
other sources of structural uncertainty (e.g. Markov model structure) do not fulfil the 
criterion.  
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Appendix 3.2 – Systematic review search terms and inclusion 
criteria 
Search terms 
In order to minimise the risk of omitting potentially relevant studies, the search terms 
were broad, combining two requirements: the study is an economic evaluation and uses 
a statistical method.  The search terms used for the MEDLINE and EMBASE databases 
are listed in Appendix 3.2 Table 1, and were adapted for the NHS EED (through 
Cochrane Library) and HEED (through Wiley Online library) databases. 
Appendix 3.2 Table 1 - Search terms for NHS EED (adapted for HEED, MEDLINE and 
EMBASE databases) 
#1 "economic evaluation" OR "cost effectiveness " OR "cost-effectiveness" OR "cost 
utility" OR "cost-benefit" in Economic Evaluations 
#2 "regression" OR "covariate adjustment" OR "ordinary least square*" OR "OLS" or 
"generalised estimating equation*" OR "linear model*" OR "nonlinear model*" OR "logistic 
model*"  in Economic Evaluations 
#3 ("double robust" OR "doubly robust" OR  "inverse probability weight*" OR "inverse 
probability of treatment") OR (weight* AND "propensity score*") 
 in Economic Evaluations 
#4 (stratification OR stratify OR stratified OR blocking OR block OR strata) AND 
"propensity score*"  in Economic Evaluations 
#5 "propensity score*" in Economic Evaluations 
#6 "matching" or "matched" in Economic Evaluations 
#7 "two stage least squares" OR "two-stage least squares" OR "2SLS" OR "instrumental 
variable*" in Economic Evaluations 
#8 "panel data" OR "difference in differences" OR "repeated cross section" OR 
"repeated cross-section" OR "fixed effect*"  in Economic Evaluations 
#9 "regression discontinuity" in Economic Evaluations 
#10 "control function" OR "Heckman selection" OR "selection model" in Economic 
Evaluations 
#11 (#1 AND ( #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 )), from 
2000 to 2010 
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Inclusion criteria 
From the results of the broad search, relevant studies were narrowed down using the 
following inclusion criteria. Examples for excluded studies are provided. 
1. Individual patient level observational data are used to calculate at least one of the 
following parameters:  incremental cost, effectiveness or cost effectiveness 
parameters or relative surrogate outcomes, for example, relative risk of mortality. 
Examples for excluded studies: when a decision analytical model uses aggregate inputs 
only, or when a study uses individual level RCT data only. 
2. The study is a full economic evaluation: cost-effectiveness, cost-utility or cost-
benefit analysis. Examples for excluded studies:  
- Cost-minimisation or cost-consequences analysis. 
- A study labelled as cost-benefit analysis which accounts cost-saving as 
benefits. 
3. A statistical method is used to address selection bias when calculating at least one 
of the following parameters: incremental cost, incremental effectiveness or cost-
effectiveness or relative surrogate outcomes, for example, relative risk of mortality. 
Statistical methods are defined as in Appendix 3.1. 
      Examples for excluded studies are as follows: 
- No statistical adjustment when calculating incremental quantities (e.g. 
uncontrolled before and after analysis). 
- Statistical method is not used to address selection bias, but for other 
purposes (e.g. to create predictive equations stratified by risk factors). 
4. Study is published in English.  
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Chapter 4 - Statistical methods for estimating subgroup 
effects in CEA that use patient-level observational data  
4.1 Preamble to research paper 2 
The conceptual review (chapter 2) found that an important challenge in CEA that use 
observational data is to estimate cost-effectiveness for patient subgroups. PS methods, 
such as PS matching and IPTW can estimate cost-effectiveness for subgroups, but can 
only provide unbiased estimates if they create balance between the distributions of 
confounders. The critical appraisal of applied studies (research paper 1) highlighted that 
CEA rarely assess balance appropriately. GM, a multivariate matching method, uses 
machine learning to directly balance the distributions of observed confounders, and 
provides a promising alternative.  GM has not been used to estimate cost-effectiveness 
parameters for subgroups or compared to IPTW before. To help address these gaps in 
the methodological literature of CEA, research paper 2 compares the relative 
performance of GM, PS matching and IPTW for estimating cost-effectiveness in patient 
subgroups.  
This paper first considers the methods in a motivating case study of the CEA. The 
subsequent simulation study is grounded in features of this case study and uses insights 
from the conceptual review to generate hypotheses (chapter 2).  The paper provides 
guidance for choosing among the statistical methods considered, in order to obtain 
unbiased, precise estimates of cost-effectiveness by patient subgroup. In order to help 
the applied researcher, this paper provides sample code for implementing the methods 
(Appendix 4.2). 
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Additional page for Question (3) on LSHTM cover sheet form: 
 
The research question for this paper was linked to the ESRC project and identified by 
the principal investigator, RG. I designed the simulation study, with RG. I wrote the 
simulation code, with help from post-doctoral researchers employed by the ESRC 
project, R Ramsahai and R Radice.  R Ramsahai helped me run simulations on the 
LSHTM high-performance computational cluster. I assisted ZS on the analysis of the 
motivating case study. I led on the reporting and interpretation of the results of the case 
study and the simulation studies, and wrote the first draft of the manuscript. I managed 
each round of comments and suggestions from the co-authors, in collaboration with RG. 
All authors read and approved the final draft prior to journal submission and inclusion 
in the dissertation. I  built on insights from another study linked to the ESRC project 
(Radice et al., 2012). In this study, aimed at a biostatistics audience, I contributed to the 
design and the implementation of the simulations and to the interpretation of the results, 
as well as to writing sections of the manuscript. 
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Abstract 
Decision makers require cost-effectiveness estimates for patient subgroups. In non-
randomized studies, propensity score (PS) matching and inverse probability of treatment 
weighting (IPTW) can address overt selection bias, but only if they balance observed 
covariates between treatment groups. Genetic Matching (GM) matches on the PS and 
individual covariates using an automated search algorithm to directly balance baseline 
covariates. This paper compares these methods for estimating subgroup effects in cost-
effectiveness analyses (CEA).The motivating case study is a CEA of a pharmaceutical 
intervention, Drotrecogin alfa (DrotAA) for patient subgroups with severe sepsis 
(n=2,726). Here GM reported better covariate balance than PS matching and IPTW.  
For the subgroup at a high level of baseline risk, the probability that DrotAA was cost 
effective ranged from 30% (IPTW) to 90% (PS matching and GM), at a threshold of 
£20,000 per QALY. 
We then compared the methods in a simulation study, where initially the PS was 
correctly specified, and then misspecified, for example by ignoring the subgroup-
specific treatment assignment. Relative performance was assessed as bias and root mean 
squared error (RMSE) in the estimated incremental net benefits. When the PS was 
correctly specified and inverse probability weights were stable, each method performed 
well; IPTW reporting the lowest RMSE. When the subgroup-specific treatment 
assignment was ignored, PS matching and IPTW reported covariate imbalance and bias; 
GM reported better balance, less bias, and more precise estimates.  We conclude that if 
the PS is correctly specified and the weights for IPTW are stable, each method can 
provide unbiased cost-effectiveness estimates. However, unlike IPTW and PS matching, 
GM is relatively robust to PS misspecification.  
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Introduction6 
Health care decision-makers often use cost-effectiveness information for overall 
populations, when setting priorities (Vanness and Mullahy, 2006). However, focusing 
on overall mean cost-effectiveness may hide important heterogeneity, and can lead to 
over (or under) treatment of particular subgroups (Coyle et al., 2003, Sculpher, 2008, 
Koerkamp et al., 2010). For cost-effectiveness analyses (CEA) to help maximize 
population health, they are required to provide results for patient subgroups (NICE, 
2008). CEA ideally use evidence from pragmatic randomized controlled trials (RCTs) 
with broad entry criteria; these can provide unbiased estimates of relative cost-
effectiveness for policy-relevant subgroups. However, for many decision problems 
appropriate RCT data are not available, for example because trials have excluded 
important subgroups, or have tightly-regulated protocols that hinder accurate cost 
estimation. In such circumstances, the best available data may come from non-
randomized studies (NRS), such as prospective cohort studies (Deeks, 2003, Rubin, 
2010). 
In any NRS, the crucial concern is that treatment assignment is non-random leading to 
selection bias from confounding. If individual patient data are available for both 
treatment groups, statistical methods can tackle potential selection bias, but only when 
their key underlying assumptions are plausible (Rubin, 2010). Instrumental variable 
approaches can handle confounding and heterogeneity according to both observed and 
unobserved characteristics (Basu et al., 2007), but in some settings the assumptions 
required are implausible (Hernán and Robins, 2006). Instead, regression and matching 
                                                 
6 US spelling conventions are used throughout this paper, due to the target journal criteria.  
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approaches warrant consideration, provided that the crucial assumption, that all 
potential confounders have been observed can be justified (Greenland et al., 1999). 
Regression methods, recommended for subgroup analysis in CEA of RCTs (Nixon and 
Thompson, 2005, Willan et al., 2004), are common in CEA that use NRS (Kreif et al., 
2012). Here, even if the assumption of no unobserved confounding is justified, cost-
effectiveness estimates can be highly sensitive to the specification of the regression 
model (Grieve et al., 2008). If the model is misspecified, results may suffer from overt 
bias (Thompson and Nixon, 2005). Instead, propensity score (PS) approaches that aim 
to balance baseline covariates between treatment groups are advocated for estimating 
treatment effectiveness (Ho et al., 2007, Stuart, 2010), and cost-effectiveness (Mitra and 
Indurkhya, 2005, Pullenayegum and Willan, 2011). Austin (2009) has demonstrated that 
PS matching and inverse probability of treatment weighting (IPTW) can perform 
relatively well. IPTW has particular appeal for subgroup analysis; if the PS is correctly 
specified, IPTW can provide more precise estimates of treatment effects than matching 
(Hirano et al., 2003). A general concern is that these approaches assume the PS is 
correctly specified (Cole and Hernán, 2008). An alternative method, Genetic Matching 
(GM), harnesses an automated search algorithm to match on individual covariates as 
well as the PS. The explicit aim of GM is to balance distributions of observed covariates 
between the treatment groups. GM can provide some protection against PS 
misspecification (Sekhon and Grieve, 2011, Diamond and Sekhon, 2012) but has not 
previously been compared with IPTW. 
A major gap in the CEA methods literature is that no previous study has compared 
alternative methods for subgroup analysis with data from NRS. A recent review of 80 
published studies found most CEA that use NRS fail to balance baseline covariates for 
patient subgroups, potentially leading to biased cost-effectiveness estimates (Kreif et al., 
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2012).7  The aim of this paper is to compare the relative performance of alternative PS 
approaches for reporting subgroup effects in CEA.  
We reanalyze a high profile case study, a CEA of Drotrecogin alfa (DrotAA) for 
patients with severe sepsis. The effectiveness of DrotAA may differ by subgroup 
(Bernard et al., 2001, Ely et al., 2003), but it is unclear whether the intervention is cost-
effective for either subgroup; we consider this issue using data from a NRS (Rowan et 
al., 2008). This case study illustrates some general challenges that arise when aiming to 
report unbiased cost-effectiveness estimates by subgroup from an NRS. Here, statistical 
methods are required to balance baseline covariates between treatment and control 
groups within each subgroup. Balancing covariates at the subgroup level may prove 
particularly challenging if the treatment assignment mechanism differs systematically 
across subgroups. A PS approach has to then recognize the differential treatment 
assignment mechanism, for example by estimating separate PS models for each 
subgroup. We extend a previous study that matched on a single PS estimated across 
subgroups (Rowan et al., 2008), by estimating a separate PS for each subgroup.  In the 
reanalysis, we employ PS matching, GM, and IPTW to report cost-effectiveness by 
subgroup.  
We report a new Monte Carlo Simulation that builds on the case study by considering 
circumstances in which the treatment assignment mechanism differs by subgroup. The 
simulation study incorporates other features of the case study such as nonlinearities in 
the PS and unstable PS weights. The next section describes the statistical methods and 
the challenges they face when reporting CEA for different patient subgroups. We 
                                                 
7 Note that other concerns such as missing data and non-compliance with treatment may also arise, and 
can lead to biased estimates if not handled appropriately. Methods for handling these issues are beyond 
the scope of this paper.  
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describe the case study methods and findings, then the design and results of the Monte 
Carlo simulations. The last section discusses the findings and outlines areas for further 
research. 
Statistical methods  
Each statistical method considered here assumes that there is no unobserved 
confounding (Greenland et al., 1999). This assumption implies that, conditional on the 
observed covariates, there are no differences in the distributions of unobserved 
confounders between treatment groups. As this assumption cannot be directly tested, it 
is important to draw on external evidence or expert opinion and consider a priori which 
baseline factors are potential confounders (Rubin, 2007). In the context of CEA, the 
study should carefully consider adjustment for baseline covariates that are potential 
confounders for either the cost or effectiveness endpoint (Hoch et al., 2002).  
Each statistical method then aims to balance the distribution of those potential 
confounders that are observed. Balance can be achieved by matching (PS matching or 
GM) or by re-weighting the treatment and control samples (IPTW). Relative 
performance of weighting and matching methods can be assessed with weighted balance 
statistics (Stuart, 2010, Austin, 2009a). A recommended balance statistic (Austin, 
2009a) is the weighted absolute standardized mean difference, often termed the 
weighted standardized difference.  
When treatment effectiveness estimates for subgroups are required, the study should 
consider whether the treatment assignment mechanism differs by subgroup. For 
example, the relative influence of factors explaining treatment assignment may differ 
for high-risk versus low-risk patients. Hence, balancing baseline characteristics for 
overall samples of treated and control observations can leave potential confounders 
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imbalanced at the subgroup-level, possibly resulting in biased cost-effectiveness 
estimates for patient subgroups. An important aim of these methods is to balance 
baseline covariates in each subgroup of interest. The next sections describe the main 
distinguishing features of PS matching, GM, and IPTW. 
PS matching 
The true PS is the conditional probability of treatment assignment given observed 
baseline covariates (Rosenbaum  and Rubin, 1983): 
𝑝𝑖 = 𝑃𝑟(𝑡𝑥𝑖 = 1|𝑋𝑖)                       𝑖 = 1, . . . . , 𝑛 
where 𝑡𝑥𝑖 is a binary treatment variable for the ith individual,  𝑋𝑖 is a vector of 
measured baseline confounders and n is the sample size. The true PS is a balancing 
score: conditional on the PS, treatment and control groups are expected to have the 
same distribution of observed baseline characteristics. Matching on a correctly specified 
PS can therefore be expected to eliminate bias (Rubin and Thomas, 1992). However, in 
NRSs the specification of the true PS is generally unknown; i.e. just as the investigator 
does not know the specification of the relationship between covariates and endpoints 
they seldom know how covariates influence treatment receipt. 
If the PS is misspecified, for example by disregarding differences between subgroups in 
the treatment assignment mechanism, then PS matching can lead to biased estimates of 
treatment effects (Cole and Hernán, 2008). It is unclear which forms of PS 
misspecification will lead to large biases when reporting subgroup results in CEA.  
Methods guidance for estimating the PS suggests two ways of improving the resultant 
covariate balance. Firstly, the PS should be repeatedly reestimated, with balance 
reassessed until the analyst finds the best PS, the one that maximizes balance  (Stuart, 
2010). In this context, the PS is required to maximize balance at the subgroup level. 
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Second, to improve balance, matching on the PS should be combined with matching on 
individual covariates (Rosenbaum  and Rubin, 1985). However, finding the correct PS 
specification and the best metric for matching on individual covariates is challenging 
(Austin, 2008), particularly when covariate balance at the subgroup level is required. 
Instead, a search algorithm can be used to help improve balance. 
Genetic Matching 
GM is a multivariate matching approach whose explicit aim is to optimize covariate 
balance (Diamond and Sekhon, 2012, Ramsahai et al., 2011, Sekhon, 2011, Sekhon and 
Grieve, 2011). GM extends standard PS matching in two ways. First, rather than the 
manual process of modifying the PS and balance-checking, GM harnesses an automated 
search algorithm that iteratively checks balance on observed confounders, and directs 
the search toward those matches that optimize balance (Diamond and Sekhon, 2012, 
Sekhon, 2011). Second, the GM algorithm can maximize covariate balance by matching 
on individual covariates as well as the PS. Hence, at the expense of computational time, 
the GM search algorithm optimizes covariate balance to the extent possible, given the 
data (Diamond and Sekhon, 2012, Sekhon, 2011). When the PS is misspecified, Sekhon 
and Grieve (2011)  report that GM can improve covariate balance and reduce bias and 
variability in the cost-effectiveness estimates.  
For subgroup analysis, the GM algorithm can be modified to maximize balance for each 
subgroup. A challenge GM shares with other multivariate matching estimators is that if 
required to balance covariates that are not true confounders, this increases the 
dimensionality of the matching problem. This can lead to loss of precision (Abadie and 
Imbens, 2006), which can be of particular concern when reporting cost-effectiveness 
results by subgroup as sample sizes can be relatively small.  
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The appendices offer further explanation (Appendix 4.1) and code for implementing the 
method (Appendix 4.2). Full details of the method are provided by Diamond and 
Sekhon (2012)  and Sekhon (2011) .  
Inverse probability of treatment weighting 
In CEA, IPTW has been introduced for reducing selection bias in cost analysis (Basu et 
al., 2011) and for handling censored costs (Pullenayegum and Willan, 2011).  IPTW has 
not previously been considered for addressing selection bias in CEA. In this context, 
IPTW can reweight the treatment and control samples, when estimating cost-
effectiveness. The weight 𝑤𝑖 is the inverse of the estimated probability of the treatment 
received, 𝑤𝑖 =
𝑡𝑥𝑖
𝑝𝑖
+ 
1−𝑡𝑥𝑖
1−𝑝𝑖
  where ?̂?𝑖 is the estimated PS. If the PS is correctly specified, 
IPTW will provide unbiased estimates of the ATEs and can reach semiparametric 
efficiency (Hirano et al., 2003). Covariate balance can be assessed following IPTW 
according to weighted standardized differences (Austin, 2009a), where the weights are 
the inverse probability weights.  
A potential concern is that IPTW can be highly sensitive to PS misspecification; for 
example when treated observations have a true PS close to zero, even slight 
discrepancies in the estimated PS translate into large errors in the weights. This can lead 
to biased and inefficient estimates  (Kang and Schafer, 2007).  Unstable weights can 
arise with sparse data and lead to inefficient estimates even if the PS model is correctly 
specified. As Cole and Hernán (2008) demonstrate, even with good overlap between the 
treatment and control groups, estimated PS values close to zero can occur by chance. 
This tends to arise with small sample sizes or if the PS has many continuous covariates. 
Methods guidance suggest that extreme weights can be progressively truncated (Cole 
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and Hernán, 2008). The implications of unstable weights and weight truncation have not 
been reported before when using IPTW to reduce selection bias in CEA.  
Issues arising when applying these methods to report cost-effectiveness by subgroup 
 Each approach can estimate average treatment effects (Polsky and Basu, 2006) - 
incremental costs (ΔC), incremental effects (ΔE), and incremental net monetary benefits 
(INBs) - for each prespecified subgroup. We identified 3 particular areas of potential 
concern when applying these methods to report cost-effectiveness by subgroup.  
1. Subgroup specific treatment assignment. 
  When the treatment assignment mechanism differs by subgroup, the methods are 
required to balance baseline covariates in each subgroup of interest.  In the case study 
we, illustrate how the methods can attempt to balance covariates in each subgroup.  The 
simulation study then considers circumstances where the treatment assignment 
mechanisms differ by subgroup. The simulation study investigates how the statistical 
methods perform after incorrectly assuming that there is a single treatment assignment 
mechanism, rather than recognizing that treatment assignment differs by subgroup.  The 
simulation study reports the relative bias and root mean squared error (RMSE) of the 
cost-effectiveness estimates across the methods. 
2. Sensitivity of estimates to misspecification of the PS. 
The methodological literature suggests that matching methods can be less sensitive to 
PS misspecification than IPTW (Lee et al., 2010). Specifically, if the estimated PS 
weights are unstable, IPTW can report biased and imprecise treatment effects. We 
consider issues raised by the unstable PS weights found in the motivating case study, 
when the true PS is not known. In the second simulation scenario, we compare the 
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relative performance of the methods when PS weights are extreme, for the first time in a 
CEA context.  
3. Different set of confounders in the cost and effectiveness endpoints. 
In CEA, different covariates can be potential confounders for the estimates of 
incremental costs versus effectiveness. One approach is to include in the PS all potential 
confounders for either endpoint. However, previous studies have shown that adjusting 
for a covariate which influences treatment assignment but not the endpoint can lead to 
estimates that are statistically inefficient (Brookhart et al., 2006). We designed a 
simulation scenario to consider the bias and RMSE across the methods of including a 
covariate in the PS, which is only a confounder for one of the endpoints. 
Motivating case study 
Overview 
We present a CEA in which observational data are used to report cost-effectiveness by 
subgroup. The case study considers the implications for covariate balance of ignoring, 
then recognizing the subgroup–specific treatment assignment. We then report cost-
effectiveness results for each subgroup. This case study also illustrates circumstances 
where the inverse PS weights are unstable.  
This CEA evaluates DrotAA for patients with severe sepsis admitted to intensive care 
units (ICUs). The National Institute for Health and Clinical Excellence previously 
recommended DrotAA for severe sepsis patients with two or more organ systems failing 
(NICE, 2007), based on a CEA that used a US phase 3 RCT (Bernard et al., 2001). 
However, this trial, while not powered to detect treatment effects by subgroup, provided 
some evidence to suggest that the effectiveness of DrotAA may differ across patient 
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subgroups; the intervention was found to be relatively effective for patients at high 
levels of baseline risk (Bernard et al., 2001, Ely et al., 2003). Subsequent RCTs that 
only included low-risk patients were stopped early because of futility (Abraham et al., 
2005, Barton et al., 2004) or lack of benefit (Silva et al., 2010). Given the controversy 
about the effectiveness, but also the infusion’s costs (around £5,000 per patient)  there is 
interest in the cost-effectiveness of  DrotAA for patients with different risk profiles 
(NICE, 2007). A CEA for subgroups of patients defined according to baseline risk of 
death can help address this question. However, such analyses require the use of 
observational data, hence, the possibility of selection bias must be addressed. 
We reanalyzed data from a large UK observational database (Rowan et al., 2008) which 
represents relevant real-world clinical practice for the subgroups of interest. Following 
previous analysis of this data (Rowan et al., 2008), we first used a single PS model 
estimated across all patient subgroups. Rowan et al. (2008) reported treatment 
effectiveness for subgroups defined according to high (3 to 5 organ failures at baseline) 
and low (2 organ failures) levels of baseline risk, and found that  DrotAA reduced 
hospital mortality for high risk patients, but increased mortality for low risk patients. 
We extended this analysis by deploying the alternative statistical methods described to 
try and maximize covariate balance for each subgroup.  
Data 
We used the same data as the previous prospective cohort study (Rowan et al., 2008), 
from the UK Case-Mix Programme dataset co-ordinated by the Intensive Care National 
Audit and Research Centre (ICNARC). Of patients who met the study’s inclusion 
criteria and were defined as having severe sepsis and multiple organ failures at 
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admission, 1,076 received DrotAA (treated) and 1,650 contemporaneous admissions did 
not receive DrotAA (controls).  
The CEA estimated individual-level lifetime QALYs, based on individual patient’s 
mortality data collected for a follow-up period of four years and, for those who 
survived, age- and gender-specific expected survival and quality of life.   Costs of 
DrotAA and all hospitalizations were estimated at the patient level, over the same 
period of follow-up. QALYs and costs were discounted at the recommended rate of 
3.5% (NICE, 2008). The subsequent statistical analysis used the individual level data on 
costs and lifetime QALYs. Further details on the CEA, including data sources are 
reported elsewhere (Sadique et al., 2011). 
Statistical analysis of the case study 
We extended the previous PS matching (Rowan et al., 2008) in creating subgroup-
specific PS models, but also by considering GM and IPTW. The PS models were 
estimated by logistic regression and included the same potential confounders as the 
previous study. The baseline characteristics included were hospital type, number of 
critical care beds in the ICU, age, ICNARC model physiology score (IMscore), gender, 
number of organ systems failing, type of organ failures (cardiovascular, respiratory, 
renal, haematological, metabolic acidosis), source of admission to critical care (via the 
emergency department, theatre or recovery, ward, clinic or home), diagnostic category, 
and serious conditions in the past medical history.  Age and IMscore were defined as 
nonlinear terms, fitted as smoothed functions using restricted cubic splines; other 
continuous measures were assumed to have a linear relationship with the logit of 
treatment assignment. 
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Each statistical method first aimed to maximize covariate balance in the overall sample 
by using a single PS model estimated across all subgroups (see example code for 
implementation in Appendix 4.1). The GM algorithm was required to minimize 
standardized differences for the overall sample.  PS models were then estimated for 
each subgroup (2 or 3 to 5 organ failures) and GM was required to optimize balance for 
each subgroup. In a sensitivity analysis, GM optimized balance according to paired t-
tests and Kolmogorov-Smirnoff tests (Sekhon, 2011). 
We report lifetime incremental costs, QALYs and INBs of DrotAA versus control. 
Statistical uncertainty was considered by reporting 95% confidence intervals 
(CIs)(Davison and Hinkley, 1997), and cost-effectiveness acceptability curves (CEACs) 
using the nonparametric bootstrap to maintain the correlation between costs and QALYs 
(Fenwick et al., 2004). The resultant inferences should be regarded as conditional on the 
estimated PSs and the matched data (Hill and Reiter, 2005). For all statistical analyses, 
the R platform was used.  
Case study results 
Covariate balance 
Before matching, the treatment groups were highly imbalanced; compared with 
controls, the DrotAA patients were on average younger, with a higher baseline 
probability of death (Table 4.1).   
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Table 4.1 - Case study results: baseline characteristics and covariate balance for DrotAA 
versus Control group, before matching or weighting. 
Covariate 2 organ failures subgroup 3 to 5 organ failures subgroup 
 DrotAA 
(n=198) 
Control 
(n=630) 
Standardized 
difference (%) 
DrotAA 
(n=878) 
Control 
(n=1020) 
Standardized 
difference (%) 
Age 57.58 63.04 26.49 58.96 65.16 32.32 
IMprob * 0.42 0.39 10.76 0.64 0.58 20.12 
IMscore† 22.83 20.44 29.53 32.08 27.96 40.83 
% vent. ‡ 88.38 70.16 40.02 93.39 78.53 38.90 
Abbreviations: *:  ICNARC model predicted probability of acute hospital mortality † ICNARC model 
physiology score  ‡ % of patients mechanically ventilated 
 
 
Following PS matching and IPTW, standardized differences (%) remained large for 
both subgroups, both with the overall and the subgroup-specific PSs. GM reported 
better balance than the other methods, even when required to maximize balance across 
the overall sample. The lowest standardized differences were reported when GM was 
required to optimize balance for each subgroup (Figure 4.1). Subsequent results are 
reported just for the subgroup-specific PS models and GM algorithms. 
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Figure 4.1 - Case study: covariate balance reported as weighted standardized differences 
(%), after PS matching, GM and IPTW, for overall and subgroup specific PSs and GM 
algorithms 
 
Abbreviations: IMprob - ICNARC model predicted probability of acute hospital mortality, IMscore - 
ICNARC model physiology score, vent -  % of patients mechanically ventilated 
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Lifetime cost-effectiveness results  
For patients with two organs failing, the INBs were all negative, but following IPTW, 
the 95% CI was relatively wide and included zero (Table 4.2). For the subgroup with 3 
to 5 organs failing, the incremental QALYs were positive and relatively high for both 
matching methods. For IPTW, the QALY gain was smaller with 95% CI that included 
zero. The INB was lower following IPTW than for the matching methods, and again 
had a wide CI. 
 
Table 4.2 - Case study: Lifetime incremental costs (£), QALYs and INBs 
 (WTP=£20,000) for DrotAA versus Control group. Estimates are from subgroup specific 
PSs and GM algorithms. 
 PS matching GM IPTW 
   2 organ failures subgroup   
Incremental costs 
(95%CI*) 
12,710 
(11,058 to 14,361 ) 
14,703  
(12,763 to 16,644) 
13,750 
(9,873 to 17,597) 
Incremental 
QALYs (95% 
CI*) 
-1.01 
(-1.60 to -0.41) 
-0.97  
(-1.62 to -0.32) 
-0.30 
(-1.77 to 1.15)  
INBs (95% CI*) -32,846 
(-44,704 to -20,987) 
-34,031  
(-47,028 to -21,034) 
-19,764 
(-49,546 to 9,835) 
   3-5 organ failures subgroup 
Incremental costs 
(95% CI*) 
19,384 
(17,696 to 21,071 ) 
19,948  
(17,610 to 22,286) 
19,023 
(15,636 to 22,102) 
Incremental 
QALYs (95% 
CI*) 
0.98 
(0.65 to 1.33) 
1.28 
(0.86 to 1.70) 
0.542  
(-0.66 to 1.55) 
INBs (95% CI*) 391 
(-6,350 to 7,133) 
5,690 
(-2,543 to 13,924) 
-8,175 
(-31,787 to 11,845) 
Notes: * Bootstrapped confidence intervals, conditional on the estimated PS and matched data.  
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Figure 4.2 - Case study: Cost-effectiveness acceptability curves for DrotAA versus Control 
group using subgroup specific PSs and GM algorithms 
 
 
Notes: For the 2 organ failures subgroup, CEACs for GM and PS matching are indistinguishable 
 
Figure 4.2 presents CEACs which suggest that DrotAA is not cost-effective for the 2 
organ failures subgroup. The CEACs for the 3 to 5 organ failures subgroup differ 
somewhat by method; at realistic levels of WTP for a QALY gain in the UK (£20,000 to 
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£30,000) the probability that DrotAA is cost-effective is 30% following IPTW versus 
90% for the other methods. 
When the extreme inverse probability weights were truncated (Appendix 4.3, Figure 1), 
we found that covariate balance worsened (Appendix 4.3, Table 1), and the 95% CIs 
around the INBs were only slightly reduced (Appendix 4.3, Figure 2). When the GM 
algorithm was required to optimize alternative balance statistics (Kolmogorov-Smirnoff 
tests and paired t-tests), the results were similar to the base case. 
Monte Carlo simulation study 
Overview  
Monte Carlo simulations were conducted to examine the relative performance of the 
methods, for estimating cost-effectiveness in prespecified subgroups. The study design 
extended previous simulations comparing PS matching with IPTW (Austin, 2009b) or 
GM (Sekhon and Grieve, 2011), to recognize the specific challenges that arise when 
reporting cost-effectiveness by subgroup.  In particular, motivated by the case study, the 
treatment assignment mechanism was assumed to differ by subgroup. Cost and 
effectiveness data were simulated to recognize heterogeneity, and it was assumed that 
cost-effectiveness estimates were required by subgroup.  The case study also illustrated 
that the weights for IPTW can be unstable. Here, we investigate the implications of such 
unstable weights by including a nonlinear term in the PS. We also consider an issue 
specific to CEA, which concerns the choice of covariates when attempting to address 
selection bias for both cost and effectiveness endpoints.  The simulation study reported 
covariate balance, bias and RMSE of the estimated cost-effectiveness across the 
methods. 
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Description of scenarios 
In the 3 scenarios, each estimation method was initially assumed to follow the true 
treatment assignment mechanism, and then a misspecified treatment assignment as 
described below. In the first scenario, each approach assumed that the same treatment 
assignment mechanism applied for both subgroups, but in fact it differed by subgroup. 
The second scenario recognized that treatment assignment was subgroup-specific, but 
each estimation approach was misspecified by excluding a nonlinear term. This scenario 
also considered the hypothesis that IPTW may provide  inefficient estimates when, as in 
the case study, the estimated inverse probability weights are unstable (Cole and Hernán, 
2008).   
The third scenario considered the challenge of choosing the correct set of covariates 
when attempting to address selection bias for both cost and effectiveness endpoints. 
Here we build on a previous simulation (Brookhart et al., 2006) by introducing an 
additional covariate which is not a confounder for the cost endpoint, but does influence 
the effectiveness endpoint and the treatment assignment. We anticipate that 
conditioning on this variable will reduce bias in the estimated effectiveness, but will 
lead to more uncertainty in the estimation of incremental costs. The simulation 
scenarios are summarized in Table 4.3.  
Data generating process 
We simulated an observational dataset, extending previous data generating processes 
(DGPs) (Austin, 2009c, Austin, 2009b) to the context where cost-effectiveness 
estimates by subgroup are required. The main features of the DGP were grounded in the 
case study. In particular, there were two prespecified subgroups, heterogeneous 
treatment effects, a treatment assignment mechanism that differed by subgroup, 
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nonlinearities in the PS and unstable PS weights. For each subject, 3 confounders, 2 
continuous (𝑋1 and 𝑋2) and 1 binary (𝑋3), were generated from a bivariate normal and a 
Bernoulli distribution, respectively: 
(
𝑋1
𝑋2
) ~𝑁 {(
2
4
) , (
1 0.2
0.2 1
)} , 
𝑋3~𝐵𝑒𝑟𝑛 {
0.6 for 𝑋1 > 2
0.4 for 𝑋1 ≤ 2
} , 
where for example 𝑋1 has a mean of 2, standard deviation of 1, and the covariance 
between 𝑋1  and 𝑋2 is 0.2. The variable 𝑋3 defines the prespecified patient subgroup 
(subgroup 1 for 𝑋3=0 and subgroup 2 for 𝑋3=1). The treatment indicator, 𝑡𝑥,  was 
randomly generated from a Bernoulli distribution with parameter 𝑝, the PS, determined 
by a different logistic model for each pair of scenarios. 
To reflect a typical CEA, costs and outcomes (QALYs) were drawn from a bivariate 
normal-gamma distribution, using a copula function (Trivedi and Zimmer, 2005, 
Mihaylova et al., 2010, Quinn, 2007), with the correlation coefficient equal to 0.4.8  
QALYs were drawn from a normal distribution 
𝑄𝐴𝐿𝑌~𝑁(𝜇𝑄𝐴𝐿𝑌, 0.2) , 
 and costs from a gamma distribution with identity link, and shape and scale parameters 
defined as 
𝐶𝑜𝑠𝑡~Γ(10, 𝜇𝑐𝑜𝑠𝑡/10). 
The mean costs and QALYs, specific to each scenario are given below. 
                                                 
8 The copula function can generate draws from a flexible multivariate distribution (in this case the 
bivariate) with different marginal distributions (here, the normal and the gamma).  
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Scenario 1 
The true PS allowed the confounders to have a differential effect on treatment 
assignment according to subgroup, by including interaction terms in determining the 
logit of the PS as: 
𝑙𝑜𝑔𝑖𝑡(𝑝) = ln(0.2) + 0.1𝑋1 + 0.2𝑋2 + 0.3𝑋3 + 0.2𝑋1𝑋3 − 0.2𝑋2𝑋3 
The linear predictors for the cost and QALY endpoints also included interactions 
between 𝑋3 and 𝑡𝑥 to ensure heterogeneity in the incremental costs and QALYs: 
            𝜇𝑐𝑜𝑠𝑡 = 4000 + 4000𝑡𝑥 + 5000𝑋1 + 4000𝑋2 + 3000𝑋3 − 1000𝑋3𝑡𝑥, 
  
𝜇𝑄𝐴𝐿𝑌
= 9 + 0.25tx − 1𝑋1 − 0.6𝑋2 − 0.8𝑋3 + 0.5𝑋3𝑡𝑥. 
In scenario 1a (correct specification), subgroup-specific PSs were used for matching and 
weighting. Similarly, for each subgroup, GM was required to match on and balance 𝑋1, 
𝑋2 and the linear predictor of the estimated PS. In Scenario 1b, the PS and the GM 
algorithm were both misspecified; the PS was estimated for the overall sample 
(including 𝑋1, 𝑋2 and 𝑋3 in the logistic regression). The GM was required to match on, 
and maximize balance for 𝑋1, 𝑋2  and 𝑋3 across the overall sample.  
Scenario 2  
In Scenario 2 the term 𝑋1
2 was added to the true PS model. The coefficient for the 
𝑋1
2 term was  set to create unstable inverse probability weights for subgroup 2: 
𝑙𝑜𝑔𝑖𝑡(𝑝) =  𝑙𝑛(0.2) + 0.1𝑋1 + 0.2𝑋2 + 0.3𝑋3 + 0.2𝑋1
2𝑋3. 
In scenario 2a, we assumed correctly specified PS models: 𝑋1, 𝑋2 and 𝑋1
2 were all 
included in separate logistic regression models for each subgroup. For each subgroup, 
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GM was required to maximize balance on each term contributing to the true PSs, 
including  𝑋1
2. In scenario 2b, separate PS models and GM algorithms were specified as 
before. However, for subgroup 2,   𝑋1
2 was excluded from the PSs and from the terms 
GM was required to match on and balance.  
Scenario 3  
This scenario extended scenario 1a by introducing a new continuous variable in the 
assignment model,  𝑋4~𝑁(3,1), which was a confounder for the QALY but not for the 
cost endpoint. The logit of the PS model and the linear predictor of the QALY were 
defined as: 
𝑙𝑜𝑔𝑖𝑡(𝑝) = ln(0.2) + 0.1𝑋1 + 0.2𝑋2 + 0.3𝑋3 + 0.2𝑋1𝑋3 − 0.2𝑋2𝑋3 +  0.4𝑋4
− 0.2𝑋4𝑋3 
𝜇𝑄𝐴𝐿𝑌 = 9 + 0.5𝑡𝑥 − 1𝑋1 − 0.2𝑋2 − 0.8𝑋3 + 0.25𝑋3𝑡𝑥 +  0.1𝑋4  
In scenario 3a, the subgroup-specific PS models and the GM algorithms included 𝑋4, 
while in scenario 3b, this covariate was excluded. 
  
141 
 
Table 4.3 - Monte Carlo simulations: summary of scenarios 
 
PS matching, IPTW GM  
Scenario 1 : Subgroup-specific treatment assignment  
 1a  Correct specification Subgroup-specific 
PS 
Subgroup-specific PS and GM 
algorithm 
 
 1b   Misspecification Overall PS Overall PS and GM algorithm 
 
 
Scenario 2: Nonlinear term in PS   
2a  Correct specification Nonlinear term 
included in PS 
Nonlinear term included in PS and 
GM algorithm 
 
2b   Misspecification Nonlinear term 
excluded from PS 
Nonlinear term excluded from PS 
and GM algorithm 
 
 
Scenario 3:  Confounder for QALY   
 3a  Correct specification Confounder included 
in PS  
Confounder included in PS and 
GM algorithm 
 
3b   Misspecification Confounder excluded 
from  PS 
Confounder excluded from PS and 
GM algorithm 
 
 
Implementation  
One thousand datasets of sample size 2000 were simulated. Both PS matching and GM 
matched one-to-one to the nearest neighbor, with replacement. GM was required to 
maximize balance according to weighted standardized differences. In scenario 2a, as a 
sensitivity analysis, IPTW results were also reported after progressively truncating the 
extreme PS weights. INBs were calculated at a societal WTP of £20,000 per QALY 
gained. For scenarios 1 and 2, the true INBs were set to £1,000 (subgroup 1) and 
£12,000 (subgroup 2), and for scenario 3 to £6,000 and £12,000. The methods were 
compared by calculating weighted standardized differences (reported as percentage), 
relative bias, and RMSE for the estimated incremental costs, QALYs and INBs. 
Appendix 4.2 provides sample R code for the data generating processes and for 
implementing each method. 
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Results of the Monte Carlo simulations  
Covariate balance 
Table 4.4 reports the weighted standardized differences averaged over 1000 
replications. When each approach recognized the true treatment allocation mechanism 
(scenarios 1a, 2a, 3a), all the standardized differences were small. When the PS model 
was misspecified by fitting an overall PS, and the GM algorithm failed to match and 
balance at the subgroup level (scenario 1b), both PS matching and IPTW reported high 
standardized differences, whereas following GM, covariates were balanced.  In scenario 
2b, when the PS model for subgroup 2 excluded the nonlinear term 𝑋1
2, the 
standardized differences for 𝑋1
2 were 14% (IPTW), 4% (PS matching) and 3% (GM). In 
scenario 3b, when each method ignored 𝑋4, the standardized differences for this 
variable were high. 
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Table 4.4 - Monte Carlo simulations: covariate balance reported as weighted standardized 
differences (%). 
  
Subgroup 1 Subgroup 2 
 
Scenario Method X1 
 
X2 
 
X4 
 
X1 
 
X2 
 
X4 
 
        
1a PS matching 2.58 1.35  0.62 3.08  
 GM 0.10 0.12  0.19 0.15  
 IPTW 0.50 0.56  0.80 0.59  
1b PS matching 7.91 8.54  8.36 8.55  
 GM 1.69 1.88  1.82 1.82  
 IPTW 8.09 8.12  8.51 8.12  
2a  PS matching 2.50 1.68  1.78 4.88  
 GM 0.20 0.24  1.43 1.87  
 IPTW 0.44 0.58  5.35 3.49  
2b PS matching 2.58 1.35  2.21 4.97  
 GM 0.10 0.12  1.57 1.01  
 IPTW 0.50 0.56  5.09 2.06  
3a   PS matching 3.17 2.79   1.70 1.76 2.89 2.49 
 GM 0.32 0.30   0.38 0.20 0.18 0.18 
 IPTW 0.84 0.89   1.11 0.41 0.28 0.33 
3b  PS matching 2.40 1.31 39.82 0.57 2.83 20.08 
 GM 0.09 0.11 39.74 0.14 0.10 20.07 
 IPTW 0.44 0.47 39.62 0.31 0.20 19.98 
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Bias and RMSE 
Table 4.5 reports the relative bias and RMSE in the estimated INB, over 1000 
replications for each scenario. The corresponding results for the incremental costs and 
QALYs are reported in Appendix 4.3. In scenario 1a, when the subgroup-specific 
treatment allocation was recognized, bias was low following each method, and IPTW 
reported the lowest RMSE for both subgroups. When the subgroup-specific assignment 
mechanism was ignored (scenario 1b), bias and RMSE were higher following PS 
matching and IPTW than for GM. 
In scenario 2a, when the nonlinear term was correctly included in the PS for subgroup 2, 
biases were low but IPTW reported RMSE twice that of the matching methods. Insights 
as to why the precision for IPTW is worse can be gained from plotting the weights in a 
large sample (n=1,000,000), simulated by the same DGP.  Visual inspection suggests 
these weights are highly variable for the controls in subgroup 2 (Appendix 4.3, Figure 
3). When in the sensitivity analysis, weights are progressively truncated, the problem is 
not resolved; while the IPTW estimator for scenario 2a is less variable, bias increases 
(Appendix 4.3, Figure 4).  In Scenario 2b after omitting the nonlinear term from the PS  
for subgroup 2, IPTW reported the highest bias and RMSE. 
In scenario 3a, when each approach balanced all confounders including 𝑋4, IPTW 
reported the lowest RMSE. In scenario 3b, the failure to balance  𝑋4 resulted in biased 
estimates of the incremental QALY and the INB for all methods, with IPTW reporting 
the lowest RMSE. 
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Table 4.5 - Monte Carlo simulations: relative bias and RMSE for the INBs 
(WTP=£20,000) 
 
Subgroup 1 Subgroup 2 
Scenario Method Relative Bias 
(%) 
RMS
E 
Relative Bias 
(%) 
RMSE 
1a      
 PS matching 4.4 961 0.6 1068 
 GM  2.9 756 0.8 825 
 IPW  1.5 675 0.3 782 
1b      
 PS matching 58.0 1988 5.7 2031 
 GM  11.6 1060 1.6 1088 
 IPTW  71.3 1802 6.6 1875 
2a      
 PS matching 5.0 989 3.2 1484 
 GM  4.2 744 4.4 1267 
 IPTW  2.2 676 2.2 2535 
2b      
 PS matching 4.1 963 0.9 1306 
 GM  2.4 756 3.7 1210 
 IPTW  2.0 673 10.3 1839 
3a      
 PS matching  0.6 1271 0.7 1043 
 GM  0.7   699 0.3 784 
 IPTW  0.2   686 0.0 689 
3b      
 PS matching 12.5 1229 3.0 927 
 GM  12.4 1036 3.0 885 
 IPTW  12.7   999 3.3 802 
Notes: For scenarios 1 and 2 the true INBs are £1,000 (subgroup 1) and £12,000 (subgroup 2), and the 
corresponding INBs for scenario 3 are £6,000 and £12,000.  
 
  
146 
 
Discussion 
This paper compares alternative statistical methods for reducing selection bias when 
cost-effectiveness results are required for patient subgroups. The Monte Carlo 
simulation finds that if the treatment assignment mechanism ignores differential 
treatment allocation by subgroup, then cost-effectiveness estimates can be biased and 
inefficient. GM appears relatively robust to this misspecification, because it aims to 
balance confounders directly using an automated search algorithm. This is also 
highlighted in the case study, where GM achieves better balance than the other methods 
even if required to maximize balance across the overall treatment and control groups.  
This paper extends the work of Sekhon and Grieve (2011), who showed that GM can 
create good balance and reduce bias in CEA, even if the PS model is misspecified. Our 
article considers the important context of subgroup analysis and includes IPTW as a 
comparator. We find that IPTW provides unbiased, precise cost-effectiveness results for 
subgroups, if the PS is correctly specified and the weights are stable.  However, IPTW 
is sensitive to extreme probability weights (Kang and Schafer, 2007).  In the case study, 
we find that IPTW has unstable weights and reports INBs with wider CIs than the 
matching approaches, and is anticipated to provide divergent estimates of the expected 
value of further information (Fenwick et al., 2004). In the simulation scenario with 
unstable weights (due to nonlinearity in the PS model), IPTW reports high RMSE 
compared to matching. Truncating the weights (Cole and Hernán, 2008) improves 
precision, but increases imbalance and bias. 
Our work considers 2 distinct examples of PS misspecification: first, when the 
estimated PS  disregards differences in the treatment assignment between subgroups, 
and second, when a nonlinear term is omitted. The simulations demonstrate that IPTW 
is more sensitive to either misspecification than the matching methods. In the case 
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study, IPTW reported poor balance and, for the high risk subgroup, divergent point 
estimates, compared to either matching approach. GM reported good balance for both 
subgroups and PS approaches, and hence a relatively sound basis for the ensuing cost-
effectiveness estimates.  
This article also contributes to the general methodological literature by considering the 
methods in a bivariate context.  In CEA, potential confounders can differ between the 
cost and effectiveness endpoints; for example, baseline health-related quality of life 
might be associated with the QALY but not the cost endpoint. The simulations highlight 
that balance should be maximized on potential confounders for either endpoint. When a 
baseline covariate that influences just the QALY is left unbalanced, the estimates of the 
QALY gain are biased, and the only advantage is a slight improvement in the precision 
of the cost estimate. These findings extend previous univariate analyses showing that 
including covariates not associated with outcome reduces precision (Brookhart et al., 
2006).   
Our paper considers circumstances when subgroups are prespecified, informed by prior 
reasoning from the previous literature (Bernard et al., 2001, Ely et al., 2003). In other 
circumstances there may be insufficient information to predefine the subgroups of 
interest. Here, the optimal number and definition of subgroups could be established as 
part of the CEA,  based on expected health benefits (Espinoza et al., 2011). 
Alternatively, to report subgroup-specific treatment effects, regression analysis with 
treatment by covariate interactions (Nixon and Thompson, 2005) could be applied to the 
matched or weighted data.  The general requirement to choose an approach that 
minimizes selection bias is still of paramount importance, and can be informed by the 
results presented here. 
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This paper focuses on CEA that use patient-level data from a NRS. For many policy 
questions input parameters in decision analytical models are taken from studies that use 
either patient-level or aggregated estimates from NRS (Briggs et al., 2006, NICE, 2008, 
Kreif et al., 2012, Briggs et al., 2004). In this more general context to provide cost-
effectiveness results by subgroup, heterogeneity may need to be recognized for a range 
of model input parameters (e.g. rates of adverse events, estimates of health-related 
quality of life and transition probabilities) (Sculpher, 2008, Koerkamp et al., 2010). The 
potential for selection bias must be recognized when estimating subgroup-specific input 
parameters from NRS whether using patient-level data or extracting aggregate input 
parameters from the literature. By highlighting the selection biases that can arise, this 
study provides important insights both for those doing CEA using patient-level data 
without a decision model and for those developing and interpreting decision models that 
report cost-effectiveness estimates by patient subgroup. 
The major limitation of the methods described is that they all rely on the assumption of 
no unobserved confounding (Greenland et al., 1999).  The case study followed 
recommendations by identifying potential confounders a priori (Rubin, 2007) and a rich 
set of measured confounders were selected for adjustment, based on previous literature 
(Rowan et al., 2008) and clinical expert opinion. As in any observational study, 
unmeasured confounding can still be present. In our case study, the potential for hidden 
bias is greatest in the 2 organ failures subgroup. Here, approximately one-third of 
DrotAA cases were treated with delay, possibly leading to unobserved differences in 
baseline severity between the comparison groups. However, as the simulations 
highlight, omitting a confounder can lead to similar levels of hidden bias for each 
method. Hence, unmeasured confounding is unlikely to drive any differences in cost-
effectiveness results across the methods considered. Unobserved confounding can be 
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addressed with instrumental variables (Terza et al., 2008, Grootendorst, 2007) or control 
functions (Polsky and Basu, 2006). These approaches can potentially accommodate 
unobserved heterogeneity, and identify those patients who can make the largest health 
gains from treatment (Basu, 2011, Basu et al., 2007, Basu, 2009). 
This article raises several areas for further research. The performance of the methods 
presented here can be improved by exploiting information on the data-generating 
process for the cost and effectiveness endpoints (Imbens and Wooldridge, 2009a). 
Regression models can then be applied to the matched data to adjust for any remaining 
imbalances in observed characteristics between the treatment groups (Abadie and 
Imbens, 2011). Regression post matching can be relatively insensitive to the choice of 
model specification (Ho et al., 2007). Doubly robust methods (Robins et al., 1995, Kang 
and Schafer, 2007, Robins et al., 2007, van der Laan and Gruber, 2010) can be deployed 
that use the estimated PS as weights (Hirano and Imbens, 2001) or adjustment terms 
(Glynn and Quinn, 2010) in the endpoint models.  
We conclude that the key criterion for choosing amongst the proposed statistical 
methods is the level of covariate balance for each subgroup.  IPTW can provide 
unbiased, precise cost-effectiveness estimates for patient subgroups, but only if the PS 
is correctly specified, and the PS weights are stable. If the inverse probability weights 
are unstable, IPTW estimates can be biased and imprecise.  In most CEA that use 
observational data, the treatment assignment mechanism is unknown, and GM, which is 
an example of an automated approach, is relatively robust to PS misspecification. GM is 
publicly available  in standard software packages (Sekhon, 2011, Hartman and Sekhon, 
2011), and should be considered by future CEA that use NRS to report cost-
effectiveness by patient subgroup.  
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Appendix 4.1 - Genetic Matching 
Overview 
Genetic matching (GM) automates the process of maximizing balance on observed 
covariates in the matched sample by using an evolutionary search algorithm to 
determine the weight each individual covariate is given. As with any matching method, 
GM requires choices to be made a priori about which covariates to include in the 
matching and assessment of balance, and which balance statistic to use. In GM the key 
innovations are the generalised distance metric, and the use of an iterative search 
algorithm to maximize covariate balance. Full details of the method and its properties 
are covered in a general context elsewhere (Diamond and Sekhon, 2012, Sekhon, 2011), 
so here we summarize the key aspects. 
Selection of covariates for matching algorithm 
Before matching, it is necessary to choose which potential confounders to condition on. 
The researcher should follow general guidance and only include those covariates 
anticipated to influence the endpoints (Rubin, 2007). This selection process should also 
consider interaction effects as well as main effects and nonlinear terms. The choice can 
be informed by previous empirical analyses, expert opinion, and causal diagrams 
(Rubin, 2007, Pearl, 2001). The GM algorithm will only use those matching variables 
that are pre-specified. The choice of variables for balance assessment should include 
those anticipated to be of high prognostic importance whether or not they are included 
in the matching. For example, a summary prognostic measure may be excluded from the 
matching because it is highly correlated with the underlying covariates, and better 
overall balance may be achieved by just matching on the covariates. However, balance 
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should be checked on both the underlying covariates and the summary measure. GM 
can also be tailored to prioritize achieving covariate balance on particular covariates 
designated as “high priority”, for further details see Ramsahai et al. (2011) (Ramsahai et 
al., 2011). 
Covariate balance statistics 
A recommended statistic for checking covariate balance is the weighted standardized 
mean difference: 
𝑑 =
?̅?𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡−?̅?𝑐𝑜𝑛𝑡𝑟𝑜𝑙
√𝑠
2
𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡+ 𝑠
2
𝑐𝑜𝑛𝑡𝑟𝑜𝑙
2
, 
where for continuous covariates, ?̅? and 𝑠2 denote the covariate’s weighted means and 
variances. This balance statistic allows matching methods to be compared to IPTW, by 
using the appropriate weights. For matching these are the frequency weights from the 
matched datasets, and for IPTW the weights calculated from the PS. This balance 
statistic can be adapted for binary variables (Austin, 2009a).  
In some circumstances, the weighted standardized mean differences are an insufficient 
measure of balance as they are insensitive to imbalances in aspects of the covariate 
distribution beyond the mean (e.g., variance, maximum, skew, kurtosis). To address 
imbalances beyond differences in means for linear terms, matching methods can 
consider standardized differences for higher order terms, but also alternative balance 
statistics such as Kolmogorov-Smirnov (KS) tests and empirical quantile-quantile plots 
(Austin, 2009a).  The drawback with these non-parametric measures is that weighted 
versions that would enable comparisons between matching and IPTW are not currently 
available. 
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Distance metric 
The Mahalanobis distance (MD) between any two observations (one from treatment and 
the other from control) is:  
𝑀𝐷(𝐗𝑖, 𝐗𝑗) = {(𝐗𝑖−𝐗𝑗)
T
(𝐒−1/2)
T
𝐒−1/2(𝐗𝑖−𝐗𝑗)}
1
2
 
where S is the sample covariance matrix of X and 𝐗T is the transpose of the matrix X. 
Using this metric, the distance between individual covariates is collapsed into a single 
scalar. The PS can be combined with MD by, for example, including the PS as a 
variable in the X matrix. GM generalizes the MD by including an additional weight 
matrix W: 
𝐺𝑀𝐷(𝐗𝑖, 𝐗𝑗) = {(𝐗𝑖−𝐗𝑗)
T
(𝐒−1/2)
T
𝐖𝐒−1/2(𝐗𝑖−𝐗𝑗)}
1
2
 
where W is a 𝑘 ×  𝑘 positive definite weight matrix with 𝑘 being the number of 
matching covariates , and 𝑺−
1
2 is the Cholesky decomposition of S. GM essentially 
matches by minimizing the generalized version of MD. W is chosen to be the weight 
matrix that minimizes covariate imbalance according to the balance statistics the user 
chooses (e.g., standardized differences, KS statistics). The GM algorithm uses the 
distance measure, 𝐺𝑀𝐷, in which (by default) all elements of W are zero except down 
the main diagonal. The main diagonal is the vector of weights chosen by the algorithm. 
If each of the weights for the covariates are set equal to one and the weight for the PS is 
zero, 𝐺𝑀𝐷 is the same as 𝑀𝐷. That is, GM will converge to the MD if this is the 
optimal distance metric. If the PS contains all the information required to maximize 
covariate balance, the algorithm will converge to the corresponding distance metric, that 
is, the PS will be given full weight, and the other elements in W will be given zero 
weight. Hence, both PS and MD matching can be considered as limiting cases of GM. 
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The inclusion of individual covariates in the X matrix, rather than relying solely on the 
specification of the PS, helps ensure covariate balance when the PS is misspecified. In 
this sense, GM is robust to misspecifications in the PS. 
The iterative search algorithm 
Here we provide an overview of the optimization algorithm. Further details are 
available elsewhere (Sekhon and Mebane, 1998, Mebane and Sekhon, 2011). The aim 
of the GM algorithm is to find the optimal weights, W, that is the weight matrix which 
produces the matched sample with the best balance. GM uses a genetic search algorithm 
to search the weight matrices W, where each possible W corresponds to a different 
distance metric. The algorithm proposes batches of weights, Ws and moves towards the 
batch which contains the optimal weights. Each batch is a 𝑔𝑒𝑛𝑒𝑟𝑎𝑡𝑖𝑜𝑛 and is used 
iteratively to produce a subsequent generation with better candidate Ws. The size of 
each generation is the 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑠𝑖𝑧𝑒 (e.g., 1000) and is constant for all generations. 
For each generation the sample is matched according to each metric, corresponding to 
each W, to produce as many matched samples as the population size. Balance is 
evaluated for each matched sample and the algorithm identifies the weights 
corresponding to the best balance. The generation of candidate Ws evolves towards 
those containing, on average, better W and asymptotically converges to contain the 
optimal W: the one which maximizes balance. 
The X matrix includes all variables which are matched on and is used to define the GMD 
between units. The balance matrix consists of columns of data for each variable used to 
measure balance. By default, the balance matrix is identical to the X matrix. 
Optimization can be stopped either if there is no significant improvement in the 
minimum loss over a specified number of generations or after a fixed number of 
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generations (e.g., 200). The algorithm will optimize whichever balance statistics are 
chosen, recommended statistics include t-statistics from paired t-tests, D-statistics from 
Kolmogorov-Smirnov tests (Sekhon, 2011, Diamond and Sekhon, 2012)  and weighted 
standardized differences (Austin, 2009a, Stuart, 2010). 
Previous simulation evidence 
Diamond and Sekhon (2008) (Sadique et al., 2011) conducted an extensive simulation 
study to compare the performance of GM to other matching methods (PS matching, MD 
matching, PS and MD matching combined). The results showed that GM produced 
better covariate balance. Where the PS was correctly specified and the covariates were 
multivariate normal, GM dominated the other multivariate matching methods in terms 
of bias and RMSE, and reported lower MSE than PS matching. When the PS was 
misspecified, GM reported lower bias and RMSE than the other estimators. Sekhon and 
Grieve (2011) (Sekhon and Grieve, 2011) compared GM to PS matching in a 
challenging setting where some covariates were discrete, and others continuous but with 
highly skewed distributions. The simulation reported that GM achieved better covariate 
balance, lower bias and MSE, compared with PS matching. 
Diamond and Sekhon (2010) (Diamond and Sekhon, 2012) also compared the 
performance of GM to PS matching, where the PS was estimated by a linear logistic 
regression model, random forests and boosted Classification and Regression Trees 
(CART). The simulations considered scenarios that differed in the degree of linearity 
and additivity in the true PS model, that is the extent to which the PS model included 
quadratic and interaction terms. GM reported the smallest MSE and bias, apart from one 
scenario where matching on the correctly specified PS model gave least bias. 
160 
 
Implementation 
Various matching options can be implemented in the  software for GM (Sekhon, 2011). 
For example, matching can be performed with or without replacement, with calipers, 
1:1 or 1:n, with or without ties. Software and further details can be found at 
http://sekhon.berkeley.edu/matching. 
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Appendix 4.2 - Illustrative R code for the simulation study of 
research paper 2 
For scenario 1a the following code was used for the data generating process, and to 
report balance and average treatment effects (ATEs). For the remaining scenarios, the 
code was modified accordingly.  
Data generating process 
The following libraries are required for the code: 
library(Rlab) 
library(Matching) 
library(stats) 
library(boot) 
library(copula) 
 
A simulated dataset, including the covariates X1,X2,X3 the treatment variable tx and 
the endpoints cost and Y (denoting QALY) was created using the following 
commands: 
Sigma<-matrix(c(1,0.2,0.2,1),2,2)     
   Data generating 
X12<-mvrnorm(n,c(2, 4), Sigma)     
  
X1<-X12[,1]         
  
X2<-X12[,2]         
  
X3<-rbern(n,0.5+ifelse(X1>2,0.1,-0.1))    
   
psc_logit<-log(0.2)+(0.1*X1)+(0.2*X2)+(0.3*X3)+(0.2*X1*X3)-
(0.2*X2*X3) 
 
psc<-inv.logit(psc_logit) 
tx<-rbern(n,psc) 
 
E.cost<- 4000+ 4000*tx+5000*X1+4000*X2+3000*X3-1000*X3*tx 
E.cost=ifelse(E.cost<=0,0.1,E.cost) 
E.Y <- 9+0.25*tx-(1*X1)-(0.6*X2)-(0.8*X3)+(0.5*X3*tx)  
 
ngmvdc <- mvdc(normalCopula(0.4), c("norm", "gamma"), 
          list(list(mean = E.Y, sd =0.2), 
list(shape=10,rate=10/E.cost))) 
rng <- rmvdc(ngmvdc, n) 
 
Y <- rng[,1] 
cost <- rng[,2] 
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dataset<-cbind(X1,X2,X3,Y,cost,tx) 
dataset<-as.data.frame(dataset)      
   
dataset.X3 <- dataset[dataset$X3==1,]                       
dataset.noX3 <- dataset[dataset$X3==0,] 
 
The object dataset denotes the whole sample, dataset.noX3 and dataset.X3 are 
the subsamples for subgroup 1 and subgroup 2, respectively. 
PS model fitting 
Two PS models were fitted for subgroup 1 and subgroup 2. Subgroup specific 
propensity scores (pscore.noX3 and pscore.X3), linear predictors (pscore.lin.noX3 
and pscore.lin.X3) and inverse probability weights (pscorwght.noX3 and 
pscorwght.X3) were calculated, and attached to the datasets: 
pmodel.noX3<-glm(tx~X1+X2+X3,family=binomial,data=dataset.noX3) 
pscore.lin.noX3<-pmodel.noX3$linear.predictor     
pscore.noX3<-pmodel.noX3$fitted.values      
pscorwght.noX3<-(dataset.noX3$tx/pscore.noX3)+ 
((1-dataset.noX3$tx)/(1-pscore.noX3))   
 dataset.noX3<-
cbind(dataset.noX3,pscore.noX3,pscore.lin.noX3, 
pscorwght.noX3)       
rm(pscore.lin.noX3,pscore.noX3,pscorwght.noX3) 
pmodel.X3<-glm(tx~X1+X2+X3,family=binomial,data=dataset.X3)   
pscore.lin.X3<-pmodel.X3$linear.predictor     
 pscore.X3<-pmodel.X3$fitted.values      
pscorwght.X3<-(dataset.X3$tx/pscore.X3)+((1-dataset.X3$tx)/ 
(1-pscore.X3)) 
dataset.X3<-
cbind(dataset.X3,pscore.X3,pscore.lin.X3,pscorwght.X3)
 rm(pscore.lin.X3,pscore.X3,pscorwght.X3) 
 
In the following sections, the implementation of PS matching, GM and IPTW is 
described, for subgroup 1. For subgroup 2, the code was modified accordingly.  
PS matching 
First, matched datasets were created, using the Match() function from the Matching 
library.  
attach(dataset.noX3)              
           
mtchout.Y.noX3<-Match(Y=Y,Tr=tx, 
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X=cbind(pscore.lin.noX3),exact=c(FALSE), 
estimand="ATE")  
mtchout.cost.noX3<-
Match(Y=cost,Tr=tx,X=cbind(pscore.lin.noX3),exact=c(FALSE),estim
and="ATE")  
 
detach(dataset.noX3) 
 
mtch.data.noX3<-
rbind(dataset.noX3[mtchout.Y.noX3$index.treated,] 
,dataset.noX3[mtchout.Y.noX3$index.control,])   
mtch.data.noX3<-
cbind(mtch.data.noX3,weights=c(mtchout.Y.noX3$weights,mtchout.Y.
noX3$weights)) 
 
After matching, ATEs for the QALY and cost endpoint can be extracted as follows: 
 
Y_ps.noX3<-mtchout.Y.noX3$est 
cost_ps.noX3<-mtchout.cost.noX3$est  
 
The covariate balance measured as weighted standardized differences can be reported, 
for example for the covariate X1 as follows:  
attach(mtch.data.noX3) 
 
X1.ps.sdiff.X3<-100*abs(weighted.mean(x=as.matrix(X1[tx==1]), 
w=weights[tx==1])- 
weighted.mean(x=as.matrix(X1[tx==0]),w=weights[tx==0])) 
/sqrt((cov.wt(x=as.matrix(X1[tx==1]), 
wt=weights[tx==1])$cov+ 
cov.wt(x=as.matrix(X1[tx==0]),wt=weights[tx==0])$cov)/2) 
 
detach(mtch.data.noX3) 
Genetic Matching 
The automated GM algorithm was run using the GenMatch() function from  the 
Matching library: 
genmtchout.noX3<-GenMatch(Tr=tx,X=cbind(pscore.lin.noX3,X1,X2), 
estimand="ATE", 
fit.func = my.fitfunc_sdiff,  
starting.values=c(10000,0,0),exact=c(FALSE,FALSE, 
FALSE),pop.size=gpop,unif.seed=seedin, 
int.seed=seedin)           
 
Matched datasets were then created:  
attach(dataset.noX3)                   
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gmtchout.Y.noX3<Match(Y=Y,Tr=tx,X=cbind(pscore.lin.noX3,X1,X2), 
exact=c(FALSE,FALSE,FALSE),Weight.matrix=diag(w8s), 
estimand="ATE") 
 
gmtchout.cost.noX3<-       
Match(Y=cost,Tr=tx,X=cbind(pscore.lin.noX3,X1,X2), 
exact=c(FALSE,FALSE,FALSE),Weight.matrix=diag(w8s), 
estimand="ATE") 
detach(dataset.noX3)  
mtch.data.noX3<rbind(dataset.noX3[gmtchout.Y.noX3$index.treated,
], 
dataset.noX3[gmtchout.Y.noX3$index.control,])    
    
mtch.data.noX3<cbind(mtch.data.noX3, 
weights=c(gmtchout.Y.noX3$weights, 
gmtchout.Y.noX3$weights))        
  
ATEs can then be extracted as previously:     
Y_gn.noX3<-gmtchout.Y.noX3$est 
cost_gn.noX3<-gmtchout.cost.noX3$est       
 
The covariate balance for the covariate X1 can be calculated as follows:  
attach(mtch.data.noX3)  
X1.gn.sdiff.noX3<- 
100*abs(weighted.mean(x=as.matrix(X1[tx==1]), 
w=weights[tx==1])- 
weighted.mean(x=as.matrix(X1[tx==0]),w=weights[tx==0]))/ 
sqrt((cov.wt(x=as.matrix(X1[tx==1]), 
wt=weights[tx==1])$cov 
+cov.wt(x=as.matrix(X1[tx==0]), 
wt=weights[tx==0])$cov)/2) 
 
detach(mtch.data.noX3)  
Inverse probability of treatment weighting 
The inverse probability weights (variable pscorwght.noX3) calculated previously 
were used in a weighted mean difference of the respective endpoints, to calculate the 
average treatment effects. 
attach(dataset.noX3)       
    
Y_ipw.noX3<-weighted.mean(x=Y[tx==1], 
w=pscorwght.noX3[tx==1])-
weighted.mean(x=Y[tx==0],w=pscorwght.noX3[tx==0]) 
 
cost_ipw.noX3<-weighted.mean(x=cost[tx==1], 
w=pscorwght.noX3[tx==1])-
weighted.mean(x=cost[tx==0],w=pscorwght.noX3[tx==0]) 
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Balance can be calculated as standardized mean difference, where the treated and 
control samples are weighted with the inverse probability weights: 
X1.ipw.sdiff.noX3<-100*abs(weighted.mean(x=as.matrix(X1[tx==1]), 
w=pscorwght.noX3[tx==1])-
weighted.mean(x=as.matrix(X1[tx==0]),w=pscorwght.noX
3[tx==0]))/sqrt((cov.wt(x=as.matrix(X1[tx==1]),wt=ps
corwght.noX3[tx==1])$cov+cov.wt(x=as.matrix(X1[tx==0
]),wt=pscorwght.noX3[tx==0])$cov)/2) 
 
detach(dataset.noX3) 
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Appendix 4.3 - Supplementary tables and figures for research 
paper 2 
Appendix 4.3 Table 1 - Sensitivity analysis for the case study. Covariate balance (% 
weighted standardized differences) after IPTW with weights truncated to different 
percentiles. 
Covariate Percentile 2 organ failures 3 to 5 organ failures 
Age    
 0,100 9.06 7.24 
 1,99 9.13 2.72 
 5,95 14.83 8.33 
 10,90 20.33 13.29 
 25,75 26.19 24.52 
IMprob    
 0,100 5.58 9.86 
 1,99 7.49 0.27 
 5,95 8.17 4.88 
 10,90 9.04 7.75 
 25,75 10.47 14.01 
IMscore    
 0,100 3.88 12.41 
 1,99 9.97 4.93 
 5,95 16.31 12.89 
 10,90 21.66 18.45 
 25,75 27.92 30.61 
% Ventilated   
 0,100 5.99 13.19 
 1,99 13.39 5.54 
 5,95 20.23 10.55 
 10,90 24.89 14.60 
 25,75 30.74 24.44 
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Appendix 4.3 Table 2 - Monte Carlo simulations: relative bias for estimated incremental 
costs (ΔC), QALYs (ΔE) and INBs (WTP=£20,000) 
Scenario Method Relative bias (%) 
ΔC 
 
Relative bias (%) 
ΔE 
 
Relative bias (%) 
INB 
 
  Subgr. 1 Subgr. 2 Subgr. 1 Subgr. 2 Subgr. 1 Subgr. 2 
        
1a        
 
PS 
matching 0.3 0.0 0.6 0.5 4.4 0.6 
 GM  0.1 1.2 0.5 0.4 2.9 0.8 
 IPTW 0.2 0.0 0.1 0.2 1.5 0.3 
1b        
 
PS 
matching 1.3 2.5 10.6 4.0 58.0 5.7 
 GM  0.7 1.2 1.8 1.0 11.6 1.6 
 IPTW 2.1 3.0 12.6 4.7 71.3 6.6 
2a        
 
PS 
matching 0.4 3.0 0.7 1.9 5.0 3.2 
 GM  0.3 3.9 0.6 2.8 4.2 4.4 
 IPTW 0.2 2.5 0.3 1.3 2.2 2.2 
2b        
 
PS 
matching 0.3 0.4 0.6 0.8 4.1 0.9 
 GM  0.1 2.0 0.4 2.5 2.4 3.7 
 IPTW 0.3 8.7 0.2 6.5 2.0 10.3 
3a        
 
PS 
matching 0.8 0.0 0.0 0.5 0.6 0.7 
 GM  0.4 0.6 0.2 0.3 0.7 0.3 
 IPTW 0.3 0.3 0.0 0.1 0.2 0.0 
3b        
 
PS 
matching 0.5 0.5 7.7 2.3 12.5 3.0 
 GM  0.3 0.0 7.6 2.4 12.4 3.0 
 IPTW 0.3 0.4 7.8 2.6 12.7 3.3 
        
Notes: True value of incremental costs is £3,000 (Subgroup 1) and £4,000 (Subgroup 2), for all 
Scenarios.  True value of incremental QALYs for Scenarios 1 and 2 are 0.25 (Subgroup 1) and 0.75 
(Subgroup 2), and for Scenario 3, 0.5 and 0.75. The true INBs are therefore £1,000 and £12,000 for 
Scenarios 1 and 2, £6,000 and £12,000 for Scenario 3.  
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Appendix 4.3 Table 3 - Monte Carlo simulations: RMSE for estimated incremental costs 
(ΔC), QALYs (ΔE) and INBs (WTP=£20,000) 
Scenario Method 
 
RMSE: ΔC 
 
RMSE: ΔE 
 
RMSE: INB 
 
  Subgr. 1 Subgr. 2 Subgr. 1 Subgr. 2 Subgr. 1 Subgr. 2 
        
1a        
 
PS 
matching 788 915 0.03 0.03 961 1,068 
 GM  819 889 0.02 0.02 756 825 
 IPTW 679 773 0.02 0.02 675 782 
1b        
 
PS 
matching 853 953 0.08 0.08 1,988 2,031 
 GM  818 888 0.03 0.03 1,060 1,088 
 IPTW 765 841 0.07 0.07 1,802 1,875 
2a        
 
PS 
matching 787 1,231 0.03 0.04 989 1,484 
 GM  790 1,173 0.02 0.03 744 1,267 
 IPTW 681 1,155 0.02 0.09 676 2,535 
2b        
 
PS 
matching 788 1,224 0.03 0.03 963 1,306 
 GM  820 1,192 0.02 0.03 756 1,210 
 IPTW 680 920 0.02 0.07 673 1,839 
3a        
 
PS 
matching 812 866 0.04 0.03 1,271 1,043 
 GM  755 845 0.02 0.01 699 784 
 IPTW 682 730 0.02 0.01 686 689 
3b        
 
PS 
matching 769 835 0.05 0.03 1,229 927 
 GM  771 856 0.04 0.02 1,036 885 
 IPTW 668 724 0.04 0.02 999 802 
        
Notes: True value of incremental costs is £3,000 (subgroup 1) and £4,000 (subgroup 2), for all scenarios.  
True value of incremental QALYs for scenarios 1 and 2 are 0.25 (subgroup 1) and 0.75 (subgroup 2), and 
for scenario 3, 0.5 and 0.75. The true INBs are therefore £1,000 and £12,000 for Scenarios 1 and 2, 
£6,000 and £12,000 for scenario 3.  
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Appendix 4.3 Figure 1 - Sensitivity analysis for the case study. Distribution of inverse 
probability weights for DrotAA and control groups  
 
 
Notes: The boxplots show the median, interquartile distance and extreme values of the inverse probability 
weights. 
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Appendix 4.3 Figure 2 - Sensitivity analysis for case study. 95% bootstrapped CIs 
following IPTW, after truncation of the weights according to different percentiles  
 
Notes: 0,100 corresponds to no truncation, 1,99 corresponds to the case where weights are truncated at 
the first and 99th percentiles 
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Appendix 4.3 Figure 3 - Sensitivity analysis for the Monte Carlo simulations, Scenario 2a. 
Distribution of inverse probability weights for treated and control observations, generated 
for a typical sample (n=1,000,000)  
 
Notes: The boxplots show the median, interquartile distance and extreme values of the inverse probability 
weights. 
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Appendix 4.3 Figure 4 - Sensitivity analysis for the Monte Carlo simulations, scenario 2a. 
Boxplots of the INBs (WTP= £20,000) after IPTW with truncated weights.  
 
Notes: Dotted lines indicate the true values of the INBs (1,000 for subgroup 1 and 12,000 for subgroup 
2). 100 corresponds to no truncation, 99 corresponds to the case where weights are truncated at the first 
and 99th percentiles. Results are across 1000 replications. 
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Chapter 5 - Statistical methods that combine the PS with 
endpoint regression models, for estimating cost-
effectiveness 
5.1 Preamble to research paper 3 
The conceptual review (chapter 2) highlighted the challenges in CEA of correctly 
specifying the PS and the regression models for the cost and effectiveness endpoints. 
The critical appraisal of the applied literature (research paper 1) found that most applied 
CEA used regression or PS matching for addressing selection bias; however they did 
not carefully assess whether it was plausible to assume that the PS and the endpoint 
regression models were correctly specified.  
Research paper 2 proposed the use of GM to protect against misspecification of the PS. 
The conceptual review (chapter 2) also suggested methods that combine the PS with 
endpoint regression models: DR methods and regression-adjusted matching. These 
methods can provide unbiased estimates even when either the PS or the endpoint 
models is misspecified. These methods have not been considered for addressing 
selection bias in CEA before. Research paper 3 aims to address this gap in the literature. 
This paper compares DR with regression-adjusted PS matching, traditional PS and 
regression approaches, for estimating incremental cost-effectiveness.  The simulation 
study is grounded in a motivating CEA. The paper provides insights on the relative 
performance of the methods across typical CEA settings. To assist applied researchers 
who wish to implement the proposed methods, the paper provides sample software code 
(Appendix 5.1) 
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Abstract 
Regression and propensity score (PS) methods can reduce selection bias when 
estimating average treatment effects (ATEs), if their underlying models are correctly 
specified. In cost-effectiveness analysis (CEA), the correct specification of these models 
can be challenging, due to potential nonlinear functional form relationships. Double-
robust (DR) methods and regression-adjusted matching can protect against bias from 
model misspecification, but their relative performance has not been previously assessed. 
This paper compares selected DR methods (weighted regression and augmented inverse 
probability of treatment weighting), regression-adjusted matching, regression and PS 
methods for addressing selection bias in CEA. 
We contrast the methods in a CEA of a pharmaceutical intervention, Drotrecogin alfa, 
for severe sepsis. We find that cost-effectiveness estimates differ across methods, and 
methods that combine the PS with endpoint regression report narrower confidence 
intervals than methods that use the PS alone. Motivated by the case study, our 
simulation study compares the methods in scenarios with estimated PSs close to 0 or 1, 
that have unstable inverse probability of treatment (IPT) weights. The simulations 
include settings with functional form misspecification in the PS and endpoint regression 
models (e.g. cost model with log instead of identity link). Measures of relative 
performance include bias and root mean squared error (RMSE) of the incremental net 
benefit.   
We found that combining PS methods with endpoint regression reduced bias and RMSE 
compared to using PS only. With unstable IPT weights and misspecifications to the PS 
and regression models, regression-adjusted matching reported less bias than DR 
methods, and the lowest RMSE of all the approaches considered.  
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Introduction 
Recent investments in large observational datasets offer new opportunities for 
comparative effectiveness research, including cost-effectiveness analysis (CEA). CEA 
ideally use evidence from pragmatic randomised controlled trials (RCTs) which include 
patients, centres and comparators appropriate to the decision context (Willan and 
Briggs, 2006, Glick et al., 2007, Gray et al., 2010). For many decision problems RCTs 
may be unavailable or insufficient, and so the CEA may be reliant partly or entirely on 
non-randomised studies (NRS) (Kreif et al., 2012b). While instrumental variable 
methods  (Basu et al., 2007) can remove selection bias due to observed and unobserved 
confounding, in many circumstances plausible instruments are not available. The 
majority of CEA that use individual patient data from NRS rely on regression and 
propensity score (PS) methods (Kreif et al., 2012b). These approaches assume 
“unconfoundedness”, but also that the functional form of the regression model or the PS 
is correctly specified. Alternatively, regression and PS approaches can be combined, for 
example in double-robust (DR) estimation (Bang and Robins, 2005), or regression-
adjusted matching (Ho et al., 2007). Both “combined approaches” can protect against 
bias from misspecification of the PS or regression models, but they have not been 
compared before.  
DR methods combine inverse probability of treatment (IPT) weights with endpoint 
regression models. Under the “double-robust” property, unbiased estimates of average 
treatment effects (ATEs) can be obtained if either one of the regression or PS models is 
correctly specified (Robins et al, 1994). However, when estimated propensity scores are 
close to 0 or 1, the IPT weights can be unstable. In circumstances where there is dual 
misspecification and unstable IPT weights, certain DR approaches have been reported to 
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be more biased and less efficient than  ordinary least squares (OLS) regression (Kang 
and Schafer, 2007, Freedman and Berk, 2008).   
An alternative “combined approach” is regression-adjusted matching (Hill and Reiter, 
2005, Ho et al., 2007), which aims to create balanced comparison groups before 
regression adjustment. This approach purports to reduce the sensitivity of the regression 
estimates to the choice of model specification (Dehejia and Wahba, 2002, Ho et al., 
2007).   
Regression-adjusted matching and DR methods warrant particular consideration for 
CEA that use data from NRS. A recent systematic review found that most studies use 
regression or PS matching, but do not carefully assess model specification (Kreif et al., 
2012b). DR methods have been proposed for addressing censoring (Pan and Zeng, 
2011, Bang and Tsiatis, 2000), or selection bias in cost analyses (Basu et al., 2011), but 
have not been considered for CEA. Previous findings on the relative merits of 
alternative DR methods (Porter et al., 2011, van der Laan and Gruber, 2010, Robins et 
al., 2007) may not translate to the CEA setting. Here typical circumstances include: 
baseline covariates that are widely imbalanced between the treatment groups, unstable 
IPT weights, and misspecified parametric models for both costs (Jones, 2010) and 
health outcomes (Basu and Manca, 2011).  
The aim of this paper is to compare selected DR estimators with a regression-adjusted 
PS matching estimator, and common PS or regression approaches for estimating ATEs 
in CEA. We illustrate the approaches with a case study, a CEA of a pharmaceutical 
intervention, Drotrecogin alfa (DrotAA) for patients with severe sepsis. We consider the 
relative performance of the methods in a simulation study that extends an influential 
methodological paper in medical statistics (Kang and Schafer, 2007, Robins et al., 2007, 
Porter et al., 2011) to a bivariate CEA context. The simulation study design is grounded 
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in the characteristics of the case study, for example by including scenarios with unstable 
IPT weights.  
In the next section, we outline the statistical methods under comparison. The following 
section presents the motivating example. We then report the design and results of the 
simulation study. The last section discusses the findings and suggests areas for further 
research.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
Statistical methods 
The methods considered assume no unobserved confounding, and require choices about 
potential measured confounders, 𝑥, to be made in advance, for example drawing on 
theory (Rubin, 2007), published literature, expert opinion or causal diagrams (Pearl, 
1995). We denote by 𝑌𝑖𝑘 the observed outcome (cost if 𝑘 = 𝐶 and effectiveness if 𝑘 =
𝐸), for individual 𝑖 = 1, . . . . , 𝑛, where 𝑛 is the sample size. The parameter of interest is 
the average treatment effect (ATE) of a binary treatment 𝑡,  which in CEA corresponds 
to the incremental cost and effectiveness parameters.  
Regression adjustment  
Incremental cost, effectiveness and cost-effectiveness can be modelled with simple 
generalised linear models (GLM) (Barber and Thompson, 2004), two-part models  
(Buntin and Zaslavsky, 2004, Basu, 2011), semi-parametric methods such as extended 
estimating equations (Basu and Rathouz, 2005), or flexible parametric methods such as 
beta-type size distributions (Jones et al., 2011). These approaches have the potential to 
address skewness, heavy tails and nonlinear relationships between covariates and 
endpoints. A general concern is that, even a flexible parametric approach is not a 
substitute for finding the correct model specification (Manning et al., 2005).  
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We consider common GLMs for estimating incremental cost and effectiveness. 
Following Barber and Thompson (2004), GLMs for 𝑌𝑖𝑘 can be written as 
                      𝑔𝑘(𝜇𝑖,𝑘) = 𝛾𝑘𝑡𝑖 + 𝑥𝑖𝛽𝑘;     𝑌𝑖𝑘~𝐹𝑘.                                    (1) 
Here 𝜇𝑖,𝑘 = 𝐸(𝑌𝑖,𝑘) is the expectation of 𝑌𝑖,𝑘,  𝑔𝑘 is the link function which describes 
the scale on which 𝑥𝑖 are related to 𝑌𝑖,𝑘, 𝛾𝑘 and 𝛽𝑘  are the regression coefficients, and 
𝐹𝑘 is an exponential family distribution. Parameters can be estimated via maximum 
likelihood (ML), quasi ML or Bayesian methods (Basu and Manca, 2011). The joint 
uncertainty in the estimates of the incremental cost-effectiveness can be recognised by 
bivariate models (Nixon and Thompson, 2005) or with the nonparametric bootstrap  
(Davison and Hinkley, 1997). A common GLM for estimating incremental costs uses 
the gamma distribution with a log link (Buntin and Zaslavsky, 2004), and assumes that 
the covariates have multiplicative effects on the endpoint. A general way to obtain 
ATEs, which can handle such nonlinearities is with the method of recycled predictions 
(Basu and Rathouz, 2005) : 
1
𝑛
∑ {?̂?𝑖,𝑘(𝑥𝑖,, 𝑡𝑖 = 1) − ?̂?𝑖,𝑘(𝑥𝑖,, 𝑡𝑖 = 0)},               
𝑛
𝑖=1                       (2) 
 where ?̂?𝑖,𝑘(. ) is the predicted mean of 𝑌𝑖𝑘 from the GLM (1)  given 𝑥𝑖, and 𝑡𝑖 is set to 1 
and 0 for the whole sample.  
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Propensity score methods 
Propensity score matching 
The PS is the conditional probability of treatment assignment given 𝑥𝑖 (Rosenbaum  and 
Rubin, 1983): 
                𝑝𝑖 = 𝑃𝑟(𝑡𝑖 = 1|𝑥𝑖). 
Consistent estimates of the ATE can be obtained by creating matched treated and 
control comparison groups, using the estimated PS, ?̂?𝑖 as a distance metric (Rosenbaum  
and Rubin, 1983). However, in finite samples even a correctly specified PS can leave 
some baseline covariates imbalanced, which can lead to bias if these variables are 
highly prognostic (Stuart, 2010). Implementations of PS matching include pair 
matching, nearest neighbour or kernel matching (Imbens and Wooldridge, 2009a, 
Stuart, 2010, Basu et al., 2011). Here we consider nearest neighbour 1:1 matching with 
replacement, without callipers9 (Austin, 2008, Caliendo and Kopeinig, 2008, Stuart, 
2010). 
The matching estimator is the weighted mean difference between matched treated and 
control groups, which can be written as:  
1
𝑛
∑{(2𝑡𝑖 − 1)(1 + 𝐾𝑖)𝑌𝑖,𝑘},               
𝑛
𝑖=1
 
where 𝐾𝑖 is the sum of the frequency  weights unit 𝑖 has as a match for other units 
(Abadie et al., 2004a).   
                                                 
9 Here a calliper is defined as the pre-specified amount by which propensity scores of matched 
pairs are allowed to differ. 
183 
 
Inverse probability of treatment weighting 
IPTW can estimate ATEs, by reweighting the observed cost and effectiveness endpoints 
for treatment and control samples10. The IPT weight 𝑤𝑖 is the inverse of the estimated 
probability of the observed treatment, 𝑤𝑖 =
𝑡𝑖
𝑝𝑖
+ 
1−𝑡𝑖
1−𝑝𝑖
 . If the PS is correctly specified, 
IPTW can provide consistent estimates and reach semi-parametric efficiency (Hirano et 
al., 2003). However, even when the PS model is correctly specified, practical violations 
of the positivity assumption (Westreich and Cole, 2010) resulting in unstable weights, 
can lead to estimates of ATEs that are biased and inefficient (Kang and Schafer, 2007, 
Lee et al., 2010, Busso et al., 2011). Here we implement the normalised IPTW estimator 
(Hirano and Imbens, 2001, Kang and Schafer, 2007), defined as: 
∑ 𝑡𝑖𝑤𝑖𝑌𝑖,𝑘  
𝑛
𝑖=1
∑ 𝑡𝑖𝑤𝑖  
𝑛
𝑖=1
−
∑ (1 − 𝑡𝑖)𝑤𝑖𝑌𝑖,𝑘
𝑛
𝑖=1
∑ (1 − 𝑡𝑖)𝑤𝑖  
𝑛
𝑖=1
 
Combining regression and PS adjustment 
Double-robust methods 
Double-robust (DR) methods combine models for the PS and for the endpoint. The 
distinctive property of DR estimators is that they are consistent if either (but not 
necessarily both) the PS or the regression model is correctly specified (Robins et al., 
1994, Robins et al., 1995, Bang and Robins, 2005). If both components are correct, the 
DR estimator is a semiparametric efficient estimator (Robins et al., 2007). Compared to 
IPTW, DR methods can increase efficiency, by stabilising the IPT weights (Glynn and 
Quinn, 2010). However when both the PS and the endpoint model are misspecified, DR 
                                                 
10  Further possible ways of balancing with the PS include stratification (blocking) by the quintiles of the 
PS and adding the PS as a covariate (Rosenbaum and Rubin, 1983). They have been demonstrated to be 
dominated by IPTW and matching (Lunceford and Davidian, 2004, Austin, 2009b). 
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estimators generally provide biased and inefficient estimates of ATEs (Kang and 
Schafer, 2007, Porter et al., 2011, Freedman and Berk, 2008, Basu et al., 2011).  
Here, we consider DR methods that are commonly used in the causal inference literature 
(Lunceford and Davidian, 2004, Funk et al., 2011, Freedman and Berk, 2008). The 
augmented IPTW (AIPTW) (Robins et al., 1994, Basu et al., 2011) estimator weights 
residuals from a regression model. The AIPTW estimator is: 
 
∑ 𝑡𝑖𝑤𝑖(𝑌𝑖,𝑘 − ?̂?𝑖,𝑘(𝑥𝑖))  
𝑛
𝑖=1
∑ 𝑡𝑖𝑤𝑖  
𝑛
𝑖=1
−
∑ (1 − 𝑡𝑖)𝑤𝑖(𝑌𝑖,𝑘 − ?̂?𝑖,𝑘(𝑥𝑖)) 
𝑛
𝑖=1
∑ (1 − 𝑡𝑖)𝑤𝑖  
𝑛
𝑖=1
+ 
1
𝑛
∑ {?̂?𝑖,𝑘(𝑥𝑖, 𝑡𝑖 = 1) − ?̂?𝑖,𝑘(𝑥𝑖, 𝑡𝑖 = 0)}
𝑛
𝑖=1 , 
where ?̂?𝑖,𝑘(. ) is the predicted endpoint from the GLMs defined in equation (1), and 𝑤𝑖 
is the IPT weight. 
One alternative is the weighted regression estimator (Freedman and Berk, 2008, Kang 
and Schafer, 2007), which can be constructed by combining 𝑤𝑖 with the GLMs for 
𝑌𝑖𝑘.  ATEs can be obtained using the method of recycled predictions: 
1
𝑛
∑{?̂?𝑖,𝑘,𝑤𝑟𝑒𝑔(𝑥𝑖,, 𝑡𝑖 = 1) − ?̂?𝑖,𝑘,𝑤𝑟𝑒𝑔(𝑥𝑖,, 𝑡𝑖 = 0)},
𝑛
𝑖=1
 
where ?̂?𝑘,𝑤𝑟𝑒𝑔(. ) is the predicted endpoint from a weighted GLM. 
Regression-adjusted matching  
It is generally recommended that matching is followed by regression adjustment (Rubin, 
1973, Rubin and Thomas, 2000, Abadie and Imbens, 2006). The idea is similar to 
double- robustness, and also to regression-adjustment in randomised trials: regression is 
used to “clean up” imbalances between treatment groups after matching (Stuart, 2010). 
We consider regression-adjusted matching undertaken as a two stage process: matching, 
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that forms the design stage of the analysis, is followed with regression modelling using 
the matched data (Ho et al., 2007). This approach can reduce the sensitivity of the 
estimated ATEs to the specification of the endpoint model (Hill and Reiter, 2005, Ho et 
al., 2007),  and can reduce finite sample bias and increase efficiency compared to 
matching alone. We implement this approach by undertaking PS matching, and using 
the frequency weights from the matching to weight the GLMs (1). The regression-
adjusted matching estimator of the ATEs for each endpoint can be obtained as:  
1
𝑛
∑{?̂?𝑖,𝑘,𝑟𝑒𝑔𝑚𝑎𝑡𝑐ℎ(𝑥𝑖,, 𝑡𝑖 = 1)−?̂?𝑖,𝑘,𝑟𝑒𝑔𝑚𝑎𝑡𝑐ℎ(𝑥𝑖,, 𝑡𝑖 = 0)},   
𝑛
𝑖=1
 
where  ?̂?𝑖,𝑘,𝑟𝑒𝑔𝑚𝑎𝑡𝑐ℎ(. )  is the predicted endpoint obtained from applying GLMs to the 
matched data. 
Motivating case study 
Case study overview 
We compared the methods in a CEA that evaluated Drotrecogin alpha (activated) 
(DrotAA), a pharmaceutical for patients with severe sepsis admitted to intensive care 
units (ICUs), using observational data from the UK Case-Mix Programme dataset 
coordinated by the Intensive Care National Audit and Research Centre (ICNARC) 
(Rowan et al., 2008). We revisit a previous CEA (Kreif et al., 2012a, Sadique et al., 
2011) and consider high-risk patients defined as having 3, 4 or 5 organ systems failing 
at ICU admission (n=878 DrotAA and n=1020 controls). The CEA estimated 
individual-level lifetime quality-adjusted life years (QALYs), based on individual 
patient’s mortality data collected for a follow-up period of four years, and for those who 
survived, age- and gender-specific expected survival and quality of life. Costs of 
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DrotAA and all hospitalisations were estimated at the patient level, over the same 
period of follow-up. QALYs and costs were discounted at 3.5%  (NICE, 2008).  
Statistical analysis 
We used a previously published PS (Rowan et al., 2008), which included the following 
baseline covariates: hospital type, number of critical care beds in the ICU, age, 
ICNARC model physiology score (IMscore), gender, number of organ systems failing, 
type of organ failures (cardiovascular, respiratory, renal, haematological, metabolic 
acidosis), source of admission to critical care (via the emergency department, theatre or 
recovery, ward, clinic or home), diagnostic category, and serious conditions in the past 
medical history. The PS was estimated by logistic regression, the potential nonlinear 
effects of age and IMscore on the logit of treatment assignment were recognised with 
restricted cubic splines. 
Regression models were developed for the cost and QALY endpoints drawing on the 
literature (Rowan et al., 2008). Linear predictors included a treatment indicator, 
treatment by covariate interaction terms, and cubic splines of age and IMscore to take 
into account possible nonlinearities. Model fit was evaluated using the Akaike 
information criterion and split sample cross validation (Buntin and Zaslavsky, 2004). A 
gamma GLM with log link, and a normal model with identity link were selected for the 
cost and QALY endpoints, respectively. 
Both treated and control individuals were matched to their nearest neighbour in the 
comparison group, one-to-one, with replacement, based on the linear predictor of the 
PS, using the “Matching” package (Sekhon, 2011). Balance on those potential 
confounders anticipated to be most important  (Sadique et al., 2011), was reported with 
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weighted standardised differences (Austin, 2009a)11.  The AIPTW estimator used 
predictions from the GLMs described above, with both IPTW and AIPTW using 
normalised weights (Kang and Schafer, 2007). Weighted regression applied the GLMs 
on data with IPT weights, while regression-adjusted matching applied the same 
regression models to the matched data, using the frequency weights from the matching.  
We reported lifetime incremental costs, QALYs and INBs (£20,000 per QALY) of 
DrotAA versus control. Statistical uncertainty was considered by reporting 95% 
confidence intervals (CIs), and cost-effectiveness acceptability curves (CEACs) 
(Fenwick et al., 2004). For variance estimation, the non-parametric bootstrap (Davison 
and Hinkley, 1997) was used to maintain correlation between incremental costs and 
QALYs. After all methods except for regression alone, inferences should be regarded as 
conditional on the estimated PS and, for  the matching estimators, inferences were also 
conditional on the matched  data (Hill and Reiter, 2005). For all statistical analyses the 
R platform was used (R Development Core Team, 2011).  
Case study results 
Before adjustment, potential confounders were highly imbalanced between the 
treatment groups; compared with controls, DrotAA patients were on average younger, 
with a higher baseline probability of death (Table 5.1).  Following PS matching and 
IPTW, standardised differences somewhat decreased, but PS matching and particularly 
IPTW still reported high imbalances for important potential confounders such as the 
proportion of patients with five organ systems failing, and the baseline probability of 
death (IMprob).  
                                                 
11 Standardised differences are weighted using matching frequency weights and IPT weights.  
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Table 5.1 - Case study results: baseline characteristics and covariate balance for DrotAA 
versus control group, before and then after matching or weighting  
Covariate Unadjusted PS matching IPTW 
 DrotAA 
(n=878) 
Control 
(n=1020) 
Standardised 
difference (%) 
Standardised    
difference 
(%) 
Standardised 
difference (%) 
Age 58.96  65.16  32.32 1.25 7.24 
IMprob   0.64    0.58  20.12 6.82 9.86 
IMscore 32.08 27.96 40.83 3.95       12.41 
% vent.  93.39 78.53 38.90 2.48       13.19 
Medical history:      
    Cardiovascular  0.34   1.86 13.58 7.05 5.08 
    Respiratory  1.60   2.94    7.78 1.53 1.30 
    Renal  0.91   1.47    4.39          0.97 2.45 
    Liver  0.68   1.77    8.70          0.17       29.30 
    
Immunosuppressed 
 7.29 12.75  15.55 
3.93 4.33 
Number of organ 
systems failing: 
     
  3       49.09 62.94 22.88          2.98 4.60 
  4       41.12 29.31 20.07  9.3 1.98 
  5  9.80   7.75   5.82        10.62       11.55 
Abbreviations: IMprob:  ICNARC model predicted probability of acute hospital mortality, IMscore: 
ICNARC model physiology score, %vent: % of patients mechanically ventilated 
 
A comparison of the distribution of the estimated PSs shows good overlap between the 
treatment groups, however there are some values close to 0 and 1 (e.g. minimum 0.014 
for DrotAA), resulting in unstable IPT weights (Figure 5.1). 
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Figure 5.1 - Panel (a): Distribution of the estimated PSs for DrotAA (grey line) and control 
(black line) observations. Panel (b): IPT weights for DrotAA and control observations in 
the case study.  
 
Notes: The rug plots, at the top and bottom of panel (a), shows the values of the PS. 
 
After regression adjustment, the INB was large, with 95% CI that excluded zero. After 
PS matching and IPTW, the point estimates were much lower, with CIs that included 
zero, IPTW reporting the widest CIs (Table 5.2). Combined methods reported 
somewhat differing point estimates, and narrower CIs than their PS method 
counterparts. AIPTW reported narrower CIs than IPTW, but less certain estimates than 
the other combined approaches. The probability that DrotAA is cost-effective at the 
WTP threshold of £20,000 per QALY is 30% following IPTW versus 90% for 
regression (Figure 5.2). The corresponding probability that DrotAA is cost-effective is 
around 50% following weighted regression and regression-adjusted matching.   
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Table 5.2 - Case study: Lifetime incremental costs (£), QALYs and INBs (WTP=£20,000) 
for DrotAA versus control group.  
 
Incremental costs 
(£) (95% CI*) 
Incremental 
QALYs (95% 
CI*) 
INBs (£) 
(95% CI*) 
Regression 
19,390 
(16,086 to 22,084 
1.47 
(0.98 to 1.93) 
9997 
(762 to 19,353) 
PS matching 
19,384 
(17843 to 21,061) 
0.99 
(0.65 to 1.33) 
391 
(-6,413 to  6,911) 
IPTW 
19,023 
(15946 to 22,506) 
0.54 
(-0.97 to 1.44) 
-8175 
(-36,763 to 9,547) 
AIPTW 
20,262 
(16,723 to 25,026) 
0.77 
(-0.01 to 1.36) 
-4861 
(-22,251 to 7887) 
Weighted regression 
19,728 
(16587 to 22,951) 
0.96 
(0.37 to 1.48) 
-430 
(-13,304 to 9,920) 
Reg. -adjusted  
matching 
19,705 
(18012 to 21,286) 
0.93 
(0.68 to 1.18) 
-1147 
( -6,072 to 3,820) 
Notes: * The non-parametric bootstrap is used for all CIs. After all methods except for regression alone, 
inferences should be regarded as conditional on the estimated PS and, for matching methods, on the 
matched data. 
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Figure 5.2 - Cost-effectiveness acceptability curves for DrotAA versus control groups in 
the case study 
 
 
In summary, while the estimated incremental costs were similar across approaches, 
there were differences in the incremental QALYs leading the estimated INBs to differ 
somewhat by method. For each PS method, adding regression led to narrower CIs. To 
assess the relative bias and efficiency of the methods in a CEA context, we now use 
salient features of this case study, such as nonlinear relationships between covariates 
and endpoints, and unstable IPT weights in the subsequent Monte Carlo simulation 
study.  
Monte Carlo simulation study 
Simulation overview 
Monte Carlo simulations were conducted to examine the relative performance of single 
and combined methods, for estimating cost-effectiveness. We extended previous 
simulation studies (Kang and Schafer, 2007, Porter et al., 2011) to generate cost-
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effectiveness data that reflected the settings typified by the case study. In particular, key 
features of the case study were that there were estimated PSs close to 0 and 1 i.e. 
unstable IPT weights, and some continuous confounders were modelled nonlinearly in 
the PS model (Rowan et al., 2008). The study also built on other simulation studies 
which compared alternative single PS approaches in estimating incremental 
effectiveness (Austin, 2009b, Radice et al., 2012) and cost-effectiveness (Kreif et al., 
2012a). 
The simulation study aimed to investigate the following main hypotheses: 
1.  Combined methods can increase precision and reduce bias compared to single PS 
methods only, even if the PS is correctly specified. Regression adjustment using a 
correctly specified model is expected to correct for finite sample imbalances and 
therefore reduce finite sample bias, and increase efficiency compared to PS matching 
alone (Rubin and Thomas, 2000). Adding a misspecified regression model after 
applying PS matching can also reduce finite sample bias (Abadie and Imbens, 2011).  
With stable weights, IPTW can be consistent and asymptotically efficient (Hirano et al., 
2003), but with unstable weights IPTW is expected to be inefficient (Kang and Schafer, 
2007). Under such circumstances AIPTW and weighted regression are expected to 
increase efficiency, by stabilising IPT weights (Glynn and Quinn, 2010). 
2. Compared to using regression alone, combined methods can reduce bias due to the 
misspecification of the regression models. The DR property ensures that AIPTW and 
weighted regression with correctly specified IPT weights can protect from bias due to a 
misspecified regression model. Using PS matching for balancing the data before 
regression adjustment can reduce bias compared to regression alone (Dehejia and 
Wahba, 2002, Ho et al., 2007), even when the PS is misspecified (Busso et al., 2011). 
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3. When IPT weights are unstable, regression-adjusted matching can be less sensitive to 
PS misspecification than weighted regression or AIPTW. Weighted regression and 
AIPTW are expected to be sensitive to unstable IPT weights and misspecification of the 
PS (Basu et al., 2011, Kang and Schafer, 2007, Freedman and Berk, 2008).  Here 
regression-adjusted matching might perform better (Busso et al., 2011) than the DR 
methods considered. AIPTW can report higher bias than weighted regression when both 
models are misspecified (Kang and Schafer, 2007). 
We considered four scenarios (Table 5.3). We assumed a PS mechanism that generates 
stable IPT weights (Scenario 1 and 2) and one that generates unstable weights (Scenario 
3 and 4). We considered a “mild” (Scenario 1) and “major” (Scenario 2 and 3) 
misspecification of the PS and regression models. In Scenario 4 we also considered a 
further regression misspecification where the wrong link function was chosen. In each 
scenario, four different settings were considered: when the PS and regression models 
were correct (a), when one of the two was misspecified (b and c), and when neither 
model was correctly specified (d).   
Bias and RMSE were obtained to provide information about the accuracy and the 
precision of the estimated incremental costs, effectiveness and INB across the methods. 
Relative bias was calculated as the difference between the true parameter value and the 
mean of the estimated parameter, expressed as a percentage of the true value. The 
RMSE was taken as the square root of the mean squared differences between the true 
and estimated parameter values.   
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Table 5.3 - Monte Carlo simulations, summary of scenarios 
Scenario 1:  Stable IPT weights + “mild” misspecification 
 Regression correctly 
specified 
Regression misspecified 
PS correctly specified 1a 1b 
PS misspecified 1c 1d 
Scenario 2:  Stable IPT weights + “major” misspecification 
 Regression correctly 
specified 
Regression misspecified 
PS correctly specified 2a (= 1a) 2b 
PS misspecified 2c  2d 
Scenario 3:  Unstable IPT weights + “major” misspecification 
 Regression correctly 
specified 
Regression misspecified 
PS correctly specified 3a 3b 
PS misspecified 3c 3d 
Scenario 4:  Unstable IPT weights + “major” misspecification (as in Scenario 3, but 
regression misspecification also includes log instead of identity link for costs) 
 Regression correctly 
specified 
Regression misspecified 
 
PS correctly specified 4a (= 3a) 4 b 
PS misspecified 4c (= 3c) 4d 
 
Data generating process 
1000 CEA datasets were simulated, each with 2000 subjects. For each subject, 
continuous confounders (𝑍1, 𝑍2, 𝑍3, 𝑍4) were generated from bivariate normal 
distributions with the following means, standard deviations and correlation: 
(
𝑍1
𝑍2
) ~𝑁 {(
2
4
) , (
1 0.2
0.2 1
)}                                      
(
𝑍3
𝑍4
) ~𝑁 {(
2
4
) , (
1 0.2
0.2 1
)}. 
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The treatment indicator 𝑡 was randomly generated from a Bernoulli distribution with 
parameter 𝑝 (the PS), determined by a logistic model with a nonlinear term in the logit, 
as seen in the case study: 
𝑙𝑜𝑔𝑖𝑡(𝑝𝑆𝑐𝑒𝑛 1,2) = 0.4 − 1𝑍1 + 0.5𝑍2 + 0.025𝑍2
2 − 0.25𝑍3 − 0.1𝑍4         (3)                 
Costs and effectiveness endpoints were drawn from a bivariate gamma-normal 
distribution, with a copula function12 (Trivedi and Zimmer, 2005, Mihaylova et al., 
2010, Quinn, 2007). The dependence between the two endpoints was recognised by 
setting the correlation between the error terms equal to 0.413.  The effectiveness 
endpoint was drawn from a normal distribution: 
                       𝑌𝐸~𝑁(𝜇𝐸 , 0.2) , 
 and costs from a gamma distribution with identity link, shape and scale parameters14:  
                       𝑌𝐶~Γ(10, 𝜇𝐶/10). 
The relationship between the covariates with 𝜇𝐶 and 𝜇𝐸 was assumed linear, with a 
constant treatment effect, as: 
𝜇𝐶  = 10000 + 6000𝑡 − 2000𝑍1 + 2000𝑍2 − 2000𝑍3 + 2000𝑍4 ,    
  
             𝜇𝐸
= 9 + 0.4𝑡 + 0.1𝑍1 − 0.05𝑍2 + 0.05𝑍3 − 0.05𝑍4 .                       (4) 
Simulation scenarios 
Scenarios 1 and 2 considered stable IPT weights (Figure 5.3). Scenarios 3 and 4 used 
unstable weights similar to the case study, in that a large portion of the true PSs were 
                                                 
12 The copula function can generate draws from a flexible multivariate distribution (in this case the 
bivariate) with different marginal distributions (here, the gamma and the normal).  
13 This resulted in a correlation of 0.34 between the cost and QALY variable, which reflects the 
correlation (0.22) found in the case study. 
14 The choice of normal distribution for 𝑌𝐸  and the identity link function for 𝑌𝐶  was made for transparency 
reasons and to facilitate replication. 
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close to 0 and 1 (Figure 5.3).  This was achieved by modifying the coefficients in the PS 
model (equation (3)) as: 
𝑙𝑜𝑔𝑖𝑡(𝑝𝑆𝑐𝑒𝑛 3,4) = 1.5 − 2𝑍1 + 1𝑍2 + 0.05𝑍2
2 − 0.5𝑍3 − 0.2𝑍4. 
In each scenario a common functional form misspecification for the PS and the endpoint 
model was defined as in Kang and Schafer (2007): we assumed that instead of the true 
confounders Z1 to Z4, their nonlinear functions, X1 to X4 were observed, both when 
modelling the PS and the endpoints.  Scenario 1 had a “mild” functional form 
misspecification, with the nonlinear functions defined as:  
  X1 = exp (
Z1
10
), 
                    X2 = Z2 ∗ (1 + Z1) + 10, 
              X3 = (Z3/25 + 0.6)
2, 
      X4 = (Z4 + 20)
2. 
 
In addition, when the PS was misspecified, the squared term was omitted from the 
logistic regression. Scenarios 2-4 had “major” misspecifications of the PS and endpoint 
models. Here, the misspecification of X1 and X4 was increased: 
X1 = exp (
Z1
3
),  
                    X4 = (Z2/10 + Z4 + 20)
2. 
 
 Scenario 4 extended scenario 3, here the cost regression model had a further 
misspecification in that a log rather than the correct identity link function (equation 4) 
was chosen. This setting was again motivated by the case study15.   
                                                 
15 The proportion of individuals in the treatment group were typically around 50% (scenarios 1 and 2) and 
60% (scenarios 3 and 4), compared with 46% in the case study.  
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Figure 5.3 - Densities of the true PS in the Monte Carlo simulation study, using data from 
a typical sample (n = 1,00,000) for treated (grey line) and control (black line). The rug 
plots, at the top and bottom of each graph show the values of the PS. 
 
 
Simulation results 
Table 5.4 reports the relative bias (%) and RMSE of the estimated INB, over 1000 
replications for the different scenarios.  Tables containing simulation results for the 
incremental costs and QALYs are presented in Appendix 5.1. 
When the IPT weights were stable and both the PS and the endpoint models were 
correctly specified (scenario 1a), all methods provided relatively low bias, with 
regression reporting the lowest RMSE.  In scenario 2d with stable IPT weights and a 
“major” misspecification of the regression and the PS models, PS matching and 
regression-adjusted matching performed best, with lower bias and RMSE then DR 
methods (relative bias of 11% after regression-adjusted matching versus 53% after 
AIPTW and 29% after weighted regression).  
Under unstable IPT weights (scenario 3), combined methods outperformed correctly 
specified PS methods. In general, DR methods reported lower bias and RMSE than 
IPTW, and regression-adjusted matching performed better than PS matching alone. 
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These combined methods performed better even when a misspecified regression model 
was applied, after matching or weighting with a correctly specified PS (scenario 3b). 
Under dual misspecification (scenario 3d), all methods reported bias. Regression-
adjusted matching again provided estimates with the lowest relative bias (20% versus 
50% with regression and 89% with IPTW) and RMSE.  
When the regression for the cost endpoint used a log rather than the correct identify link 
function (scenario 4d), PS matching reported slightly lower bias than regression-
adjusted matching, however regression-adjusted matching again reported the lowest 
RMSE.  
Across the scenarios, regression-adjusted matching reported lower RMSE than PS 
matching alone, and in most scenarios lower bias. DR methods always reduced RMSE 
compared to IPTW only, and under unstable IPT weights they also reduced bias. 
However in these scenarios (3d and 4d), both DR methods were outperformed by 
regression-adjusted matching. 
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Table 5.4 - Monte Carlo simulations results: relative bias and RMSE for the INBs (WTP=£20,000) 
Scenarios 1: Stable IPT weights, 
“mild” misspec. 
2: Stable IPT weights, 
“major” misspec. 
3: Unstable IPT weights, 
“major” misspec. 
4: Unstable IPT weights, “major” 
misspec. (link function misspecified)  
 Relative bias  RMSE Relative bias  RMSE Relative bias RMSE Relative bias RMSE 
a:  PS and regression correctly specified        
        Regression 0.2% 330 0.2% 330 0.9% 376 0.9% 376 
        PS matching 1.9% 439 1.9% 439 9.4% 860 9.4% 860 
        IPTW 0.0% 402 0.0% 402 3.1% 1372 3.1% 1372 
        AIPTW 0.2% 348 0.2% 348 1.0% 795 1.0% 795 
        Weighted regression 0.2% 348 0.2% 348 0.7% 660 0.7% 660 
        Reg.-adjusted PS matching 0.3% 406 0.3% 406 1.0% 735 1.0% 735 
b:  PS  correct and regression  misspecified        
        Regression 11.1% 396 34.8% 770 51.3% 1087 52.0% 1102 
        PS matching 1.9% 439 1.9% 439 9.4% 860 9.4% 860 
        IPTW 0.0% 402 0.0% 402 3.1% 1372 3.1% 1372 
        AIPTW 0.2% 361 0.1% 381 2.3% 872 2.1% 875 
        Weighted regression 0.2% 359 0.3% 377 2.1% 735 10.8% 725 
        Reg.-adjusted PS matching 0.3% 408 0.1% 414 3.3% 748 12.2% 760 
c:  PS  misspecified and regression  correct        
        Regression 0.2% 330 0.2% 330 0.9% 376 0.9% 376 
        PS matching 6.1% 440 12.4% 485 26.0% 897 26.0% 897 
        IPTW 4.7% 621 44.4% 2161 88.6% 4069 88.6% 4069 
        AIPTW 0.4% 370 1.1% 784 2.6% 2105 2.6% 2105 
        Weighted regression 0.2% 359 0.2% 445 0.7% 863 0.7% 863 
        Reg.-adjusted PS matching 0.2% 393 0.0% 400 0.8% 684 0.8% 684 
d:  PS  misspecified and regression  misspecified       
        Regression 11.1% 396  34.8% 770 51.3% 1087 52.0% 1102 
        PS matching 6.1%  440  12.4% 485 26.0% 897 26.0% 897 
        IPTW 4.7% 621  44.4% 2161 88.6% 4069 88.6% 4069 
        AIPTW 10.3% 446 53.6% 1966 69.0% 3012 79.5% 3140 
        Weighted regression 9.4%  409 29.0% 713 34.2% 986 44.2% 1165 
        Reg.-adjusted PS matching 4.6%  408  11.2% 459 19.5% 769 30.2% 881 
Notes:  The RMSE was taken as the square root of the mean squared differences between the true and estimated parameter values.
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Discussion 
This paper finds that regression-adjusted matching can reduce overt selection bias and 
increase precision in the estimates of ATEs versus alternative approaches such as 
regression, PS matching and IPTW, across a range of scenarios typical of CEA. We 
show that regression-adjusted PS matching is relatively insensitive to functional form 
misspecifications of both the PS and the regression models, even when there are 
positivity violations, i.e. estimated PS values close to 0 and 1, resulting in unstable IPT 
weights. Here, both DR approaches reported higher bias and RMSE than regression-
adjusted matching. In the case study, the cost-effectiveness estimates and the reported 
CIs differed across methods.  The differences in the cost-effectiveness estimates were 
driven by the estimated incremental QALY which may reflect imbalances in important 
potential confounders that remained after PS matching, and especially after IPTW. 
This paper builds on previous simulation studies that compared alternative methods for 
addressing overt selection bias in cost and cost-effectiveness analysis (Basu et al., 2011, 
Sekhon and Grieve, 2011, Kreif et al., 2012a). Our paper considers combined methods 
for the first time in a CEA setting. This setting provoked the new simulation scenarios 
considered. The case study had typical characteristics of CEA that use observational 
data (Kreif et al., 2012a) and helped ground the simulation study. While the example 
used previously published PS models, and regression models were selected based on 
model fit, there were concerns about model misspecification and unstable IPT weights. 
Hence the simulation scenarios most relevant to applied studies are when both the PS 
and the regression models are misspecified. We find that even with dual 
misspecification, weighted regression and regression-adjusted matching can reduce bias 
and RMSE compared to using a single method alone. Amongst the combined methods 
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considered, regression-adjusted matching appears the least sensitive to misspecification, 
and this advantage was most apparent with unstable IPT weights.    
Our simulation scenarios considered settings characteristic of CEA. Here, while GLM 
approaches have been recommended (Barber and Thompson, 2004, Glick et al., 2007), 
the analyst has to choose the correct functional form of the linear predictors and the 
appropriate link function; in practice these are seldom known. We found that using PS 
matching in conjunction with GLMs can mitigate bias due to either misspecification. To 
help analysts consider these approaches further in different settings, we append R and 
Stata code for each combined method (see Appendix 5.2), and the code for simulating 
the data (Appendix 5.3).  
Our work also builds on previous simulation studies in the more general methodological 
literature (Kang and Schafer, 2007, Porter et al., 2011, Basu et al., 2011) by considering 
a range of scenarios with stable and unstable IPT weights. Similarly to previous studies 
(Kang and Schafer, 2007, Basu et al., 2011, Radice et al., 2012) we find that IPTW can 
be inefficient under unstable IPT weights, even if the PS is correctly specified, and can 
be highly biased due to the misspecification of the PS. In contrast to Kang and Schafer 
(2007), we find that under dual misspecification and unstable IPT weights, weighted 
regression and regression-adjusted matching can outperform regression. The current 
paper finds that regression-adjusted matching, an estimator not considered in previous 
comparisons (Basu et al., 2011), can be relatively robust to misspecification of the PS 
and the regression models. Related simulation work reports that  another 
implementation of matching combined with regression, “bias-corrected matching” 
(Abadie and Imbens, 2011) also performed well compared to DR methods  (Busso et al., 
2011). 
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This work has some limitations. The methods and the simulation settings all assume no 
unobserved confounding. This paper could not consider all circumstances that may arise 
in practice; for example in CEA, further endpoint model misspecifications can arise 
with quality of life data (Basu and Manca, 2011). To aid transparency we considered 
relatively simple matching and regression estimators. Rather than nearest neighbour PS 
matching one could use other multivariate matching approaches such as Genetic 
Matching (GM), (Diamond and Sekhon, 2012, Sekhon, 2011), previously demonstrated 
to reduce selection bias in a range of applications (Grieve et al., 2008, Sekhon and 
Grieve, 2011, Radice et al., 2012, Kreif et al., 2012a). More flexible regression models 
could also be compared, including extended estimating equations (Basu et al., 2011) or 
beta-type size distributions (Jones et al., 2011), which can outperform GLMs. These 
methods can also be combined with PS methods such as matching.  
This work also opens up areas for further research. Further studies could consider 
alternative DR methods such as targeted-maximum likelihood estimation (van der Laan, 
2010, van der Laan and Gruber, 2010, Gruber and van der Laan, 2010). When IPT 
weights are unstable, these approaches can perform better than the DR approaches 
considered, but they have not been compared to the regression-adjusted matching 
estimators described (Porter et al., 2011). New developments in machine learning 
methods for the estimation of the PS and the endpoint regression (Lee et al., 2010, 
Austin, 2012, van der Laan, 2007, Westreich et al., 2010) can further reduce bias due to 
functional form misspecification. These methods warrant careful consideration in 
further simulation studies relevant to health economic evaluations. 
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Appendix  5.1 - Additional tables for research paper 3 
Appendix 5.1 Table 1 - Monte Carlo simulation results: relative bias and RMSE of the estimated incremental cost  
Scenarios 1: Stable IPT weights, “mild”  
misspec. 
2: Stable IPT weights, 
“major” misspec. 
3: Unstable IPT weights, 
“major” misspec. 
4: Unstable IPT weights, “major” misspec 
(link function misspecified)   
 Relative bias  RMSE Relative bias  RMSE Relative bias  RMSE Relative bias  RMSE 
a:  PS and regression correctly specified        
Regression 0.1% 341 0.1% 341 0.3% 390 0.3% 390 
PS matching 0.5% 433 0.5% 433 1.8% 826 1.8% 826 
IPTW 0.1% 380 0.1% 380 0.8% 1004 0.8% 1004 
AIPTW 0.1% 358 0.1% 358 0.4% 821 0.4% 821 
Weighted regression 0.1% 357 0.1% 357 0.2% 685 0.2% 685 
Reg.-adjusted PS matching 0.2% 416 0.2% 416 0.2% 768 0.2% 768 
b:  PS  correct and regression  misspecified        
Regression 2.5% 372 6.9% 534 10.0% 702 10.2% 718 
PS matching 0.5% 433 0.5% 433 1.8% 826 1.8% 826 
IPTW 0.1% 380 0.1% 380 0.8% 1004 0.8% 1004 
AIPTW 0.1% 365 0.1% 372 0.7% 822 0.6% 827 
Weighted regression 0.1% 363 0.1% 370 0.5% 719 3.4% 699 
Reg.-adjusted PS matching 0.2% 416 0.2% 419 0.7% 765 3.7% 762 
c:  PS  misspecified and 
regression  correct 
        
Regression 0.1% 341 0.1% 341 0.3% 390 0.3% 390 
PS matching 1.6% 437 2.3% 442 4.7% 723 4.7% 723 
IPTW 0.5% 485 7.1% 1347 14.6% 2812 14.6% 2812 
AIPTW 0.0% 379 0.3% 776 1.3% 2071 1.3% 2071 
Weighted regression 0.1% 369 0.1% 457 0.3% 891 0.3% 891 
Reg.-adjusted PS matching 0.2% 413 0.1% 415 0.3% 723 0.3% 723 
d:  PS  misspecified and regression  misspecified       
Regression 2.5% 372 6.9% 534 10.0% 702 10.2% 718 
PS matching 1.6% 437 2.3% 442 4.7% 779 4.7% 779 
IPTW 0.5% 485 7.1% 1347 14.6% 2812 14.6% 2812 
AIPTW 2.4% 410 10.2% 1273 12.3% 2356 15.9% 2454 
Weighted regression 2.2% 389 5.8% 528 6.5% 817 9.8% 974 
Reg.-adjusted PS matching 2.5% 372 2.2% 431 3.8% 732 7.4% 799 
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Appendix 5.1 Table 2 - Monte Carlo simulation results: relative bias and RMSE of the estimated incremental QALYs  
Scenarios 1: Stable IPT weights , “mild” misspec. 2: Stable IPT weights, “major” misspec. 3 and 4: Unstable IPT weights, “major” 
misspec. 
 Relative bias  RMSE Relative bias  RMSE Relative bias  RMSE 
a:  PS and regression correctly specified       
Regression 0.1% 0.01 0.1% 0.01 0.0% 0.01 
PS matching 0.1% 0.01 0.1% 0.01 1.0% 0.02 
IPTW 0.1% 0.01 0.1% 0.01 0.2% 0.04 
AIPTW 0.1% 0.01 0.1% 0.01 0.1% 0.02 
Weighted regression 0.1% 0.01 0.1% 0.01 0.0% 0.02 
Reg.-adjusted PS matching 0.1% 0.01 0.1% 0.01 0.1% 0.02 
b:  PS  correct and regression  misspecified       
Regression 0.9% 0.01 3.5% 0.02 5.3% 0.02 
PS matching 0.1% 0.01 0.1% 0.01 1.0% 0.02 
IPTW 0.1% 0.01 0.1% 0.01 0.2% 0.04 
AIPTW 0.1% 0.01 0.1% 0.01 0.1% 0.03 
Weighted regression 0.1% 0.01 0.1% 0.01 0.1% 0.02 
Reg.-adjusted PS matching 0.1% 0.01 0.1% 0.01 0.3% 0.02 
c:  PS  misspecified and regression  correct       
Regression 0.1% 0.01 0.1% 0.01 0.0% 0.01 
PS matching 0.3% 0.01 1.3% 0.01 3.0% 0.02 
IPTW 0.8% 0.02 5.8% 0.05 11.2% 0.10 
AIPTW 0.1% 0.01 0.0% 0.03 0.3% 0.06 
Weighted regression 0.1% 0.01 0.1% 0.01 0.1% 0.03 
Reg.-adjusted PS matching 0.2% 0.01 0.0% 0.01 0.0% 0.02 
d:  PS  misspecified and regression  
misspecified 
      
Regression 0.9% 0.01 3.5% 0.02 5.3% 0.02 
PS matching 0.3% 0.01 1.3% 0.01 3.0% 0.02 
IPTW 0.8% 0.02 5.8% 0.05 11.2% 0.10 
AIPTW 0.8% 0.01 5.7% 0.05 7.9% 0.08 
Weighted regression 0.7% 0.01 2.9% 0.02 3.7% 0.03 
Reg.-adjusted PS matching 0.9% 0.01 1.2% 0.01 2.0% 0.02 
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Appendix 5.2 – Code for implementing the methods in research 
paper 3 
This section provides code for the implementation of the combined statistical 
approaches proposed in the paper, using the R (R Development Core Team, 2011)  and 
Stata statistical softwares (StataCorp, 2011). The user-written functions implemented 
here call some pre-written R routines, for example “glm” for generalised linear models, 
or the “Matching” library (Sekhon, 2011).  When implementing the methods in Stata, 
we use the NNMATCH routine (Abadie et al., 2004b) for matching. 
R code for AIPTW 
First, the regression models for the cost and effectiveness endpoints need to be defined: 
rmodel_Y<-glm(Y~tx+Z1+Z2+Z3+Z4,family=gaussian,data=dataset) 
rmodel_cost<-glm(cost~tx+Z1+Z2+Z3+Z4,family=gaussian,data=dataset)  
 
The IPT weights (pscw) need to be created: 
 ps.formula<- as.formula(tx~Z1+Z2+I(Z2^2)+Z3+Z4) 
 
pmodel_func=function(data, formula) { 
 
  pmodel<-glm(formula,family=binomial,data=data)    
  pscore.lin<-pmodel$linear.predictor     
   pscore<-pmodel$fitted.values   
     
  pscw=data$tx/pscore+(1-data$tx)/(1-pscore) 
  return(cbind(pscore,pscore.lin,pscw) 
  rm(pscore,pscore.lin,pscw) 
                                         } 
         dataset=cbind(dataset,pmodel_func(dataset,ps.formula)) 
 
The function for AIPTW will take the above objects as in: 
ate_aipw=function(data, model, weight, endpoint) { 
data_new0=data 
data_new0$tx=0 
data_new1=data 
data_new1$tx=1 
m0=predict(model, newdata=data_new0, type="response") 
m1=predict(model, newdata=data_new1, type="response") 
m=predict(model, type="response") 
211 
 
mu1 <- sum(data$tx * weight * (endpoint-m) )/sum(data$tx                                       
* weight) + mean(m1) 
mu0 <- sum((1-data$tx)* weight* (endpoint-m))/sum((1-data$tx) * weight) 
+ mean(m0) 
  my.ate.aiptw=mu1-mu0 
  return(my.ate.aiptw) 
 
                                 } 
To obtain the estimate for example for the incremental QALYs, we call the above 
function: 
aipw_Y=ate_aipw(dataset,rmodel_Y, dataset$pscw,dataset$Y)     
R code for weighted regression 
Weighted GLMs are constructed, using the IPT weights (pscw) defined above: 
wrmodel_Y<glm(Y~tx+Z1+Z2+Z3+Z4,family=gaussian,data=dataset,weight=pscw)  
wrmodel_cost<glm(cost~tx+Z1+Z2+Z3+Z4,family=gaussian,data=dataset,weight=pscw)
  
 
The function ate_reg is called to obtain the estimates of ATE, for example for the 
incremental QALYs:  
ate_reg=function(data, model) { 
  data_new0=data 
  data_new0$tx=0 
  data_new1=data 
  data_new1$tx=1 
  m0=predict(model, newdata=data_new0, type="response") 
  m1=predict(model, newdata=data_new1, type="response") 
  mu1 <- mean(m1) 
  mu0 <- mean(m0) 
  my.ate.reg=mu1-mu0 
  return(my.ate.reg) 
                              } 
wreg_Y=ate_reg(dataset,wrmodel_Y)   
R code for regression-adjusted matching 
We create the matched datasets, using the linear predictor of the estimated PS 
(pscore.lin) as a proximity measure. 
PSmatch_data=function(data){                
attach(data) 
mtchout.Y=Match(Y=Y,Tr=tx,X=cbind(pscore.lin),estimand="ATE") 
detach(data) 
mtch.data<rbind(data[mtchout.Y$index.treated,],data[mtchout.Y$index.control,])  
mtch.data<cbind(mtch.data,weights=c(mtchout.Y$weights,mtchout.Y$weights)) 
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  return(mtch.data) 
      } 
The matched data is stored in the object mdataset, where the matching frequency 
weights are stored as mtch.data$weights. 
      mdataset=PSmatch_data(dataset) 
 
The PS matching estimator of ATE is the following: 
rmatch_ate=function(data,endpoint,formula){ 
            model=glm(formula,family=gaussian,data=data,weights=weights) 
      data_new0=data 
      data_new0$tx=0 
      data_new1=data 
      data_new1$tx=1 
            m0=predict(model, newdata=data_new0, type="response") 
            m1=predict(model, newdata=data_new1, type="response")  
      mu1 <- mean(m1) 
      mu0 <- mean(m0) 
      my.ate.match.reg=mu1-mu0 
      return(my.ate.match.reg)       
            } 
 
This function is called to obtain the estimates of the ATE, for example:  
rPSmatch_Y=rmatch_ate(mdataset,mdataset$Y,reg.formula_y)  
Stata code for AIPTW  
use "L:\mylibrary\statasim.dta", clear 
First, run an unweighted regression: 
  reg Y tx Z1 Z2 Z3 Z4 
      gen truetx = tx 
Generate the predicted potential outcomes: 
 replace tx=1 
 predict mu1 
 replace tx=truetx 
 
 replace tx=0 
 predict mu0 
 replace tx=truetx 
Generate the predicted observed outcome: 
 predict mu 
Calculate the mean the predicted potential outcomes: 
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       summ mu1  
 scalar Ytreated=r(mean) 
  
 summ mu0  
 scalar Ycontrol=r(mean)  
Estimate the PS: 
 logit tx Z1 Z2 Z3 Z4 
 predict pscorelin, xb 
 predict pscore, pr 
Construct IPT weights:   
       gen pscw=1 
   replace pscw=1/invlogit( pscorelin) if tx==1 
    replace pscw=1/invlogit(-pscorelin) if tx==0 
Generate the sum of these weights, in order to obtain a normalised estimator: 
      egen sumpscw1= total(pscw) if tx==1 
      egen sumpscw0= total(pscw) if tx==0 
Generate augmented mean potential outcomes: 
    egen mu1Y = total(pscw*(Y-mu)/sumpscw1) if tx==1 
 egen mu0Y = total(pscw*(Y-mu)/sumpscw0) if tx==0   
  
       summ mu1Y 
       scalar meanmu1Y=r(mean)+ Ytreated 
       summ mu0Y 
       scalar meanmu0Y=r(mean) + Ycontrol  
 scalar aiptw_Y=meanmu1Y-meanmu0Y 
       di aiptw_ 
Stata code for weighted regression  
Again, the method of recycled predictions is used, using regression models weighted 
with the IPT weights (pscw):  
  reg Y tx Z1 Z2 Z3 Z4 
  reg Y tx Z1 Z2 Z3 Z4 [pweight= pscw] 
       gen truetx = tx 
  replace tx=1 
  predict mu1 
  replace tx=truetx 
replace tx=0 
  predict mu0 
  replace tx=truetx 
  summ mu1  
  scalar Ytreated=r(mean) 
  summ mu0  
  scalar Ycontrol=r(mean) 
  scalar wreg_Y  = Ytreated-Ycontrol  
  dis wreg_Y  
  
  drop mu1 mu0  
  scalar drop Ytreated Ycontrol wreg_Y 
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Stata code for regression-adjusted matching 
First we create an id which can be used to merge the main dataset the matched data: 
egen id= seq() 
sort id   
We save the data before the matching: 
save "L:\mylibrary\statasim1.dta", replace  
 
We perform nearest neighbor,  1:1 PS  matching, using the NNmatch package by 
Abadie et al. (2004) (Abadie et al., 2004b): 
  nnmatch Y tx pscorelin,  keep(matchdata_Y) replace 
  use matchdata_Y.dta, clear 
    
In order to be able to use the frequency weights for later analysis, the weight variable 
needs to be generated as follows:   
       gen km_mod=km+1 
We store these frequency weights and merge it with the unmatched dataset:  
  keep id km_mod 
  rename km_mod weight 
    save  "L:\mylibrary\matchweight.dta", replace 
  merge id using "L:\mylibrary\statasim1.dta" 
We save the combined dataset:  
   save  "L:\mylibrary \statasim2.dta", replace 
Now we use the same approach as in the case of weighted regression, but instead of 
using inverse probability weights, we use frequency weights from the matching 
(weight). 
 reg Y tx Z1 Z2 Z3 Z4 [fweight= weight] 
       replace tx=1 
 predict mu1 
 replace tx=truetx 
       replace tx=0 
 predict mu0 
 replace tx=truetx 
       summ mu1  
 scalar Ytreated=r(mean) 
 summ mu0  
 scalar Ycontrol=r(mean) 
 scalar rPSmatch_Y  = Ytreated-Ycontrol  
 dis rPSmatch_Y 
 drop mu1 mu0  
 scalar drop Ytreated Ycontrol rPSmatch_Y  
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Appendix 5.3 - R code for generating data in the simulations of 
research paper 3 
Here we provide the code that was used to generate data for Scenario 1 of the 
simulations. First, the necessary libraries need to be loaded: 
library(Rlab) 
library(Matching) 
library(stats) 
library(boot) 
library(copula) 
A simulated dataset, including the covariates Z1,Z2,Z3,Z4, the treatment variable 
tx and the endpoints cost and Y (denoting QALY) was created. First we 
generated the confounders from correlated normal distributions: 
Sigma<-matrix(c(1,0.2,0.2,1),2,2)     
Z12<-mvrnorm(n,c(2, 4), Sigma)        
Z1<-Z12[,1]          
Z2<-Z12[,2]          
Z34<-mvrnorm(n,c(2, 4), Sigma)       
Z3<-Z34[,1]        
Z4<-Z34[,2]  
 
Then we drew the treatment variable tx from a Bernoulli distribution with parameter 
psc (the true PS): 
psc_logit<- 0.4 + (-1*Z1) + (0.5*Z2) + (0.025*Z2^2 )+ (-0.25*Z3) - 
(0.1*Z4) 
psc<-inv.logit(psc_logit) 
tx<-rbern(n,psc) 
 
We generated the cost and QALY endpoints using the copula package in R:  
E.cost<-10000+ 6000*tx-2000*Z1+2000*Z2-2000*Z3+2000*Z4  
E.cost=ifelse(E.cost<=0,0.1,E.cost) 
E.Y <- 9+0.4*tx+(0.1*Z1)-(0.05*Z2)+(0.05*Z3) -(0.05*Z4)  
ngmvdc <- mvdc(normalCopula(0.4), c("norm", "gamma"), 
list(list(mean = E.Y, sd =0.2), list(shape=10,rate=10/E.cost))) 
rng <- rmvdc(ngmvdc, n) 
Y <- rng[,1] 
cost <- rng[,2] 
The misspecified variables were defined as follows: 
X1 = exp(Z1/10) 
X2 = Z2*(1+Z1)+10 
X3 = (Z3/25+0.6)^2 
X4 = (Z4+20)^2 
The final dataset was created as follows: 
dataset<-as.data.frame(cbind(X1,X2,X3,X4,Z1,Z2,Z3,Z4,Y,cost,tx)) 
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Chapter 6 - Estimating treatment effectiveness under 
model misspecification:  a comparison of targeted 
maximum likelihood estimation with bias-corrected 
matching 
6.1 Preamble to research paper 4 
The critical appraisal of the applied literature (research paper 1) showed that the 
specification of the PS and cost and effectiveness regression models is rarely 
appropriately assessed, raising concerns about biased parameter estimates in CEA. One 
area which received relatively little attention in the methodological literature in CEA is 
estimating incremental effectiveness parameters from HRQoL data (Basu and Manca, 
2011). The conceptual review identified machine learning techniques for estimating the 
PS and the endpoint regression, which can reduce bias due to functional form 
misspecification. Research paper 4 contrasts two approaches, TMLE and BCM, which 
combine the PS with endpoint regression, and can be coupled with machine learning 
estimation techniques. These methods are flexible extensions of the DR and regression-
adjusted matching approaches presented in research paper 3. These methods have not 
been used to estimate the effectiveness of treatment on HRQoL, and TMLE has not 
been compared to BCM in the general literature. Research paper 4 aims to address these 
gaps in the literature.  
The motivating case study of this paper extends research papers 2 and 3 in using a 
contrasting case study, where relative effectiveness parameters need to be estimated in 
order to populate a decision-analytical model. A related simulation study compares the 
relative performance of TMLE and BCM, alongside traditional PS, regression and DR 
methods, for estimating incremental effectiveness. I contrast these methods when using 
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fixed parametric models for the PS and the endpoint regression, and when using 
machine-learning estimation.  This paper focuses on the realistic scenario when the true 
parametric models are unknown.  
This paper provides recommendations to help future studies choose more appropriate 
methods for estimating treatment effects in realistic circumstances, and includes 
software code to help implement the proposed methods (Appendix 6.1). 
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Abstract 
This paper considers two approaches which combine the propensity score (PS) with an 
endpoint regression, when the functional forms of both models are misspecified (dual 
misspecification).  Targeted maximum likelihood estimation (TMLE) is a double-robust 
(DR) approach designed to reduce bias in the estimate of the parameter of interest.  
Bias-corrected matching (BCM) adjusts covariate imbalance between matched pairs 
using regression predictions. For both methods, we consider machine learning 
techniques such as boosted classification and regression trees and “super learning”, as 
well as using fixed parametric approaches to estimate the PS and endpoint regression. 
We contrast TMLE and BCM, alongside PS, regression and DR approaches, in a 
motivating example evaluating the effect of different types of hip prosthesis on health-
related quality of life (HRQoL) of patients with osteoarthritis. We find that the 
estimated effect of prosthesis type on HRQoL was similar across methods.  
 In a related simulation study we generated HRQoL data, with nonlinear functional form 
relationships, and good and poor overlap of the PS. Performance metrics included bias, 
root mean squared error (RMSE) and the 95% confidence interval (CI) coverage. 
In the scenarios when either the PS or regression model was correct, both TMLE and 
BCM remained unbiased and reported CI coverage close to nominal levels. With 
misspecified, fixed models for the PS and the endpoint, all methods reported relatively 
high bias. With machine learning estimation, this bias was reduced. When overlap of 
the PS was good, TMLE provided estimates with the lowest bias and RMSE, and with 
poor overlap BCM performed best.  
TMLE and BCM, when coupled with machine learning, are both appropriate methods 
for estimating of treatment effectiveness across the circumstances considered.  
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Introduction 
Health policy-makers require unbiased, precise estimates of the effectiveness and cost-
effectiveness of health interventions to inform the allocation of scarce health care 
resources (Rubin, 2010, Tunis et al., 2010, Fung et al., 2011).  Observational studies are 
widely used to estimate average treatment effects (ATEs), but the major concern is 
selection bias due to confounding. Researchers often model the conditional expectation 
of the endpoint given covariates, with parametric regression models. An alternative is 
using the propensity score (PS), defined as the probability of treatment assignment, 
given the covariates.  These methods however assume that the endpoint regression or 
PS model is correctly specified (Rubin, 1997).  When estimating ATEs on health 
endpoints, such as health-related quality of life (HRQoL), correctly specifying a 
regression model can be challenging, particularly if the distribution of the endpoint is 
skewed, and the relationship between the covariates and the endpoint is nonlinear (Basu 
and Manca, 2011). In an observational setting, the PS is unknown and needs to be 
estimated, taking into account potential nonlinearities and interactions between 
covariates that can predict the treatment assignment (Dehejia and Wahba, 2002, 
Westreich et al., 2010).  
Double-robust (DR) methods (Robins et al., 1994, Robins et al., 2007) combine 
endpoint regression models with the PS, and can be consistent if either the endpoint 
regression or the PS is correctly specified. However, for practical applications, there is 
an interest in the performance of these methods when both the endpoint regression and 
PS models are misspecified (dual misspecification) (Kang and Schafer, 2007a, 
Waernbaum, 2011, Gruber and van der Laan, 2012a). A further challenge is posed by 
poor overlap, also referred to as violation of the positivity assumption, which occurs 
when a certain set of baseline covariates is almost completely predictive of the 
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treatment within the sample (Westreich and Cole, 2010). Poor overlap can lead to 
unstable inverse probability of treatment (IPT) weights (Petersen et al., 2010). In 
circumstances where there is dual misspecification and unstable IPT weights, common 
DR approaches such as weighted regression can be more biased and less efficient than  
ordinary least squares (OLS) regression (Kang and Schafer, 2007a, Freedman and Berk, 
2008).   
An innovative DR method, targeted maximum likelihood estimation (TMLE) (van der 
Laan, 2010, van der Laan and Rubin, 2006) can outperform conventional DR methods 
when there is poor overlap (Porter et al., 2011, Stitelman and van der Laan, 2010, 
Gruber and van der Laan, 2010a). TMLE is a two-stage estimator, which fluctuates an 
initial regression prediction of the endpoint, using a function of the estimated PS. 
Another approach which can exploit information from the PS and the endpoint 
regression is bias-corrected matching (BCM) (Rubin, 1973, Abadie and Imbens, 2011). 
The idea behind this method is to subtract the estimate of the asymptotic bias from the 
nearest neighbour matching estimator, using regression predictions of the endpoint. 
Both TMLE and BCM have the potential to reduce bias under dual misspecification. 
For both methods, estimates of the endpoint regression function and the PS can be 
obtained with fixed parametric models, i.e. when the functional form and distribution of 
the endpoint is chosen by the analyst. However these approaches can also accommodate 
machine learning techniques, where the best fitting model is selected by an algorithm.  
Simulation studies have demonstrated that TMLE, coupled with machine learning 
estimation for the endpoint and the PS, can report low bias when the correct parametric 
models are unknown (Porter et al., 2011, Gruber and van der Laan, 2012c). BCM can be 
relatively robust under dual misspecification. When the response surface, defined as the 
functional form relationship between the covariates and the endpoint (Rubin, 1979), is 
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moderately nonlinear, bias due to a misspecified PS can be eliminated  even if 
adjustment is performed with an OLS regression model (Abadie and Imbens, 2011, 
Busso et al., 2011, Rubin and Thomas, 2000). Adjustment with OLS might be 
insufficient with highly nonlinear response surfaces, and so recommendations for BCM 
suggest that flexible approaches such as series regression are used for the bias-
adjustment (Abadie and Imbens, 2011). However no previous studies have formally 
considered flexible regression methods for BCM. 
There is limited work on the relative performance of matching and reweighting 
estimators such as inverse probability of treatment weighing (IPTW) and DR methods 
(Busso et al., 2011, Busso et al., 2009, Waernbaum, 2011, Radice et al., 2012). These 
studies found that with correctly specified PS and good overlap, reweighting estimators 
can be less biased and more efficient than matching. However, nearest neighbour 
matching estimators are less sensitive to misspecification of the PS: while for matching 
it is sufficient for the estimated PS to be a balancing score, for weighting, the PS needs 
to be the correct conditional probability of treatment assignment (Busso et al., 2009, 
Waernbaum, 2011). The only study that, to our knowledge, considered both DR and 
BCM estimators found that, with poor overlap and correctly specified PS, BCM 
provided less biased and more efficient estimates of the average treatment effect on the 
treated (ATT) than reweighing estimators (Busso et al., 2011).  Machine learning 
estimation approaches for estimating the PS (Lee et al., 2010, Westreich et al., 2010, 
Setoguchi et al., 2008), and the endpoint regression function (Austin 2012) have been 
shown to reduce bias due to model misspecification, but few studies have investigated 
machine learning in the context of DR approaches (Porter et al., 2011, Ridgeway and 
McCaffrey, 2007) and no study has considered machine learning  for  BCM. 
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The objective of this paper is to compare the relative performance of TMLE and BCM 
in estimating the ATE of a binary treatment on a continuous endpoint, focusing on dual 
functional form misspecification of the PS and the endpoint regression.  We also 
compare TMLE and BCM to other commonly applied DR (Kang and Schafer, 2007a), 
PS matching (Austin, 2008, Caliendo and Kopeinig, 2008) and regression (Basu and 
Manca, 2011) approaches. We consider each method  with fixed parametric regression 
models but also with machine learning techniques, such as super learning for estimating 
the endpoint regression function (van der Laan et al., 2007) and boosted regression trees 
for the PS (McCaffrey et al., 2004, Lee et al., 2010, Xu et al., 2010). 
We consider the methods in a motivating case study and in a simulation study. The case 
study considers the relative effectiveness of alternative types of total hip replacement on 
post-operative HRQoL of patients with osteoarthritis. This study exploited a large UK 
survey, which collects patient reported outcome measures (PROMs). The resulting 
observational database includes HRQoL data on all patients who have had elective 
surgical procedures provided by the NHS in England (PROMs, 2010, Ousey and Cook, 
2011), with measurements of a rich set of pre-operative characteristics. While there was 
a good overlap in the distributions of potential confounders, important prognostic 
variables such as age and pre-operative health status were imbalanced. Correctly 
specifying the endpoint regression function was challenging in this dataset: the 
distribution of the HRQoL endpoint was bounded between a small negative value 
(indicating a health state worse than death) (Dolan et al., 1995) and 1 (perfect health), 
and in addition, there was a large spike at 1 in the distribution. We reported ATEs with 
each approach. 
 The simulation study was grounded in the case study, and compared the relative 
performance of the methods for a range of data-generating processes (DGPs) typical of 
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HRQoL data: in that the data were assumed to follow normal, gamma and two-part 
distributions, and the response surface was nonlinear. We considered scenarios of good 
overlap, as in the case study, but also scenarios with poor overlap, to explore the 
performance of the methods in the most challenging settings. We compare the relative 
performance of the methods according to bias, root mean squared error (RMSE), and 
coverage rates of nominal 95% confidence intervals (CIs).  
In the next section, we outline the statistical methods under comparison. The following 
section presents the motivating example. Then we report the design and results of the 
simulation study. The last section discusses the findings and suggests areas for further 
research. 
Statistical methods 
The parameter of interest is the ATE of a binary treatment 𝐴, defined as 
𝜓 = 𝐸[𝑌(1) − 𝑌(0)] , 
where 𝑌(1) is the potential outcome under treatment, i.e. the endpoint that would be 
observed under treatment state, and 𝑌(0) is the potential outcome under control state.  
The vector of confounding factors, that is all factors that influence the potential 
outcomes and treatment assignment, is defined as W.   Under unconfoundedness 
(Greenland et al., 1999), also known as conditional exchangeability, all elements of 𝑊 
are observed, and the mean of the conditional distribution of the potential outcomes 
corresponds with the mean of the conditional distribution of the observed endpoint Y:  
𝐸[𝑌(1)|𝑊] =  𝐸[𝑌|𝐴 = 1, 𝑊]  and    𝐸[𝑌(0)|𝑊] =  𝐸[𝑌|𝐴 = 0, 𝑊]. 
Under the additional assumptions of consistency and positivity, the ATE can be 
identified as 
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𝜓 = 𝐸[[𝑌|𝐴 = 1, 𝑊] − 𝐸[𝑌|𝐴 = 0, 𝑊]|𝑊]. 
The consistency assumption states that an individual’s potential outcome under the 
observed treatment is exactly the observed endpoint (Cole and Frangakis, 2009). The 
positivity assumption requires that there are both treated and control individuals at each 
combination of the values of observed confounders in the population (Westreich and 
Cole, 2010), formally, 0 < 𝑔(𝐴, 𝑊) < 1, for any stratum defined by W, where 
𝑔(𝐴, 𝑊) = 𝑃(𝐴|𝑊) is the model for the  treatment assignment. In finite samples, even 
in the absence of structural violations, practical positivity violations often arise; in 
particular covariate strata there might be few or no individuals from either treatment 
group (Westreich and Cole, 2010), and so the estimated ?̂?(𝐴, 𝑊) can be close to 0 or 1.  
The econometric literature on matching methods refers to positivity violations as “poor 
overlap” (Imbens, 2004). Here we define both structural and practical violations of the 
positivity assumption as poor overlap, and use this terminology throughout. 
Regression estimators  
We consider a general regression estimator, also known as the G-computation estimator 
(Robins, 1986) , which uses estimates of the expected potential outcomes, conditional 
on observed characteristics, defined as 𝑄(𝐴, 𝑊) = 𝐸[𝑌|𝐴, 𝑊]. 
The estimator for the ATE is given by: 
?̂?𝑟𝑒𝑔 =
1
𝑁
∑ {?̂?(1, 𝑊𝑖) − ?̂?(0, 𝑊𝑖)}
𝑁
𝑖=1 ,                        (1) 
where ?̂?(1, 𝑊) and ?̂?(0, 𝑊) are the estimated potential outcomes for each individual 
under treatment and control states, respectively, and 𝑁 is the number of subjects in the 
sample. 
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?̂?(0, 𝑊) and ?̂?(1, 𝑊) can be obtained by fitting a regression model that includes the 
observed covariates and a treatment variable, for example OLS or a generalised linear 
model (GLM). A more flexible method is to fit separate models for the treated and 
control samples (Imbens and Wooldridge, 2009b). Unbiased estimates of the ATE can 
only be achieved if 𝑄(1, 𝑊)  and 𝑄(0, 𝑊) are estimated consistently. When there is 
poor overlap, regression estimators extrapolate, which can lead to large biases if the 
regression model is misspecified (Ho et al., 2007, Rubin, 1997).  
Flexible estimation techniques of the endpoint regression function include series 
estimation (Imbens and Wooldridge, 2009b, Abadie and Imbens, 2011) and machine 
learning (Austin, 2012).  Both approaches can reduce bias which results from model 
misspecification. Here we consider a machine learning approach, the “super learning” 
algorithm (van der Laan et al., 2007). Super learning uses a collection of prediction 
algorithms pre-selected by the user, potentially including parametric and non-parametric 
regression models. The algorithm uses cross-validation to select a weighted 
combination of estimates given by the prediction procedures (Polley and van der Laan, 
2010b). Asymptotically, the super learner algorithm performs as well as the best 
possible combination of the candidate estimators  (van der Laan and Dudoit, 2003). 
Propensity score methods 
The propensity score (PS) is defined as the conditional probability of treatment 
assignment given 𝑊, 𝑔(1|𝑊) = 𝑃𝑟(𝐴 = 1|𝑊). Using the estimated PS, ?̂?(. ), as a 
distance metric, matched treated and control comparison groups can be created 
(Rosenbaum  and Rubin, 1983). The matching estimator imputes the missing potential 
outcomes, 𝑌(0) and 𝑌(1), using the observed endpoints of the closest M individuals:   
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?̂?(0, 𝑊𝑖) = { 1
𝑀
𝑌𝑖
∑ 𝑌𝑗𝑗𝜖𝜁𝑀(𝑖)     
if  𝐴𝑖 = 0
if 𝐴𝑖 = 1
  , 
?̂?(1, 𝑊𝑖) = {
1
𝑀
∑ 𝑌𝑗𝑗𝜖𝜁𝑀(𝑖)
𝑌𝑖     
if  𝐴𝑖 = 0
if  𝐴𝑖 = 1
  , 
 
where  𝜁𝑀(𝑖) is the set of M individuals matched to unit 𝑖. The estimator for the ATE is 
the mean of the estimated individual-level treatment effects: 
?̂?𝑚𝑎𝑡𝑐ℎ =
1
𝑁
∑{?̂?(1, 𝑊𝑖) − ?̂?(0, 𝑊𝑖)}
𝑁
𝑖=1
 
Inverse probability of treatment weighting (IPTW) reweights the treated and control 
samples using inverse weights  
𝐴𝑖
?̂?(1|𝑊𝑖)
  for the treated and 
1−𝐴𝑖
1−?̂?(1|𝑊𝑖)
 for the control 
observations. The normalised IPTW estimator (Hirano and Imbens, 2001, Kang and 
Schafer, 2007a) is defined as: 
?̂?𝐼𝑃𝑇𝑊 =
∑ 𝐴𝑖
𝑌𝑖
?̂?(1|𝑊𝑖)
 𝑁𝑖=1
∑
𝐴𝑖
?̂?(1|𝑊𝑖)
𝑁
𝑖=1
−
∑ (1 − 𝐴𝑖)
𝑌𝑖
1 − ?̂?(1|𝑊𝑖)
  𝑁𝑖=1
∑
1 − 𝐴𝑖
1 − ?̂?(1|𝑊𝑖)
𝑁
𝑖=1
 
Matching estimators are consistent if ?̂?(. ) is correctly specified (Waernbaum, 2011), 
but have larger finite sample bias and are less precise than a correctly specified 
regression estimator (Abadie and Imbens, 2006, Rubin, 1973).  With a correctly 
specified ?̂?(. ), IPTW can also provide consistent and efficient estimates (Hirano et al., 
2003). However, poor overlap can result in unstable IPT weights, and biased or 
inefficient estimates of the ATEs (Kang and Schafer, 2007a, Lee et al., 2010, Busso et 
al., 2011, Radice et al., 2012). In these settings, recommended approaches include 
truncating IPT weights at fixed levels (Elliott, 2008) or percentiles of ?̂?(. ) (Cole and 
Hernán, 2008), and estimating ATEs for a subsample with good overlap (Crump et al., 
2009). 
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Instead of estimating the PS with a fixed parametric model, such as a logistic regression 
including main terms, flexible approaches have been proposed to help correctly specify 
𝑔(. ). These include the series regression estimator (Hirano et al., 2003), and methods 
from the machine learning literature, including decision trees, neural networks, linear 
classifiers and boosting (McCaffrey et al., 2004, Setoguchi et al., 2008, Westreich et al., 
2010). This paper considers the machine learning approach of boosted classification and 
regression trees (CART). This approach has been shown to reduce bias in the estimated 
ATE compared to a misspecified logistic regression, under circumstances of unstable 
IPT weights (Lee et al., 2010), and outperformed alternative machine learning methods 
such as pruned CARTs. Boosted CART fits regression trees on random subsets of the 
data, and in each iteration, the data points that were incorrectly classified with the 
previous trees receive greater priority. According to general recommendations (Stuart, 
2010), the algorithm can be set to select the final PS model that maximises covariate 
balance (McCaffrey et al., 2004, Lee et al., 2010). 
 Double-robust methods 
Double-robust (DR) methods (Bang and Robins, 2005, Robins et al., 1994) combine 
models for 𝑄(. ) and 𝑔(. ) , with most estimators using ?̂?(. ) as IPT weights (Kang and 
Schafer, 2007b). The distinctive property of DR estimators is that they are consistent if 
either (but not necessarily both) 𝑔(. ) or 𝑄(. ) is correctly specified (Robins et al., 1994). 
If both components are correct, the DR estimator can be a semiparametric efficient 
estimator (Robins et al., 2007, van der Laan and Rubin, 2006). A commonly used DR 
method is the weighted regression (Freedman and Berk, 2008, Kang and Schafer, 
2007a), which weights the covariates in an endpoint regression, using IPT weights.  
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In realistic settings such as when there is poor overlap and dual misspecification, 
weighted regression can report biased and inefficient estimates of ATEs (Kang and 
Schafer, 2007a, Porter et al., 2011, Freedman and Berk, 2008, Basu et al., 2011). An 
ongoing debate discusses the relative merits of different DR estimators in these 
circumstances (Porter et al., 2011, van der Laan and Gruber, 2010, Robins et al., 2007). 
One recommendation when faced with an unknown PS and unstable IPT weights is to 
use machine learning methods to estimate 𝑔(. ) (Ridgeway and McCaffrey, 2007).  Here 
we consider the weighted least squares estimator (WLS) and implement it with weights 
obtained from a fixed logistic regression but also using boosted CART. 
It has been suggested that DR estimators should have a “boundedness property”: they 
should respect the known bounds of the endpoint,  for example that an HRQoL endpoint 
is between small negative values and 1, so that the estimated parameter will always fall 
into the parameter space (Robins et al., 2007, Rotnitzky et al., 2012). This property can 
reduce bias and increase precision when the PS is used as weights, where large weights 
can lead to estimated values of the endpoint falling outside of a plausible  range (Gruber 
and van der Laan, 2010a). Below we discuss a DR estimator, TMLE, that can have this 
boundedness property (Rotnitzky et al., 2012), and is therefore appealing for settings of 
poor overlap (Gruber and van der Laan, 2010a, Gruber and van der Laan, 2012b).  
Targeted maximum likelihood estimation 
While standard maximum likelihood estimation aims to find parameter values that 
maximise the likelihood function for the whole distribution of the data, TMLE is 
concerned with a particular feature of the distribution such as the ATE  (van der Laan 
and Rubin, 2006, Moore and van der Laan, 2009). Maximising a global likelihood 
function may not yield the least biased estimate of the target parameter, so TMLE is 
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designed to target the initial estimate to reduce bias in the estimate of the parameter of 
interest. The TMLE estimator solves the efficient influence curve estimating equation,  
where an influence curve describes the behaviour of an estimator under slight changes 
of the data distribution (Hampel, 1974).  Performing TMLE involves two stages 
(Gruber and van der Laan, 2012c), which, for estimating the ATE, are: 
1: To obtain an initial estimate of the conditional mean of 𝑌 given A and W by using 
regression to predict the potential outcomes ?̂?(1, 𝑊) and ?̂?(0, 𝑊).   
2: To fluctuate this initial estimate, ?̂?0(𝐴, 𝑊), exploiting the information in the 
treatment assignment mechanism, 𝑔(. ).  
Here, the fluctuation corresponds to extending the parametric model for 𝑄(𝐴, 𝑊) with 
“clever covariates” (ℎ): 
ℎ0(𝐴, 𝑊) =
1 − 𝐴
1 − 𝑔(𝐴 = 1|𝑊)
 
ℎ1(𝐴, 𝑊) =
𝐴
𝑔(𝐴 = 1|𝑊)
 
For continuous endpoints, it is recommended (Gruber and van der Laan, 2012b, Gruber 
and van der Laan, 2010a) that known bounds of the endpoint are exploited by rescaling  
𝑌 to between 0 and 1, to ensure the boundedness of the TMLE estimator. The rescaled 
endpoint is defined as  𝑌∗ =
𝑌−𝑎
𝑏−𝑎
 , where 𝑎 and 𝑏  are known limits of Y. Using 𝑌∗, 
𝑄∗(𝐴, 𝑊) =  
𝑄(𝐴,𝑊)− 𝑎
𝑏−𝑎
 can be defined. The fluctuation can then be performed on the 
logistic scale:  
𝑙𝑜𝑔𝑖𝑡 (𝑄∗̂
1
(0, 𝑊)) = 𝑙𝑜𝑔𝑖𝑡 (𝑄∗̂
0
(0, 𝑊)) + ε̂0ℎ̂0(0,W) and  
𝑙𝑜𝑔𝑖𝑡(𝑄∗̂
1
(1, 𝑊)) = 𝑙𝑜𝑔𝑖𝑡(𝑄∗̂
0
(1, 𝑊)) + ε̂1ℎ̂1(1,W). 
Here, ε̂0 and ε̂1 can be estimated by logistic regression with quasi-binomial distribution 
of Y∗ on  ℎ̂0 and ℎ̂1, and offset 𝑙𝑜𝑔𝑖𝑡(𝑄∗̂
0
(𝐴, 𝑊)). ℎ0 and ℎ1 are constructed to solve 
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the efficient influence curve estimating equation for the ATE. This regression can be 
interpreted as explaining the residual variability of the predicted endpoint, using 
information in the treatment assignment mechanism. ?̂?1(𝐴, 𝑊) can be obtained by 
back-transforming 𝑄∗̂
1
(𝐴, 𝑊) to the original scale. 
The resulting targeted estimates of the potential outcomes, ?̂?1(0, 𝑊) and ?̂?1(1, 𝑊) are 
applied in the G-computation formula in order to obtain the TMLE estimator: 
?̂?𝑇𝑀𝐿𝐸 =
1
𝑁
∑ Q̂1(1, 𝑊𝑖) −
𝑁
𝑖=1
Q̂1(0, 𝑊𝑖) 
TMLE has the property of double-robustness: if either the initial estimate of 𝑄(. ) or 
𝑔(. ) are correctly specified, the estimator is consistent. TMLE is also an asymptotically 
efficient estimator, and if both 𝑄(. ) or 𝑔(. ) are correct, it reaches the semiparametric 
efficiency bound (van der Laan, 2010). The estimator can use predictions from any 
fixed parametric model for the initial 𝑄(. ) (for example OLS or GLM) and 𝑔(. ) (for 
example logistic regression). However, with machine learning methods, TMLE has 
been shown to reduce bias when the models for the assignment mechanism and the 
endpoint are unknown (Porter et al., 2011). As in the previous sections, we consider 
super learning for the initial 𝑄(. ) and boosted CARTs for 𝑔(. ). 
Bias-corrected matching 
It is generally recommended that matching methods are followed by regression 
adjustment (Rubin, 1973, Rubin and Thomas, 2000, Abadie and Imbens, 2006). The 
idea is similar to regression-adjustment in randomised trials: regression is used to “clean 
up” residual imbalances between treatment groups after matching (Stuart, 2010). BCM 
(Abadie et al., 2004, Abadie and Imbens, 2011) adjusts the imputed potential outcome 
with the difference in the predicted endpoint that can be attributed to covariate 
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imbalance between the matched pairs. These predictions are obtained by a regression of 
the endpoint on covariates, stratified by treatment assignment. The bias-corrected 
predictions of the potential outcomes are obtained as follows: 
?̂?(0, 𝑊𝑖) = { 1
𝑀
𝑌𝑖
∑ 𝑌𝑗 + ?̂?(0, 𝑊𝑖) − ?̂?(0, 𝑊𝑗)𝑗𝜖𝜁𝑀(𝑖)     
if  𝐴𝑖 = 0
if 𝐴𝑖 = 1
  , 
?̂?(1, 𝑊𝑖) = {
1
𝑀
∑ 𝑌𝑗 + ?̂?(1, 𝑊𝑖) − ?̂?(1, 𝑊𝑗)𝑗𝜖𝜁𝑀(𝑖)
𝑌𝑖     
if  𝐴𝑖 = 0
if  𝐴𝑖 = 1
  , 
For example, for an individual 𝑖 who receives control, the imputed potential outcome 
under the treatment state is the average outcome of the M closest matches from the 
treatment group (indexed by j), adjusted with the difference between the predicted 
outcomes under treatment, when covariate values are set to those of its own values, 
?̂?(1, 𝑊𝑖) and the covariate values of the match, ?̂?(1, 𝑊𝑗). The corresponding estimator 
is the mean difference of these predictions: 
?̂?𝐵𝐶𝑀 =
1
𝑁
∑ ?̂?(1, 𝑊𝑖) − ?̂?(0, 𝑊𝑖)
𝑁
𝑖=1
 
BCM is consistent if 𝑄(0, 𝑊) and 𝑄(1, 𝑊) are consistently estimated (Abadie and 
Imbens, 2011). Matching can decrease the sensitivity of estimates to the 
misspecification of the endpoint regression model (Ho et al., 2007) and, for moderately 
nonlinear response surfaces, adjustment even with a misspecified OLS  model can 
reduce bias (Rubin, 1973, Rubin and Thomas, 2000, Abadie and Imbens, 2011, Busso et 
al., 2011). Because an OLS regression, even including nonlinear terms, might not 
capture highly nonlinear response surfaces, we consider super learning for predicting 
the potential outcomes, as well as fixed parametric models. Following 
recommendations, we select the number of matches (M ) to 1 (Stuart, 2010, Caliendo 
and Kopeinig, 2008), and match on the liner predictor of PS with replacement, allowing 
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for ties. As for the DR methods, we estimate the PS using logistic regression and also 
using boosted CARTs.  
 Motivating case study 
Overview 
We consider the methods in a case study that evaluates the effect of alternate hip 
prosthesis types on the HRQoL of patients with osteoarthritis, using an observational 
database on patients with total hip replacement (THR). THR is one of the most common 
surgical procedures in the UK, with over 50,000 hip procedures performed in the NHS 
in England and Wales in 2011 (NICE, 2012). With a large number of brands of 
prosthesis in use, with differing costs,  UK health care decision makers have a 
considerable interest in evaluating the clinical and cost-effectiveness of different 
prosthesis types in routine care (NICE, 2012). A large scale UK survey that collects 
patient-reported outcome measures (PROMs) on all patients who undergo elective 
surgery in the NHS provides a key data source for this evaluation. The resulting 
observational dataset, used in this case study, includes pre-  and post-operative HRQoL 
of patients with THR procedures (PROMs, 2010, Ousey and Cook, 2011).  
The dataset measures the HRQoL endpoint as EQ-5D-3L scores (EuroQol Group, 
1990). The EQ-5D-3L is a generic instrument with five dimensions of health (mobility, 
self care, usual activities, pain and discomfort, anxiety and depression) and three levels 
(no problems, some problems, severe problems). The EQ-5D-3L profiles were 
combined with health state preference values from the UK general population, to give 
utility index scores on a scale ranging from 1 (perfect health), through  0 (death) to the 
worst possible health state, -0.59 (Dolan et al., 1995). This results in a bounded 
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distribution of the endpoint that exhibited a spike at 1, posing a challenge for the 
specification of the regression model (Basu and Manca, 2011). 
A previous analysis of this dataset (Pennington et al., 2012) reported the relative 
effectiveness on EQ-5D-3L scores of common prosthesis types,  such as cemented,  
cementless, and “hybrid” prostheses. The analysis used multivariate matching and linear 
regression to adjust for confounding, and found a small but statistically significant 
advantage of hybrid compared to cementless prostheses.  
The objective of this case study is to estimate the ATE on EQ-5D-3L, 6 months after 
operation, in patients with hybrid hip prosthesis, compared to cementless hip prosthesis. 
For this motivating example, we constrained the population of interest to be UK males 
patients with osteoarthritis, aged 65-74 (n = 3583). We contrast TMLE and BCM, and 
also compare them to standard statistical approaches such as regression, matching, 
IPTW and WLS. We implement each method with fixed parametric models and 
machine learning estimation techniques. 
Statistical methods in the case study 
Measured potential confounders included patient characteristics such as age, sex, body 
mass index, pre-operative heath status (“Oxford Hip score” and HRQoL), 
comorbidities, disability, index of multiple deprivation, and characteristics related to the 
intervention, such as surgeon experience (senior surgeon or not) and hospital type 
(NHS, private sector hospital, or treatment centre). Of the 3,583 patients included in the 
analysis, 32% had missing data on post-operative HRQoL and 39% on BMI. Other 
covariates were complete for over 90% of the sample. Multiple imputation using 
chained equations was applied to impute missing covariate and endpoint values 
(Pennington et al., 2012). Following recommendations (Rubin, 1996), five multiply 
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imputed datasets were created, and the analysis described below was performed on each 
dataset. Point estimates and variances were combined using Rubin’s rule (Rubin, 1996). 
Fixed parametric approaches for estimating 𝑄(. ) included OLS regression and a two-
part model which can account for the spike in the observed distribution of the endpoint 
(Buntin and Zaslavsky, 2004, Basu and Manca, 2011). Here the continuous part (𝑌′ =
1 − 𝑌  when 𝑌 < 1)  was modelled with a gamma regression, and logistic regression 
was used for modelling 𝑃(𝑌 < 1).  The PS was estimated using logistic regression. In 
order to allow for nonlinearities, for each model, continuous variables were fitted with 
smoothing splines (using default degrees of freedom of 4).  
For machine learning estimation of 𝑄(. ), we used the R package “Super Learner” 
(Polley and van der Laan, 2010a), where the user-defined library included the following 
prediction algorithms:  “glm” (main terms linear regression), “glm.interaction” (glm 
with covariate interactions), and a package that implements multivariate adaptive 
polynomial spline regression methods, “polymars” (Kooperberg, 2010). Machine 
learning estimation of  𝑔(. ) relied on boosted (logistic) CARTs, using the R package 
“twang” (Ridgeway et al., 2006), with tuning parameters recommended by the 
developers (McCaffrey et al., 2004, Lee et al., 2010). This implementation aimed to 
minimise mean covariate imbalance measured using Kolmogorov-Smirnov tests, 
reweighed by the estimated IPT weights.   
We applied WLS using smoothing splines, with IPT weights obtained from the logistic 
model and also from the boosted CARTs. TMLE used the known minimum and 
maximum values of the endpoint as bounds, -0.59 and 1 (Dolan et al., 1995). Standard 
errors and 95% CIs were calculated using the sandwich estimator for IPTW and WLS, 
and using the influence curve (van der Laan, 2010), for TMLE. For matching and BCM, 
estimated standard errors took into account the matching process, conditional on the 
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estimated PS (Abadie and Imbens, 2011, Abadie and Imbens, 2006). For the two-part 
model and the super learning regression estimator, we used the non-parametric 
bootstrap (Davison and Hinkley, 1997) to obtain standard errors.  
Case study results 
Table 6.1 shows balance on the main pre-operative characteristics of patients with 
hybrid and cementless hip replacement, reported as absolute standardised mean 
differences. Patients with hybrid hip replacement were slightly older, had more co-
morbidities (measured as a co-morbidity score), worse social status, and were less likely 
to have been treated by a consultant or in a treatment centre.  
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Table 6.1 - Balance on pre-operative characteristics, means and % standardised mean 
differences  
Covariate Mean hybrid (n=631) Mean cementless (n=2952) SMD (%) 
Age 69.71 69.25 15.98 
Oxford hip score1 20.17 19.93 2.83 
Pre-operative EQ-5D1 0.40 0.40 0.63 
Index of deprivation1 3.26 3.03 15.92 
ASA grade 1 (%)1 1.00 0.96 4.14 
ASA grade 2 (%)1 0.09 0.12 9.55 
Disability (%) 0.74 0.74 0.52 
Obese (%)1 0.27 0.27 0.69 
Morbidly obese (%)1 0.10 0.11 4.30 
Nr of co-morbidities 1.00 0.96 4.14 
Co-morbidities 
   
    Heart disease  0.18 0.15 7.86 
    High bp 0.40 0.42 4.55 
    Stroke  0.03 0.02 7.78 
    Circulation  0.08 0.07 4.08 
    Lung disease  0.06 0.06 3.61 
    Diabetes  0.13 0.12 2.20 
    Kidney disease  0.01 0.02 6.24 
    Nervous system  0.01 0.01 5.20 
    Liver disease  0.01 0.00 7.65 
    Cancer  0.06 0.05 3.80 
    Depression   0.05 0.04 5.84 
Consultant  (%) 0.80 0.87 17.64 
Treatment centre (%) 0.05 0.12 26.16 
Notes: SMD - standardised mean difference. SMD was calculated as 𝑑 = 100 ∗
|?̅?ℎ−?̅?𝑐|
√𝑠
2
ℎ+ 𝑠
2𝑐
2
, where x̅h and x̅c 
are the means for the hybrid and cementless group, while in the denominator  includes the pooled 
standard deviation of the two groups, for a given covariate. Variables are dichotomous, with the exception 
of age, Oxford hip score, pre-operative EQ-5D score, index of deprivation and number of co-morbidities. 
1 Variables with missing values. Here, SMDs were combined using Rubin’s rule.  
 
There was good overlap between the densities of the estimated PSs for hybrid and 
cementless groups, when 𝑔(. ) was obtained using logistic regression (Figure 6.1). The 
plots obtained using boosted CART for estimating the PS were similar.   
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Figure 6.1 - Estimated PS using logistic regression, hybrid vs. cementless hip prosthesis 
 
 
Notes: Hybrid (grey line) vs. cementless (black line). The rug plots, at the top and bottom, show the 
corresponding values of the PS. Estimates are based on the first imputed dataset. 
 
Figure 6.2 shows the point estimates and 95% CIs after combining the estimates 
obtained for the imputed datasets. All methods reported a small positive advantage in 
mean EQ-5D-3L scores for hybrid versus cementless prostheses, but with CIs including 
zero.  
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Figure 6.2 - Point estimates and 95% CIs of ATE in terms of EQ-5D-3L score, hybrid vs. 
cementless hip prosthesis, across statistical methods. 
 
Notes: SL- super learner 
 
Simulation study 
Overview 
The simulation study aimed to compare the performance of BCM and TMLE, in 
estimating the ATE of a binary treatment on a continuous endpoint with a nonlinear 
response surface. As in the case study, we compared these methods to regression, PS 
-0.02 -0.01 0.00 0.01 0.02 0.03 0.04
BCM (SL + boosted CART)
BCM (2pt + logistic)
BCM (OLS + logistic)
TMLE (SL + boosted CART)
TMLE (2pt + logistic)
TMLE (OLS + logistic)
WLS (boosted CART)
WLS (logistic)
IPTW boosted CART
IPTW logistic
PS matching (logistic)
Regression (SL)
Regression (2 part model)
 Regression (OLS)
Unadjusted
Point estimates and 95% CIs
242 
 
matching, IPTW and WLS, and for each method, we considered fixed parametric 
models and machine learning estimation for 𝑄(. ) and 𝑔(. ). Motivated by the case study 
and previous methodological work, we designed a range of scenarios with typical 
characteristics of HRQoL data. Irregular distributions (Manning et al., 2005, Basu, 
2011) of HRQoL data were recognised by generating endpoints from distributions such 
as the gamma and two part distributions. Following previous simulation studies (Basu 
and Manca, 2011, Porter et al., 2011, Austin, 2012), we considered data-generating 
processes (DGPs) with nonlinear response surfaces, good and poor overlap, and with 
moderate and strong association between confounders and the endpoints. These DGPs 
were selected to highlight the differences between the performance of the methods 
under realistic circumstances, by investigating the following hypotheses: 
1. Reweighting methods are anticipated to outperform BCM when overlap is good 
(Busso et al., 2011). In such scenarios, TMLE is expected to outperform BCM in 
terms of bias and efficiency. 
 
2. When overlap is poor, BCM is expected to outperform TMLE, because matching 
can be less sensitive than weighting to extreme PS values and to the 
misspecification of 𝑔(. ) (Lee et al., 2010, Busso et al., 2011, Waernbaum, 
2011). 
 
3. Using appropriate machine learning methods is anticipated to reduce bias 
compared to using misspecified parametric models for 𝑄(. ) and 𝑔(. ) (Porter et 
al., 2011, Austin, 2012), across all methods considered. 
 
Table 6.2 summarises the selected DGPs. We assumed a PS mechanism that generated 
good overlap of the densities of the true PS (DGP 1 and 2) and one that generated poor 
overlap (DGP 3 to 5). We considered moderate (DGP 1) and strong (DGP 2 to 5) 
association between the confounders and the endpoints. DGPs 1-3 considered a normal 
endpoint with an identity link function between the linear predictor and the endpoint, 
DGP 4 considered an endpoint which followed a gamma distribution with a log link, 
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while DGP 5 considered a two part data-generating distribution, with a mixture of a 
beta-distributed random variable and values of 1.  
For each DGP, five scenarios were considered: (a) when fixed parametric models were 
used for both the PS and the endpoint regression, and these were correctly specified, (b 
and c) when one of the two was misspecified and (d) when neither model was correctly 
specified. In scenario (e) we considered machine learning estimates of 𝑄(. ) and 𝑔(. ) 
for each method, under the assumption that the investigator, similarly to (d), does not 
know the correct parametric models, hence the correct model is not included among the 
candidate prediction algorithms. For DGP 1, we report results from each of the five 
scenarios, while for DGP 2 to 5, we only report the results for scenarios (d) and (e), as 
these were a priori judged the most realistic. The results for the remaining scenarios are 
available upon request.  
Bias, variance, root mean squared error (RMSE) and the coverage rate for nominal 95% 
CIs of the estimated ATEs were obtained.  Relative bias was calculated as the 
percentage of the absolute bias of the true parameter value, where absolute bias is the 
difference between the true parameter value and the mean of the estimated parameter. 
The RMSE was taken as the square root of the mean squared differences between the 
true and estimated parameter values.  
Table 6.2 - Summary of DGPs used in the simulation study 
 Overlap Confounder-endpoint association Endpoint distribution 
DGP 1 Good Moderate Normal 
DGP 2 Good  Strong Normal 
DGP 3  Poor  Strong Normal 
DGP 4 Poor Strong Gamma 
DGP 5 Poor  Strong Two part 
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Data generating process 
For each DGP, we generated 1000 datasets of n=1000, with binary (𝑊1 to 𝑊5) and 
standard normally distributed covariates (𝑊6 to 𝑊8). This mix of binary and continuous 
covariates reflects the case study.  The correlation coefficients between the covariates 
were set between 0.075 and 0.6. All covariates were true confounders, i.e. they 
influenced both the treatment assignment and the endpoint. Treatment was assigned 
according to a true PS that, like previous simulation studies, included main terms,  
higher order terms and interactions (Austin, 2012, Waernbaum, 2011).  
For DGP 1, the PS model resulted in a good overlap of the true PS (see Figure 6.3): 
𝑙𝑜𝑔𝑖𝑡(𝑃𝑆) = −1 + 𝑘1(0.3𝑊1 − 0.1𝑊2 − 0.2𝑊3 + 0.4𝑊4 + 0.7𝑊5 + 0.2𝑊6 +
0.2𝑊7 − 0.25𝑊8 + 0.8𝑊6
2 − 0.3𝑊7
2 − 0.3𝑊8
2 − 0.05𝑊1𝑊2 − 0.05𝑊1𝑊3) , 
 
where 𝑘1 = 0.3. 
The treatment variable 𝐴 was drawn from a Bernoulli distribution, using the PS as the 
parameter of success probability. The endpoint was drawn from a normal distribution 
with mean 
𝜇𝑛𝑜𝑟𝑚 = 15 + 0.4𝐴 + 𝑘2(1𝑊1 − 0.1𝑊2 + 0.1𝑊3 − 0.1𝑊4 + 0.1𝑊5 − 0.1𝑊6 +
0.1𝑊7 + 0.1𝑊8 − 0.2𝑊6
2 − 0.1𝑊7
2 − 0.1𝑊8
2 + 0.2𝑊6
3 + 0.1𝑊7
3 + 0.1𝑊8
3 −
 0.1𝑊1𝑊2 + 0.5𝑊1𝑊7), 
 
standard deviation of 1 and 𝑘2 = 1. 
In DGP 2, setting 𝑘2 to 4 increased the strength of the confounder-endpoint association. 
In DGP 3, changing  𝑘1 to 1 created a poor overlap of the true PS distributions (see 
Figure 6.3). 
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Figure 6.3 - Densities of the true PS in the simulations for a typical sample (n =10,000) 
 
 
Notes: Treated (grey line) vs. control (black line). The rug plots at the top and bottom show the 
corresponding values of the PS. 
 
In DGP 4, the endpoint was drawn from a gamma distribution, with a log link, shape 
parameter of 100 and a scale parameter of  
μgam
100
, where the linear predictor was 
𝑙𝑜𝑔 (𝜇𝑔𝑎𝑚) = 3 + 0.2𝐴 − 0.2𝑊1 + 0.2𝑊2 − 0.2𝑊3 + 0.5𝑊4 − 1𝑊5 + 0.5𝑊6 −
0.5𝑊7 + 0.2𝑊8 − 0.2𝑊6
2 − 0.01𝑊7
2 − 0.01𝑊8
2 − 0.01𝑊6
3 − 0.01𝑊7
3 − 0.01𝑊8
3 −
                                                                                         0.01𝑊1𝑊2 − 0.4𝑊6𝑊7. 
In DGP 5, motivated by the case study and previous simulation studies (see Basu and 
Manca, 2011), the endpoint was generated as a mixture of a beta distributed continuous 
variable Y′ and 1, using a Bernoulli distribution with parameter p to select between 
values from the two distributions : 
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𝑌~(1 − 𝑝) ∗ 1 + 𝑝(1 − 𝑌′), 
where  
                                𝑙𝑜𝑔𝑖𝑡(𝑝) = 4 − 1𝐴 − 0.2𝑊1 + 0.5𝑊2 − 0.5𝑊3 − 1𝑊4 − 0.3𝑊5 +
0.2𝑊6 + 0.5𝑊7 − 0.5𝑊8, 
𝑌′~𝐵𝑒𝑡𝑎(𝜇𝑏𝑒𝑡𝑎 ∗ 𝑝ℎ𝑖,   𝜇𝑏𝑒𝑡𝑎 ∗ (1 − 𝑝ℎ𝑖)), 
𝑙𝑜𝑔𝑖𝑡(𝜇𝑏𝑒𝑡𝑎) = −1 − 0.2𝐴 − 0.5𝑊1 − 0.5𝑊2 − 0.5𝑊3 + 0.5𝑊4 − 0.5𝑊5 − 0.5𝑊6 −
                                      0.5𝑊7 −   0.5𝑊8 − 0.2𝑊6
2 − 0.2𝑊7
2 − 0.2𝑊8
2 − 0.2𝑊6
3 −
0.2𝑊7
3 − 0.2𝑊8
3 − 0.2𝑊1𝑊2 − 0.2𝑊6𝑊7). 
 
The resulting distribution with a spike at 1 reflects the observed endpoint in the case 
study. The true ATE was 0.4 in DGP 1 to 3, it was 9.98 for DGP 4 and 0.062 for DGP 
5. While in DGP 1 to 3 the treatment effect was constant across individuals, for DGP 4 
and 5, the true ATE was obtained by simulating both potential outcomes for each 
individual, and taking the mean of the individual-level additive treatment effects.  
Implementation of the methods 
Correct specification was defined as applying a fixed parametric model with the 
knowledge of features of the true DGP, such as the link function, the functional form 
between the covariates and the linear predictor, and the error distribution. For each 
DGP, the misspecified parametric 𝑔(. ) and 𝑄(. ) models were logistic and OLS 
regressions with main terms only. Machine learning estimation of 𝑔(. ) and 𝑄(. ) was as 
described in the case study section. The WLS estimator was implemented with main 
terms only, hence in this estimator the 𝑄(. ) component is misspecified. For the DGPs 
with poor overlap, in a sensitivity analysis we modified the IPTW, WLS and TMLE 
estimators, and used weights based on 𝑔(. ) truncated at fixed levels of 0.025 and 0.975. 
For calculating coverage rates of nominal 95% CIs, standard errors were obtained as 
described in the case study section. 
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Simulation study results 
Tables 6.3-6.5 report the relative bias (%), variance, RMSE and 95% CI coverage for 
the estimators considered, and Figure 6.4 presents quintiles of the estimated ATE. 
Table 6.3 reports results for DGP 1, when there was good overlap, with a moderate 
association between the confounders and a normally distributed endpoint. When both 
𝑄(. ) and 𝑔(. ) were correctly specified, all methods reported minimal bias, with 
parametric regression (OLS with nonlinear terms) and TMLE reporting the lowest 
RMSE. Regression, TMLE and BCM all provided coverage at the nominal 95%, while 
IPTW and PS matching reported coverage rates higher (98% and 99%) than the nominal 
level. When only one of the PS or endpoint model was misspecified, BCM and both DR 
methods (WLS and TML) remained unbiased. With dual misspecification, each method 
reported moderate levels of bias, but when machine learning estimation was used for 
𝑄(. ) and 𝑔(. ), bias was reduced to close to zero for all the methods that combined these 
components, with WLS and TMLE providing estimates with the lowest RMSE.  
For DGPs 2-5, results showed a similar pattern to DGP 1 when either 𝑔(. ) or  𝑄(. ) was 
correctly specified, hence we only report result with dual misspecification. In DGP 2, 
with misspecified fixed parametric methods, stronger association between the 
confounders and the endpoint led to higher biases, but with machine learning estimation 
the bias for the methods that combined 𝑔(. ) and 𝑄(. ) again decreased to below 10%. 
WLS and TMLE reported lower bias and RMSE than BCM. In DGPs 3-5, where there 
was poor overlap, with misspecified fixed parameteric models, each method reported 
high bias. For each of these DGPs, machine learning estimation improved performance 
of the methods that combined 𝑔(. ) and 𝑄(. ). In DGP 3, TMLE provided the lowest bias 
and RMSE, albeit with CI coverage that was lower than the nominal level. In DGP 4 
248 
 
where we considered an endpoint with a gamma distribution, with machine learning 
approaches BCM showed less relative bias (2.5%) than TMLE (20.7%). In DGP 5, 
where we considered an endpoint with a two-part distribution, TMLE and BCM with 
machine learning estimation performed best; BCM gave the lowest relative bias (1.1% 
vs. 7.2%) and best CI coverage whereas TMLE reported the lowest RMSE.  
 IPTW using machine learning weights often reported high bias: for example for DGP 5, 
it reported higher bias than using a misspecified, fixed logistic regression to obtain the 
PS. This indicated that using machine learning estimation for the PS alone was 
insufficient to eliminate bias.  For DGPs 3 to 5, where overlap was poor, truncating the 
IPT weights for IPTW and TMLE for either the logistic or the boosted PS models did 
not change the results.   
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Table 6.3 - Simulation results for DGP 1, over 1000 replications: normal endpoint, 
moderate association confounder-endpoint association, good overlap 
Scenario  
                   
Relative bias Variance 
    
RMSE 
     95 % CI 
coverage 
(a) Q correct - g correct     
OLS -0.1% 0.005 0.070 95% 
IPTW 0.5% 0.008 0.091 99% 
PS matching 1.2% 0.011 0.106 98% 
TMLE -0.1% 0.005 0.071 95% 
BCM -0.1% 0.007 0.082 95% 
(b) Q correct - g misspecified     
OLS -0.1% 0.005 0.070 95% 
IPTW -15.0% 0.008 0.110 97% 
PS matching -8.1% 0.013 0.117 96% 
TMLE -0.2% 0.005 0.070 94% 
BCM 0.7% 0.007 0.085 93% 
(c) Q misspecified - g correct     
OLS -11.7% 0.008 0.098 90% 
IPTW 0.5% 0.008 0.091 99% 
PS matching 1.2% 0.011 0.106 98% 
WLS 0.6% 0.008 0.087 95% 
TMLE 0.6% 0.008 0.087 95% 
BCM 0.7% 0.009 0.097 95% 
(d) Q misspecified - g misspecified     
OLS -11.7% 0.008 0.098 90% 
IPTW -15.0% 0.008 0.110 97% 
PS matching -8.1% 0.013 0.117 96% 
WLS  -12.7% 0.008 0.103 90% 
TMLE -12.9% 0.008 0.104 90% 
BCM  -7.4% 0.011 0.108 93% 
(e) Machine learning     
Regression (Q super learner) -3.1% 0.006 0.079 95% 
IPTW  (g boosted CART) 10.2% 0.007 0.091 98% 
WLS (Q OLS, g boosted CART) 0.5% 0.006 0.076 97% 
TMLE (Q SL, g boosted CART) 1.1% 0.006 0.074 94% 
BCM  (Q SL, g boosted CART) 2.1% 0.008 0.092 95% 
Notes: In DGP 1 the true ATE was 0.4 and the bias using a naive estimator based on the mean difference 
was 20%. WLS is implemented as main terms only regression; hence it is reported as a misspecified 
estimator. 
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Table 6.4 - Simulation results for DGP 2 and 3, over 1000 replications: normal endpoint, 
strong confounder-endpoint association, good and poor overlap 
DGP 2: Normally distributed endpoint, strong confounder-endpoint association, good 
overlap 
 
 
Relative 
bias Variance RMSE 
95 % CI 
coverage 
(d)    Q misspecified - g 
misspecified     
OLS regression -45.9% 0.052 0.292 86% 
IPTW -59.1% 0.067 0.350 98% 
PS matching -34.0% 0.099 0.342 96% 
WLS  -50.2% 0.059 0.315 87% 
TMLE -45.7% 0.041 0.272 86% 
BCM  -31.4% 0.074 0.299 90% 
(e)    Machine learning     
Regression (Q super learner) -8.6% 0.025 0.162 96% 
IPTW  (g boosted CART) 41.0% 0.036 0.251 99% 
WLS (Q OLS, g boosted CART) 2.6% 0.022 0.149 100% 
TMLE (Q SL, g boosted CART) 3.1% 0.011 0.106 95% 
BCM  (Q SL, g boosted CART) 9.8% 0.029 0.174 98% 
 
DGP 3: Normally distributed endpoint, strong confounder-endpoint association, poor 
overlap 
 
(d)    Q misspecified - g 
misspecified     
OLS regression -119.2% 0.050 0.527 40% 
IPTW -160.6% 0.082 0.703 71% 
PS matching -81.1% 0.100 0.453 84% 
WLS  -137.9% 0.063 0.606 39% 
TMLE -129.7% 0.046 0.561 35% 
BCM  -73.8% 0.072 0.399 74% 
(e)    Machine learning     
Regression (Q super learner) -22.0% 0.046 0.233 94% 
IPTW  (g boosted CART) 100.6% 0.034 0.442 82% 
WLS (Q OLS, g boosted CART) -12.8% 0.025 0.165 99% 
TMLE (Q SL, g boosted CART) 5.6% 0.019 0.139 87% 
BCM  (Q SL, g boosted CART) 12.3% 0.034 0.191 98% 
Notes: In DGPs 2 and 3, the true ATE was 0.4 and the biases, using a naive estimator based on the mean 
difference, were 80% and 190%, respectively. 
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Table 6.5 - Simulation results for DGP 4 and 5, over 1000 replications: Normal and 
gamma endpoints, strong confounder-endpoint relationship, poor overlap 
DGP 4: Gamma endpoint,  strong confounder-endpoint association, poor overlap 
 
Relative 
bias 
Varianc
e 
RMS
E 
95 % CI 
coverage 
(d)    Q misspecified - g 
misspecified     
OLS -93.3% 10.175 9.843 16% 
IPTW -102.7% 11.850 
10.81
7 34% 
PS matching -85.6% 19.120 9.595 59% 
WLS  -96.9% 11.475 
10.25
2 19% 
TMLE -96.4% 10.303 
10.14
0 17% 
BCM  -80.7% 17.642 9.085 37% 
(e)    Machine learning     
Regression (Q super learner) -11.8% 7.600 2.998 90% 
IPTW  (g boosted CART) -80.1% 16.585 8.974 62% 
WLS (Q OLS, g boosted CART) -32.1% 11.024 4.612 81% 
TMLE (Q SL, g boosted CART) -20.7% 6.115 3.224 70% 
BCM  (Q SL, g boosted CART) -2.5% 6.755 2.610 98% 
     
DGP 5: Two part endpoint, strong confounder-endpoint association, poor overlap 
(d)    Q misspecified - g 
misspecified     
OLS 26.0% 0.0002 0.022 78% 
IPTW 15.0% 0.0003 0.019 99% 
PS matching 26.9% 0.0004 0.026 93% 
WLS  23.9% 0.0003 0.022 83% 
TMLE 17.9% 0.0002 0.019 90% 
BCM  27.1% 0.0003 0.024 82% 
(e)    Machine learning      
Regression (Q super learner) 13.5% 0.0002 0.017 91% 
IPTW  (g boosted CART) 59.4% 0.0003 0.041 72% 
WLS (Q OLS, g boosted CART) 12.9% 0.0002 0.017 90% 
TMLE (Q SL, g boosted CART) 7.2% 0.0002 0.016 87% 
BCM  (Q SL, g boosted CART) -1.1% 0.0004 0.019 95% 
Notes: In DGPs 4 and 5, the true ATE was 9.98 and 0.062, respectively. The bias using a naive estimator 
based on the mean difference was 170% and 150%, respectively. 
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Figure 6.4 - Estimated ATEs in the simulations 
 
 
 
Notes:  The boxplots show bias and variation, as median, quartiles and 1.5 times interquartile range for the estimated ATEs across 
1,000 replications. The dashed lines are the true values. The left panel provides results for when the PS model and endpoint were 
estimated with misspecified fixed parametric methods, the right panel for when machine learning estimation was used. 
DGP 3 
DGP 4 
DGP 5 
 
Misspecified parametric models                  Machine learning estimation  
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Discussion 
This paper finds that combining information from the conditional distribution of the 
endpoint and the treatment assignment mechanism can reduce bias due to observed 
confounding. Both methods under comparison, TMLE and BCM, can exploit machine 
learning estimation of the endpoint regression function and the PS, and can be robust 
even when the true parametric models are unknown.  
We considered these methods, alongside more traditional PS, regression and DR 
methods in a case study of evaluating the effect of alternative types of hip prosthesis on 
HRQoL for patients with osteoarthritis. Here, a major challenge was to specify a 
regression model for an endpoint with a spike at 1, and bounded at a small negative 
value. This case study motivated the simulation studies, where we generated HRQoL 
data with skewed distributions and nonlinear response surfaces, in order to create 
settings where the correct specification of an endpoint regression and PS model is 
challenging. In the simulations, when machine learning techniques were used to 
estimate the endpoint regression function and the PS, both TMLE and BCM could 
almost fully eliminate bias, in contrast to the high bias where misspecified fixed 
parametric models were used. We found that the relative advantage of TMLE vs. BCM 
was dependent on the features of the DGPs considered. Confirming the first hypothesis 
of the simulation study, in favourable settings such as good overlap and moderate 
association between the confounder and the endpoint, TMLE outperformed BCM in 
terms of bias and precision. This result corresponds to previous work that found that 
reweighting estimators outperformed BCM under good overlap (Busso et al., 2011). In a 
more challenging setting, when overlap was poor, and there was a strong association 
between the confounders and the endpoint, we found a bias-variance trade off between 
the methods under comparison: BCM showed less bias, but was more variable than 
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TMLE. We also found that another DR method, WLS, performed similarly well to 
TMLE in the less challenging settings such as normally distributed endpoint and good 
overlap. However, similarly to findings from previous studies (Porter et al., 2011), WLS 
was outperformed by TMLE in the more challenging DGPs. We followed recent 
recommendations when reporting CIs after matching estimators (Abadie and Imbens, 
2006), and like previous studies, we found that they reported somewhat higher than 
nominal coverage (Abadie and Imbens, 2011). 
Our work extends the previous literature in several aspects. First, this is the first paper 
that compares the relative performance of BCM and TMLE, and also compares these 
methods to traditional approaches. Second, while BCM has been proposed with flexible 
approaches for estimating the endpoint regression function, previous studies used OLS 
for adjustment (Abadie and Imbens, 2011, Busso et al., 2011). This study considers 
super learning, a machine learning method for bias correction, and finds that when 
matching is based on a PS that was also estimated using machine learning, the bias due 
to model misspecification was almost fully eliminated. We find this result across a 
range of DGPs including highly nonlinear response surfaces. Third, unlike previous 
studies that used machine learning only for selected combined methods such as TMLE 
(Porter et al., 2011), this paper took a systematic approach, and evaluate the impact of 
using machine learning estimation for single methods, such as regression and IPTW, 
and for combined methods, such as TMLE and BCM. Our main finding is that 
combining the PS and endpoint regression from misspecified fixed parametric models 
does not in itself provide an advantage compared to using these models in single 
methods such as IPTW. This corresponds to the findings on Kang and Schafer (2007). 
Similarly, using a machine learning approach alone, for example boosted CART for 
IPTW is not sufficient to reduce bias. Possible remaining misspecification of the PS 
255 
 
using the boosted CART is indicated by the low coverage rates reported by TMLE, 
where the nominal standard errors, obtained using the influence curve, are only 
expected to be valid when 𝑔(. ) is correct. In the scenarios considered in this study, it 
was the combined use of machine learning approaches for estimating the endpoint 
regression and the PS, that helped eliminate most of the bias due to observed 
confounding.   
This work has some caveats. The methods considered and the simulation settings all 
assume no unobserved confounding.  Machine learning methods cannot replace subject 
matter knowledge when selecting the set of confounders that need to be controlled for 
(Rubin, 2007). In the case study, while we used a rich set of measured cofounders 
suggested by previous literature and clinical expert opinion (Pennington et al., 2012), 
some unobserved confounding such as unobserved patient preferences may prevail.  
This paper did not have the scope to compare alternative machine learning approaches. 
We found that boosted CARTs for estimating the PS,  a method that has been found to 
outperform logistic regression and alternative machine learning approaches (Lee et al., 
2010), did not always reduce bias compared to misspecified logistic regression. Hence 
further machine learning approaches may be considered for the PS, such as random 
forests (Lee et al., 2010) or neural networks (Westreich et al., 2010). These approaches 
also have promising application for estimating the endpoint regression function (Austin, 
2012). 
Any machine learning method relies on subjective choices of the user. For boosted 
CARTs, tuning parameters such as the shrinkage parameter had to be selected 
(McCaffrey et al., 2004). When applying the super learner, subject-matter knowledge 
can be used to select a wide range of prediction algorithms. A richer set of prediction 
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algorithms, while subject to constraints in computational resources, can facilitate the 
consistent estimation of the regression function (Polley and van der Laan, 2010b).  
This paper considered an innovative DR method, TMLE, alongside a more commonly 
used DR approach, WLS (Kang and Schafer, 2007a, Freedman and Berk, 2008). We did 
not consider another standard DR method, augmented inverse probability of treatment 
weighting (Glynn and Quinn, 2010), because  previous  studies  demonstrated that it can 
be particularly biased and inefficient under circumstances of poor overlap (Porter et al., 
2011, van der Laan and Gruber, 2010). A recently developed improved DR estimator 
(Rotnitzky et al., 2012), similarly to TMLE, is proposed to have the boundedness 
property and may be of interest in further methodological comparisons.  
This work also opens up areas for further research. In the common settings of poor 
overlap, an extension of TMLE, collaborative maximum likelihood estimation (C-
TMLE) (van der Laan and Gruber, 2010, Gruber and van der Laan, 2010b) can 
outperform TMLE. C-TMLE uses machine learning to select a sufficient set of 
covariates for inclusion in 𝑔(. ) that reduces bias while minimising overall mean 
squared error.  Furthermore, rather than PS matching, multivariate matching approaches 
such as Genetic Matching warrant consideration (Diamond and Sekhon, 2012, Sekhon, 
2011). Genetic Matching uses machine learning to directly maximise covariate balance 
in the matched data (Grieve et al., 2008, Sekhon and Grieve, 2011, Ramsahai et al., 
2011, Kreif et al., 2012, Radice et al., 2012), and can be combined with regression-
adjustment. 
We conclude that both TMLE and BCM have the potential to reduce bias due to 
observed confounding, in common settings of dual misspecification, if coupled with 
machine learning methods for estimating the PS and the endpoint regression function. 
With the increasing interest in using observational data for deriving measures of 
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effectiveness of health interventions it is crucial that statistical methods make plausible 
underlying assumptions (Rubin, 2010), and are relatively robust in challenging settings 
such as dual misspecification and poor overlap. The methods considered in this paper 
have the potential to provide robust estimates to inform clinical and policy decisions. 
TMLE is implemented as a readily available software package (Gruber and van der 
Laan, 2012c). For BCM, the available packages currently allow for regression 
adjustment using OLS only (Abadie et al., 2004, Sekhon, 2011). In order to facilitate the 
uptake of the methods, Appendix 6.1 provides code for the implementation of TMLE 
and BCM with machine learning.  
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Appendix 6.1- R code for the implementation of TMLE and BCM  
 
This section provides code for the implementation of TMLE and BCM, coupled with 
machine learning estimation approaches proposed in the paper, using the R statistical 
software (R Development Core Team, 2011). We also present code for the machine 
learning methods: “super learning” for predicting the endpoint and boosted CARTs for 
estimating the PS. The user-written functions implemented here call some pre-written R 
routines, for example the tmle (Gruber and van der Laan, 2012),   Matching 
(Sekhon, 2011), Super Learner (Polley and van der Laan, 2010) and  twang 
(Ridgeway et al., 2006)  packages. These packages need to be installed and loaded in 
the R workspace order to use the functions presented here. 
First, the necessary libraries need to be loaded: 
library(splines) 
library(twang) 
library(SuperLearner) 
library(Matching) 
 
Then, we define the data frame, data,used in the analysis. This dataset includes the 
endpoint q2_eq5d_index, the treatment indicator Hyb and the covariates. 
 
data=as.data.frame(dataset_men_M1)  
 
We create the design matrix that will be used by some of the corresponding user defined 
R functions: 
designreg=glm( Hyb ~ age 
               +  q1_score 
               +  q1_eq5d_index 
               +  factor(IMD) 
     +  ASAgrade1 
               +  ASAgrade2 
               +  q1_disability 
               +  obese 
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               +  morbobese 
               +  heart_disease 
               +  high_bp 
     +  stroke 
     +  circulation 
     +  lung_disease 
     +  diabetes 
     +  kidney_disease 
     +  nervous_system 
     +  liver_disease 
     +  cancer 
     +  depression 
               +  Consultant 
               +  TC, family=binomial(link="logit"), data=data) 
 
design=model.matrix(designreg) 
 
We also define the formula for the PS: 
 
boost.CART.form <- as.formula(Hyb ~ age 
               +  q1_score 
               +  q1_eq5d_index 
               +  IMD 
     +  ASAgrade1 
               +  ASAgrade2 
               +  q1_disability 
               +  obese 
               +  morbobese             
               +  heart_disease 
               +  high_bp 
     +  stroke 
     +  circulation 
     +  lung_disease 
     + diabetes 
     +  kidney_disease 
     +  nervous_system 
     +  liver_disease 
     +  cancer 
     +  depression 
               +   Consultant 
               +   TC) 
 
Estimating the PS 
The function named  boost.CART.func estimates a PS using boosted logistic 
CARTs. The function takes the arguments formula, which specifies the variables the 
user wants to include in the PS model, and data. The function sets the tuning 
parameters to the values recommended by the developers (McCaffrey et al., 2004), and 
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maximises balance based on the mean of the KS statistic. The function returns the 
estimated PS, the linear predictor of the estimated PS, and the IPT weight. 
boost.CART.func = function(formula, data) { 
 
                  boost.CART.ps=ps(formula=formula, 
                  data=data, 
                  shrinkage = 0.0005, 
                  n.trees=10000, 
                  interaction.depth=2, 
                  iterlim=20000, 
                  stop.method="ks.mean") 
  
                  w.boost.CART = boost.CART.ps$w 
                  ps.boost.CART = boost.CART.ps$ps 
                  linpred.boost.CART= 
predict.gbm(boost.CART.ps$gbm.obj,            data, 
boost.CART.ps$n.trees) 
return(list(w.boost.CART=w.boost.CART, 
ps.boost.CART=ps.boost.CART,  
linpred.boost.CART=linpred.boost.CART)) 
                                                                      
} 
 
By calling the function, we can obtain the estimated PS, and attach it to data: 
 
res.boost<-boost.CART.func(boost.CART.form, data=data) 
  
ps.boost = unlist(res.boost$ps.boost.CART) 
 
data=cbind(data, ps.boost) 
rm(ps.boost) 
  
Creating PS matched data                                                                     
Before BCM is performed, a matched dataset needs to be created. The function named 
PSmatch.function calls the Match() function (Sekhon, 2011), taking the 
following arguments: data, and pscore , the estimated propensity score. The 
function returns the original return object of the Match() function (Sekhon, 2011), 
which includes the matched dataset, here named mtchout.Y. The function also 
returns the matching frequency weights K, as well as transformed version of this 
vector, Kprime, later used for calculating the standard errors around for matching 
estimator (Abadie and Imbens, 2011).  
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PSmatch.function=function(data,pscore)  {  
 mtchout.Y=Match(Y=data$q2_eq5d_index,Tr=data$Hyb,X=pscore, 
            estimand="ATE", ties=TRUE)     
            n <- length(data$q2_eq5d_index) 
            K <- rep(0, n) 
            names(K) <- 1:n 
            Kprime <- K 
            extra <- by(mtchout.Y$MatchLoopC[,3],  
                   mtchout.Y$MatchLoopC[,2], sum) 
            K[rownames(extra)] <-  extra 
            Kprime.extra <- by(mtchout.Y$MatchLoopC[,3], 
mtchout.Y$MatchLoopC[,2], 
function(x){sum(x^2)}) 
            Kprime[rownames(Kprime.extra)] <-  Kprime.extra 
            return(list(mtchout.Y=mtchout.Y,K=K, Kprime=Kprime)) 
                                                                 } 
 
Now the function can be called to obtain the matched dataset, 
ps.match.data.w.boost, and the vectors of frequency weights ( K.boost and 
K.prime.boost).  
PS.match.object.boost=PSmatch.function(data,data$ps.boost) 
 
ps.match.data.boost=PS.match.object.boost$mtchout.Y 
ps.match.data.w.boost <-
rbind(data[ps.match.data.boost$index.treated,], 
data[ps.match.data.boost$index.control,]) 
 
ps.match.data.w.boost <- cbind(ps.match.data.w.boost, 
weights=c(ps.match.data.boost$weights,ps.match.data.boost$weight
s)) 
 
K.boost=PS.match.object.boost$K 
K.prime.boost=PS.match.object.boost$Kprime 
 
Predicting the expected potential outcome with the super learner 
The user defined function named my.SL.ate predicts the expected potential 
outcomes under treated and control states, using the Super Learner (Polley and van der 
Laan, 2010). The function takes the arguments W (the covariates), A (the observed 
treatment), and Y, the observed endpoint. We use super learner for estimating two 
regressions functions, stratified by treatment, as suggested by Abadie and Imbens 
(2011). This provides the algorithm flexibility to select different models for estimating 
266 
 
the potential outcomes under treatment and control states. The function returns the 
original “Super Learner” object that includes information on the final models selected, 
m0 for the regression function selected to estimate the potential outcome under control 
and m1 under treatment. The predictions for the potential outcomes are stored in the 
matrix Q.SL.object, which includes two vectors, the predicted potential outcomes 
under control and treatment, each with the length of the number of individuals in the 
sample.  
my.SL.ate=function(W,A,Y) { 
 
  matrix <- data.frame(W) 
 
 m0 <- SuperLearner(Y[A==0], matrix[A==0,], newX = matrix, 
         SL.library =  my.SL.library.short, 
             family = gaussian()) 
 
  m1 <- SuperLearner(Y[A==1], matrix[A==1,], newX = matrix, 
         SL.library = my.SL.library.short, 
             family = gaussian()) 
 
Yhat.0 <- m0$SL.predict 
   Yhat.1 <- m1$SL.predict 
 
   Q.SL.object=cbind(Yhat.0,Yhat.1) 
   ate_SL=mean(Yhat.1-Yhat.0) 
   return(list(Q.SL.object=Q.SL.object,m0=m0,m1=m1)) 
                                                         } 
                                                                 
This function can be extended to incorporate weights, the modified function is named 
my.SL.ate.matchw. This is necessary, because for the bias-corrected matching 
estimator it is recommended that regression predictions are obtained using data 
weighted with the matching frequency weights, K (Abadie and Imbens, 2011).  
my.SL.ate.matchw=function(W,A,Y,K) { 
 
 matrix <- data.frame(W) 
 
 m0 <- SuperLearner(Y[A==0], matrix[A==0,], newX = matrix,  
 SL.library =  my.SL.library.short, 
       family = gaussian(),obsWeights=K[A==0]) 
 
 m1 <- SuperLearner(Y[A==1], matrix[A==1,], newX = matrix, 
    SL.library = my.SL.library.short, 
       family = gaussian(),obsWeights=K[A==1]) 
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Yhat.0 <- m0$SL.predict 
Yhat.1 <- m1$SL.predict 
 
Q.SL.object=cbind(Yhat.0,Yhat.1) 
ate_SL=mean(Yhat.1-Yhat.0) 
 
return(list(Q.SL.object=Q.SL.object,ate_SL=ate_SL,m0=m0,m1=m1)) 
                                                                       
} 
 
Before calling the function, the super learner library, including all the prediction 
algorithms selected by the user, needs to be defined. 
my.SL.library.short <-c("SL.glm","SL.glm.interaction", "SL.polymars") 
 Here we include the algorithms "SL.glm", "SL.glm.interaction" and 
"SL.polymars". 
 
SL.object=my.SL.ate(design,data$Hyb,data$q2_eq5d_index), 
 
then with matching frequency weights. 
 
SL.object.BCM.boost   <-  my.SL.ate.matchw(design,data$Hyb, 
                          data$q2_eq5d_index,K=K.boost) 
 
Implementing BCM 
The function BCM.AI implements the BCM estimator proposed by Abadie and Imbens 
(2011). The function takes the following objects:  Y (the observed endpoint),  A (the 
observed treatment), d.match, the matched data obtained from the PS matching, 
Yhat.0, the vector of predicted potential outcomes under control, and Yhat.1, the 
vector of predicted potential outcome under treatment, as well as the K and Kprime 
vectors, describing the matching frequency weights. The function returns the point 
estimate of the ATE, tau,and the estimated variance of the ATE, AIvar. 
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BCM.AI <- function(Y,A, d.match,Yhat.0,Yhat.1, K, Kprime) { 
 Y_j.0 <- Y_j.1 <- Y   
 Ycounterfactual <- by(Y[d.match$MatchLoopC[,2]], 
                       d.match$MatchLoopC[,1], mean)   
 Y_j.1[A==0] <- Ycounterfactual[A==0] 
 Y_j.0[A==1] <- Ycounterfactual[A==1] 
 
      mu_0.Xi <- Yhat.0 
   mu_0.Xj <- by(Yhat.0[d.match$MatchLoopC[,2]], 
                 d.match$MatchLoopC[,1], mean) 
 mu_1.Xi <- Yhat.1 
   mu_1.Xj <- by(Yhat.1[d.match$MatchLoopC[,2]], 
                 d.match$MatchLoopC[,1], mean) 
  
 Ytilde.0 <- Y_j.0 
 Ytilde.1 <- Y_j.1 
 Ytilde.0[A==1] <- Y_j.0[A==1] + mu_0.Xi[A==1] - mu_0.Xj[A==1] 
 Ytilde.1[A==0] <- Y_j.1[A==0]  + mu_1.Xi[A==0] - mu_1.Xj[A==0] 
 
 tau.bcm <- mean(Ytilde.1 - Ytilde.0) 
 n <- length(Y)   
sigmasq.X <- 1/(2*n) * sum((Ytilde.1 - Ytilde.0 - 
tau.bcm)^2) 
   
 var.SATE <- 1/n^2 *  sum(( 1 + K)^2 * sigmasq.X) 
 var.PATE <- 1/n^2 * sum ( (Ytilde.1 - Ytilde.0 - tau.bcm)^2 + 
                 ( K^2 + 2*K - Kprime)*sigmasq.X) 
  
 return(list(tau = tau.bcm, AIvar=max(var.SATE, var.PATE), 
                                           var.PATE = var.PATE)) 
                                                                        
} 
 
The point estimate and CI around the ATE is estimated by calling the function: 
BCM.SL.boost <- BCM.AI(dataset_men_M1$q2_eq5d_index, 
dataset_men_M1$Hyb,                   
ps.match.data.boost, 
SL.object.BCM.boost$Q.SL.object[,1], 
SL.object.BCM.boost$Q.SL.object[,2], 
PS.match.object.boost$K, 
PS.match.object.boost$Kprime) 
 
The estimated ATE, with its standard error can be obtained as follows: 
coef.BCM.SL.boost <- BCM.SL.boost$tau 
se.BCM.SL.boost <- sqrt(BCM.SL.boost$AIvar) 
Implementing TMLE 
The R package tmle()offers an accessible implementation of TMLE (Gruber and van 
der Laan, 2012). The tmle() function takes the arguments Y (the observed 
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endpoint),  A (the observed treatment),W (the design matrix), and Q (the two vectors 
of potential outcomes). As a default, the tmle() function applies logistic fluctuation, 
and bounds the endpoint between the observed minimum and maximum values (here, 
between -0.59 and 1). 
tmle.SL.boost=tmle(Y=data$q2_eq5d_index,A=data$Hyb,W=design, Q=Q.SL, 
g1W=data$pscore.boost) 
 
The estimated ATE and its confidence intervals can be then obtained: 
coef.tmle.SL.boost <- tmle.SL.boost$estimates$ATE$psi 
ciU.tmle.SL.boost <- summary(tmle.SL.boost)$estimates$ATE$CI[2] 
ciL.tmle.SL.boost <- summary(tmle.SL.boost)$estimates$ATE$CI[1]  
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Chapter 7 – Discussion 
7.1 Introduction 
Cost-effectiveness analyses (CEA) often make use of non-randomised studies (NRS), 
when randomised controlled trials (RCTs) are inappropriate or insufficient to provide 
the evidence required to inform decisions (NICE, 2008). Here the main methodological 
challenge is to address potential selection bias, due to confounding.  Where individual 
patient data (IPD) from NRS is available for estimating parameters for CEA, selection 
bias can be addressed with appropriate statistical methods (Polsky and Basu, 2006). At 
the outset of this thesis, there was no comprehensive guidance on using statistical 
methods for CEA that use NRS, which was raised as a priority for methodological 
research in a recent review of NICE methods for health technology assessment (HTA) 
(Longworth et al., 2009).  This thesis helped address this gap in the literature.  
The overall objective of this thesis was to consider alternative statistical methods for 
addressing selection bias in CEA that use patient-level observational data. The specific 
objectives were: 
1. To develop and apply a new checklist for assessing the underlying assumptions 
made by statistical methods for addressing selection bias in CEA, that use 
patient-level observational data;  
2. To consider which further statistical methods from the general causal inference 
literature may be appropriate for addressing selection bias in CEA;  
3. To compare the relative performance of propensity score (PS) approaches and 
Genetic Matching (GM), a multivariate matching method, for estimating 
subgroup-effects in CEA; 
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4. To compare methods that combine regression with PS approaches for addressing 
selection bias when estimating incremental effectiveness and cost-effectiveness 
parameters.  
The next section discusses the overall findings from the thesis. Sections 7.3 and 7.4 
highlight the contributions of the thesis to the methodological literature. Sections 7.5 
and 7.6 summarise the limitations and identify areas for future research. Section 7.7 and 
7.8 discuss the implications for applied researchers and policy making. The last section 
concludes. 
7.2 Overall findings of the thesis 
The methods currently recommended in CEA for addressing selection bias make some 
key underlying assumptions, which the conceptual review (chapter 2) examined.  The 
unconfoundedness assumption implies that all variables which are prognostic for the 
cost or effectiveness endpoints, and also influence treatment assignment, are observed. 
The assumption of good overlap across covariate distributions between the treatment 
groups requires that there are no combinations of observed covariates which fully 
predict assignment to the treated or control group. Regression and PS approaches also 
assume that the relationship between the covariates and the endpoints, or the covariates 
and the treatment assignment is correctly specified. The conceptual review found that 
for CEA that use NRS, the correct specification of endpoint regression models and the 
PS can be challenging, especially when there is an interest in cost-effectiveness 
estimates at the subgroup-level. Due to these challenges, structural uncertainty from the 
choice or specification of the statistical method needs to be acknowledged when 
presenting and interpreting results from a CEA that use patient-level observational data.  
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I developed a new checklist (research paper 1, chapter 3) for critical appraisal of applied 
CEA, informed by the findings from the conceptual review. I then applied the checklist 
in a systematic review of published CEA. A key finding was that the majority of the 81 
studies reviewed relied on the unconfoundedness assumption, and used regression or 
matching to try and address selection bias, without appropriately assessing their 
underlying assumptions. Half of the studies did not consider structural uncertainty from 
the choice of statistical method.  
The conceptual review (chapter 2) identified alternative statistical methods that have the 
potential to make less restrictive assumptions about the specification of the PS or the 
endpoint regression model. These methods are GM, a multivariate matching method 
that uses a machine learning algorithm to directly maximise covariate balance; double-
robust (DR) methods and regression-adjusted matching. I also found that machine 
learning techniques hold promise for estimating the PS and the endpoint regression.  I 
contrasted the relative performance of these methods in simulation studies, informed by 
case studies that represented typical circumstances faced by CEA.  
In research paper 2 (chapter 4) I compared GM, PS matching and inverse probability of 
treatment weighting (IPTW) for estimating cost-effectiveness for patient subgroups. In 
the motivating CEA of Drotrecogin alfa activated (DrotAA) in patients with severe 
sepsis, I found that covariate balance for the subgroups of interest improved, when each 
method aimed to optimise balance by subgroup.  GM achieved the best balance, and the 
cost-effectiveness results for subgroups differed by method, with IPTW producing poor 
covariate balance and reporting the widest confidence intervals (CIs) of the estimated 
incremental net benefit (INB).  The simulations demonstrated that the key criterion for 
choosing among statistical methods is the covariate balance created for each subgroup.  
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I found that GM, unlike PS matching or IPTW, was relatively robust to functional form 
misspecification of the PS, such as the omission of nonlinear terms. 
In research paper 3 (chapter 5) I considered methods that combine the PS with endpoint 
regression (combined methods), such as DR methods and regression-adjusted matching, 
and compared them to regression, PS matching and IPTW. When contrasting these 
methods in the CEA of DrotAA, I found that combined methods reported differing point 
estimates and narrower CIs of the INB than methods that relied on the estimated PS 
only. In the simulations, I found that using combined methods could reduce bias and 
root mean squared error (RMSE) in the estimated INB when compared to using PS 
matching or IPTW, across a range of scenarios characteristic of CEA.  In the realistic 
scenario of functional form misspecification of both the PS and the endpoint regression 
(dual misspecification), and unstable IPT weights, regression-adjusted matching 
reported lower bias and RMSE than the DR methods considered. 
Research paper 4 (chapter 6) considered extensions of these combined methods, for 
estimating incremental effectiveness parameters. The motivating case study was an 
evaluation of the effect of alternative hip prostheses on patients’ health related quality 
of life (HRQoL), where the HRQoL endpoint had a skewed distribution with a spike at 
1.  I considered an innovative DR method, targeted maximum likelihood estimation 
(TMLE), and compared it to bias-corrected matching (BCM), where initially both 
methods were implemented with fixed parametric models. I then coupled both methods 
with using machine-learning techniques to estimate the PS and the endpoint regression. 
In the simulation study I found that both TMLE and BCM reported relatively robust 
estimates of treatment effects when coupled with machine-learning techniques, as 
opposed to when using fixed parametric models that were misspecified. When overlap 
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between the covariate distributions was good, TMLE reported the lowest bias and 
RMSE, and BCM performed best when overlap was poor.  
7.3 Main contributions of the thesis 
This thesis contributed to the literature on analytical methods for CEA (Hoch et al., 
2002, Willan et al., 2004, Nixon and Thompson, 2005, Polsky and Basu, 2006, Sekhon 
and Grieve, 2011),  drawing on insights from the causal inference (Rosenbaum  and 
Rubin, 1983, Robins et al., 2000, Imbens and Wooldridge, 2009a) and health 
econometrics literature (Jones, 2007, Jones, 2010, Jones and Rice, 2011). An important 
contribution of this thesis is that it directly compares methods across these strands of 
literature which tend to progress independently.  For example research paper 4 contrasts 
a two-part model,  recommended in the health econometrics and CEA literature for 
handling HRQoL data (Buntin and Zaslavsky, 2004, Basu and Manca, 2011), with 
TMLE, a recently recommended DR method from the causal inference literature. In the 
research papers contrasting statistical methods, I generated hypotheses based on insights 
from the general causal inference literature, but grounded in typical features of CEA 
data (chapter 2). The simulation scenarios were informed by the systematic review of 
applied CEA (research paper 1) and by the motivating examples (research paper 2, 3 
and 4). The following sections describe the specific contributions of this thesis. 
7.3.1 Developing a new checklist for critical appraisal of statistical methods 
for addressing selection bias in CEA 
I developed a critical appraisal tool for assessing the underlying assumptions made by 
statistical methods for addressing selection bias in CEA that use patient-level 
observational data (research paper 1). This checklist complements previous quality-
assessment tools and methodological guidance (Drummond et al., 2005, Philips et al., 
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2006, Glick et al., 2007), which did not include specific criteria for the statistical 
analysis of patient-level data from observational studies. The systematic review 
presented in research paper 1 was the first study that assessed an important aspect of the 
quality of CEA which use patient-level observational data: the statistical methods used 
to address selection bias. I found that the underlying assumptions of statistical methods 
were not appropriately assessed, and statistical approaches that have the potential to 
make less restrictive assumptions were not used in practice.  The main contribution of 
the new checklist is that it can raise awareness of the assumptions underlying alternative 
statistical methods. The checklist should prove helpful for the applied researcher 
conducting statistical analysis, for reviewers and journal editors considering future CEA 
articles, and for decision makers appraising and using published CEA.   
7.3.2 Methodological insights on statistical approaches for estimating 
subgroup effects in CEA that use observational data 
This thesis provided the first simulation study which compared alternative statistical 
methods for reducing selection bias when cost-effectiveness results are required for 
patient subgroups. Previous methodological guidance recommended regression methods 
for estimating cost-effectiveness parameters for subgroups (Nixon and Thompson, 
2005, Willan et al., 2004). These methods can, however, be sensitive to the choice of 
model specification in a NRS setting (Ho et al., 2007). In research paper 2, I considered 
alternative methods: PS matching, IPTW, and GM for estimating subgroup effects in 
CEA. This paper extended previous work by Sekhon and Grieve (2011) who compared 
GM to PS matching in reporting overall cost-effectiveness parameters. Research paper 2 
considered the context of subgroup analysis, and included IPTW as a methodological 
comparator.   
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7.3.3 Considering methods that combine the PS and endpoint regression for 
estimating parameters for CEA 
This thesis considered approaches that can combine information from the treatment 
assignment mechanism with that from the cost and effectiveness endpoint models for 
the first time in CEA.  Research paper 3 considered DR methods such as weighted 
regression and augmented inverse probability of treatment weighting (AIPTW), and 
regression-adjusted matching. Previous simulation studies considered DR methods for a 
generic continuous endpoint (Porter et al., 2011, Kang and Schafer, 2007), and for cost 
analysis (Basu et al., 2011). Research paper 3 extended these studies to the bivariate 
CEA context, where the correct specification of regression models for both the cost and 
effectiveness endpoints is a concern.  
Research paper 4 extended this work by investigating combined approaches on the 
forefront of causal inference research, TMLE and BCM, for estimating treatment 
effectiveness.  This study also extended a previous simulation study which estimated 
parameters  for HRQoL data using regression methods (Basu and Manca, 2011). This is 
the first study to use machine learning estimation techniques to estimate incremental 
effectiveness. 
7.4 Other general methodological contributions emerging from 
the thesis 
Findings from this thesis also contributed to the general causal inference literature on 
estimating treatment effects, by providing new methodological comparisons, as well as 
by considering statistical methods in the bivariate context of CEA for the first time.  
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7.4.1 New methodological comparisons 
This thesis contributed to the limited comparative work on the relative performance of 
DR and matching approaches (Waernbaum, 2011, Busso et al., 2011, Busso et al., 2009, 
Basu et al., 2011), by presenting two simulation studies that compared regression-
adjusted matching to DR methods. In research paper 3, I considered the implementation 
of regression-adjusted matching as “non-parametric pre-processing”,  proposed by Ho et 
al. (2007). This approach has not been considered in simulation studies before. I 
extended previous simulation studies (Kang and Schafer, 2007, Porter et al., 2011, Basu 
et al., 2011, Freedman and Berk, 2008), which found that, with unstable IPT weights 
and dual misspecification, DR methods can report more biased and less efficient results 
than ordinary least squares (OLS) regression. I found that with a more severe 
misspecification, weighted regression could outperform a misspecified regression 
estimator. I also found that regression-adjusted matching can be more robust to 
misspecification of the PS and the endpoint regression, than DR methods. 
Research paper 4 compared TMLE with BCM for the first time. I extended the findings 
of  Busso et al. (2011), who showed that with correctly specified PS and  poor overlap, 
BCM provides less biased estimates than reweighting estimators. I find similar results, 
that for the more realistic scenario of misspecified PS, BCM outperformed TMLE.  The 
main finding of research paper 4 was that when coupled with machine learning 
estimation methods, both TMLE and BCM could reduce bias due to dual 
misspecification, as opposed to using OLS for adjustment, considered in previous 
studies (Abadie and Imbens, 2011, Busso et al., 2011). 
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7.4.2 Insights from using machine learning methods for estimating 
treatment effects 
This thesis followed recent recommendations that suggest machine learning approaches 
for estimating the PS (Westreich et al., 2010, Lee et al., 2010) and the endpoint 
regression function (Austin, 2012, Porter et al., 2011). An important contribution of 
research paper 4 was that it took a systematic approach in comparing advanced, 
combined approaches to traditional methods, therefore extended previous studies which 
used machine learning only for selected methods such as TMLE (Porter et al., 2011).  
Research paper 4 demonstrated the impact of moving from single (such as IPTW) to 
combined methods (DR methods or BCM), using both fixed parametric methods and 
machine learning techniques. In addition, both within the single and combined 
approaches, I looked at the impact of moving from fixed to machine learning 
approaches. I found that in challenging circumstances such as dual misspecification and 
poor overlap, combined methods using fixed parametric models reported high bias, and 
when machine learning techniques were used, this bias was much reduced. 
7.4.3 Considering statistical methods in a bivariate context  
This thesis considers IPTW, PS matching, GM (research paper 2), DR methods and 
regression-adjusted matching (research paper 3) in the bivariate context of CEA. Here a 
general challenge is that statistical methods need to recognise that the endpoints of 
interest can be correlated (O'Hagan and Stevens, 2001, Nixon et al., 2010).  The CEA of 
DrotAA (research papers 2 and 3) demonstrated that for each of the statistical 
approaches considered, the non-parametric bootstrap can be used to calculate 
uncertainty around the estimates of incremental cost-effectiveness, while recognising 
the correlation between the endpoints. The simulation study in research paper 2 
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highlighted that in CEA, potential confounders can differ between the cost and 
effectiveness endpoints, for example, baseline HRQoL might influence the QALY but 
not the cost endpoint. The simulations showed that in order to reduce selection bias, 
balance needs to be maximised for potential confounders for both endpoints.                                                                              
7.5 Limitations 
While this thesis presented a comprehensive assessment and comparison of alternative 
statistical methods for addressing selection bias in CEA that use patient-level 
observational data, it has some limitations. In this section, I acknowledge general 
weaknesses regarding the scope of thesis, the range of statistical methods considered 
and the circumstances considered for the methodological comparisons. 
7. 5.1 Scope of the thesis  
Alternative use of observational data for CEA 
Observational data can be used to estimate a wide range of parameters in CEA, 
including  incremental cost and effectiveness endpoints, but also other parameters such 
as relative risks  (Drummond, 1998, Philips et al., 2006). The type of observational data 
available to obtain these parameters also varies, including IPD, the focus of this thesis, 
but studies commonly use aggregate data from published observational studies (Cooper 
et al., 2007).  Examples of settings that this thesis did not cover include using  
published, aggregate data to derive parameters such as effectiveness or baseline 
probabilities (Philips et al., 2006), or  where patient-level data is used to develop risk 
equations to populate decision models (Caro et al., 2012).  
While the focus of the simulation studies (research paper 2 and 3) was using IPD from a 
single observational study to calculate incremental effectiveness and cost-effectiveness 
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parameters, the case studies made more general use of observational data. The DrotAA 
case study (research paper 2 and 3) combined patient-level mortality data with 
aggregate estimates of long term survival and quality of life. Research paper 4 
reanalysed a large observational dataset on health outcomes following total hip 
replacement, where estimates of relative treatment effectiveness on HRQoL provided 
input parameters for a decision analytical model (Pennington et al., 2012). Here, when 
applying the estimated parameters in the cost-effectiveness model, hybrid hip prosthesis 
remained the dominant alternative compared to uncemented prosthesis, with lower 
mean costs, and positive incremental QALYs (0.16 for OLS, 0.11 for PS matching, and 
0.19 for BCM with machine learning). While research paper 4 did not consider methods 
in a bivariate setting, recommendations apply to the general context when patient-level 
observational data is used to estimate input parameters for CEA. The checklist (research 
paper 1) also pertains to this more general use of observational data, for example when 
only one incremental parameter is estimated using patient-level observational data.  
 Further statistical challenges in CEA that use patient-level observational data 
The focus of this thesis is to investigate statistical methods that can address selection 
bias in CEA. The use of patient-level data in CEA often poses further statistical 
challenges. Statistical analysis may also need to recognise the data hierarchy in 
multicenter trials (Grieve et al., 2007, Manca et al., 2007) and cluster-randomised trials 
(Gomes et al., 2012, Grieve et al., 2010), as well as missing data (Noble et al., 2012), 
non-compliance to randomised treatment (Hughes et al., 2001), censoring  (Willan et 
al., 2002, Willan et al., 2005, Raikou and McGuire, 2004) or measurement error 
(Marschner, 2006). These issues are beyond the scope of the thesis.  
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Some of the methods considered in this thesis, for example IPTW (Willan et al., 2002) 
and DR methods (Bang and Robins, 2005, Bang and Tsiatis, 2000) can be applied to 
account for censoring and missing data in CEA. However, it is unknown whether the 
findings from this thesis in the context of addressing selection bias would translate 
directly to the context of censored or missing CEA data, and hence further research is 
warranted. 
7.5.2 Range of statistical methods considered for this thesis 
Methods assume no unobserved confounding 
The statistical methods that were contrasted in the case studies and simulation studies 
all assumed no unobserved confounding. The conceptual review (chapter 2) highlighted 
the importance of this assumption, and proposed instrumental variable (IV) estimation 
as an alternative. IV methods can potentially reduce selection bias due to both observed 
and unobserved confounding, however, they make alternative untestable assumptions 
that may be unrealistic in a CEA setting (Polsky and Basu, 2006). The critical appraisal 
tool provides some guidance in assessing these assumptions (research paper 1). After 
careful assessment I found that neither of the case studies considered in the thesis had 
an appropriate IV.  The systematic review of applied CEA (research paper 1) identified 
only two studies which used IV methods.  
The critical appraisal tool presented in research paper 1 provides detailed guidance on 
how to appropriately assess the plausibility of the unconfoundedness assumption in the 
CEA context. Following these suggestions, the case studies carefully considered the 
previous clinical literature on prognostic factors, before selecting the potential 
confounders for adjustment. A further recommendation, not covered in this thesis, is to 
use placebo tests (Imbens, 2004, Jones, 2007, Abadie et al., 2010). Placebo tests offer 
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an indirect way to use the data to assess the validity of the no unobserved confounding 
assumption through using the set of measured confounders to estimate a treatment effect 
on a variable, where it is known to be zero, for example on the pre-treatment health 
status. 
Alternative implementations of statistical methods not considered in the thesis 
Regression methods 
This thesis considered regression methods recommended for estimating parameters of 
cost and effectiveness endpoints, such as GLMs (Barber and Thompson, 2004) and two-
part models (Buntin and Zaslavsky, 2004, Basu and Manca, 2011). More flexible 
regression approaches have recently been proposed for skewed cost and effectiveness 
data, such as extended estimating equations (Basu and Rathouz, 2005), the use of beta-
distributions with quasi-likelihood estimation (Basu and Manca, 2011), or beta-type size 
distributions (Jones et al., 2011). This thesis did not consider these methods, but took 
the approach of machine learning estimation for handling skewed HRQoL data. The 
super learner approach considered in research paper 4 is a flexible prediction method 
which can also incorporate the above regression approaches (Polley and van der Laan, 
2010). 
DR methods 
This thesis did not compare all currently available implementations of DR methods. I 
implemented methods that are commonly used in the general causal inference literature, 
such as AIPTW (research paper 3) and weighted regression (research papers 3 and 4); as 
well as a recently proposed DR method, TMLE.  Further approaches such as an 
improved DR substitution estimator (Rotnitzky et al., 2012), or an extension of TMLE, 
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collaborative maximum likelihood estimation (C-TMLE) (van der Laan and Gruber, 
2010) are promising alternatives, and warrant further consideration. 
Machine learning estimation techniques for estimating the PS and the endpoint 
This thesis highlights the potential for machine learning estimation techniques to reduce 
bias due to functional form misspecification, compared to using fixed parametric 
models. Following recommendations from previous simulation studies, this thesis 
considered boosted CARTs for estimating the PS, and super learning to estimate the 
endpoint regression function. This thesis did not compare alternative machine learning 
approaches from the computer science and data mining literature, such as bagged 
regression trees, random forests (Austin, 2012), decision trees, neural networks or linear 
classifiers (Westreich et al., 2010).  
Considering GM with bias-adjustment 
Like previous studies (Diamond and Sekhon, 2012, Sekhon and Grieve, 2011), this 
thesis found that GM can provide excellent balance and unbiased estimates of treatment 
effects, even if the PS is misspecified (research paper 2). Research papers 3 and 4 take a 
further approach for reducing bias in matching estimators, by using regression-
adjustment after matching. In order to allow for a systematic comparison across 
methods, in these papers I used the estimated PS to create matched data.  The 
methodological literature suggests bias correction for a general family of nearest 
neighbour matching estimators, including PS matching and multivariate matching 
(Abadie and Imbens, 2011). Hence the bias-reduction reported when using regression-
adjustment after matching (research papers 3 and 4) is expected to hold in the case of 
the multivariate matching approach of GM as well.  
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7.5.4 Range of circumstances considered for the methodological 
comparisons 
Types of misspecification considered in the simulations 
The simulation scenarios considered in research papers 2, 3 and 4 focused on functional 
form misspecification of the PS and endpoint regression models, following previous 
simulation studies identified in the conceptual review (chapter 2), and motivated by the 
case studies.  Types of misspecifications included ignoring differential treatment 
assignment by subgroup, misspecifying the linear predictor in the PS model, ignoring 
nonlinear functional form relationships between the covariates and the endpoints, 
misspecifying the link function of the cost endpoint, as well as misspecifying a two-part 
data generating distribution.  
A further type of misspecification often considered in the general causal inference 
literature (e.g. Glynn and Quinn, 2010, Gruber and van der Laan, 2010) is omission of 
confounders, i.e. in simulation studies ignoring variables that are known to influence the 
treatment assignment and the endpoint.  This misspecification was not the focus of this 
thesis. All the methods considered rely on the assumption of no unobserved 
confounding, and so it can be anticipated that all methods are biased when influential 
confounders are omitted. This was confirmed in the simulation study of research paper 
2, which demonstrated that unless confounders influential for both the cost and 
effectiveness endpoints are adjusted for, each method reported biased estimates of the 
INB. 
Types of heterogeneity in cost-effectiveness considered 
Research paper 2 considered heterogeneous treatment effects and heterogeneous 
assignment to treatment, across subgroups defined by an observed confounder, baseline 
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disease severity. Here, patient subgroups of interest for CEA were pre-specified using 
reasoning from the clinical literature. The optimal number and definition of subgroups 
could be also established as part of the CEA, using for example expected health benefits 
(Espinoza et al., 2011). Heterogeneity in cost-effectiveness can also stem from other 
sources (Sculpher, 2008), including unobserved patient characteristics such as 
preferences for treatment.  For decision makers implementing personalised medicine,  
accounting for such heterogeneity can be relevant (Basu, 2011, Ioannidis and Garber, 
2011). The conceptual review identified statistical methods that have potential to handle 
unobserved heterogeneity, such as instrumental variables (Basu et al., 2007, Evans and 
Basu, 2011) and control functions (Basu, 2011), this thesis however did not cover these 
approaches. 
A further form of heterogeneous treatment effects comes from non-linear response 
surfaces for cost and effectiveness endpoints (Basu et al., 2011, Basu et al., 2008). 
While applying traditional regression approaches such as OLS regression might mask 
this heterogeneity, the method of recycled predictions, considered in this thesis, can 
account for it. 
7.6 Areas of further research 
This thesis identified the following areas for further investigation: applying formal 
methods of sensitivity analysis to assess the impact of potential violations of statistical 
assumptions, further examination of methods for estimating the variance of treatment 
effects in a bivariate context of CEA, and extending the methods to estimate parameters 
other than the additive treatment effects, such as odds ratios or hazard ratios.  
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7.6.1 Using formal tools of sensitivity analysis to address structural 
uncertainty  
Structural uncertainty is a relatively under-researched area of uncertainty in CEA (Gray 
et al., 2010), hence contributing to developing methodological guidance in this area is 
warranted. Specifically, this thesis highlighted that uncertainty due to the possible 
violations of underlying assumptions of statistical methods can be characterised as a 
source of structural uncertainty in CEA (Jackson et al., 2011).  The case studies 
presented in this thesis (research papers 2 to 4) acknowledged structural uncertainty due 
to the choice or specification of statistical method by presenting a range of estimates 
obtained with different statistical approaches, and interpreting the differences in the 
estimated cost-effectiveness.  
The conceptual review (chapter 2) also identified quantitative approaches that can help 
acknowledge the uncertainty, due to possible violations of statistical assumptions.  A 
recommended approach for assessing the sensitivity of estimated treatment effects to the 
potential for unobserved confounding is to use Rosenbaum’s method of sensitivity 
analysis (Rosenbaum, 2002). This method provides a statement on the strength of 
unobserved confounding, which is necessary to change the conclusions regarding the 
estimated treatment effect. In the CEA context, this approach could be combined with 
reporting cost-effectiveness acceptability curves, to provide information on the 
necessary strength of unobserved confounding to alter the estimated probability that the 
intervention is cost-effective. Software implementation of this approach for matching 
estimators is available (Keele, 2011), and its use has been demonstrated for clinical 
evaluations (Noah et al., 2011).  
 A further source of structural uncertainty stems from the unknown nature of the correct 
endpoint regression model. Here, uncertainty in the choice of regression model 
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specification can be quantified by using Bayesian model averaging (Hoeting et al., 
1999). This approach combines estimates from competing regression models, using 
weights derived from some measure of model appropriateness, for example the Akaike 
information criterion. Bayesian model averaging has been proposed for the more 
general context of decision models in CEA (Jackson et al., 2009). 
7.6.2 Estimating uncertainty for cost-effectiveness parameters 
In the case studies presented in this thesis, I used the non-parametric bootstrap (Davison 
and Hinkley, 1997) for estimating the standard errors for the estimated INB (Nixon et 
al., 2010). Previous studies indicated that the nonparametric bootstrap can report valid 
confidence intervals around the INB (Nixon et al., 2010). Bivariate regression models 
such as “seemingly unrelated regressions” or Bayesian bivariate models (Willan et al., 
2004, Nixon and Thompson, 2005, Manca and Austin, 2008) provide alternative ways 
of estimating standard errors. This thesis did not consider bivariate approaches, because 
implementing DR methods or regression on matched data using bivariate modelling 
may prove complex (Manca and Austin, 2008). Future simulation studies can provide 
additional information on the performance of the bootstrapped variance estimator, by 
also reporting the coverage properties of the 95% CIs, and where feasible, comparing it 
to bivariate modelling approaches.  
The estimation of variance for matching approaches has been widely debated in the 
methodological literature (Hill, 2008, Hill and Reiter, 2005, Abadie and Imbens, 2006b, 
Austin, 2008a, Stuart, 2010). Inference after PS matching needs to account for several 
sources of uncertainty: from using the estimated PS instead of the true PS, as well as 
uncertainty from the matching process. There is a consensus that under relatively 
general circumstances, using the estimated PS instead of the true PS provides 
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conservative variance estimates (Stuart, 2010). Analytical variance formulas which can 
account for the matching process for certain matching estimators are available, however 
they are subject to ongoing research (Abadie and Imbens, 2009, Abadie and Imbens, 
2006a).  
In research papers 2 and 3 I followed the suggestion of estimating bootstrapped standard 
errors conditional on the matched data (Ho et al., 2007). In research paper 4, when 
considering a univariate endpoint, I applied recommended analytical formulas for 
variance estimators for PS matching and BCM (Abadie and Imbens, 2011, Abadie and 
Imbens, 2006a). The extension of these analytical formulas for a bivariate context of 
CEA is a potential subject of further methodological investigation.  
7.6.3 Extending statistical methods for different types of data 
This thesis focused on statistical methods that can address selection bias in CEA that 
use IPD to estimate incremental parameters of continuous endpoints, such as 
incremental costs, QALYs or HRQoL. Each method proposed by this thesis can be 
extended for endpoints such as binary, count or event time data, and corresponding 
estimands such as odds ratios (Radice et al., 2012, Moore and van der Laan, 2009), 
relative risks (Austin, 2008b, Austin, 2010a, Austin, 2010b) or hazard ratios (Stitelman 
and van der Laan, 2010, Thompson et al., 2010).  
This thesis compared methods that can estimate the effect of a time constant treatment. 
IPTW and DR methods can be extended to handle treatment and confounders that vary 
over time (Robins et al., 2000). Such methods can be useful when estimating parameters 
for decision models which needs to allow for cross-over between treatments, or 
treatment starting at different time points (Caro et al., 2012). Exploring these alternative 
289 
 
methods in settings characteristic of CEA is a subject of further methodological 
research.  
7.7 Recommendations for applied researchers 
Findings from this thesis can help the applied researcher conducting CEA, when 
applying statistical methods to address selection bias. This thesis recommends that the 
applied researcher follows the general steps below.   
1. To assess the plausibility of the fundamental assumptions of unconfoundendess and 
overlap. 
The checklist and accompanying guidance presented in research paper 1 suggest 
appropriate methods to assess the plausibility of these assumptions (checklist questions 
1a and 2). For example it is recommended that researchers carefully use subject matter 
knowledge to assess whether all potential confounders have been observed, both for the 
cost and the effectiveness endpoints. 
2. To use statistical methods which are potentially robust to the misspecification of the 
endpoint regression models and the PS. 
This thesis identified a number of methods that can be appropriate for estimating 
parameters in realistic CEA circumstances. In general, this thesis found that matching 
methods can help provide robust estimates of cost-effectiveness, as they are relatively 
insensitive to PS misspecification, as opposed to other methods such as IPTW.  
GM does not rely on the correctly specified PS, and can directly maximise balance in 
the matched data using machine learning.  When cost-effectiveness for patient 
subgroups are of interest, this thesis suggests that covariate balance is assessed for each 
subgroup of policy relevance. This thesis recommends that GM is applied to directly 
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maximise balance for patient subgroups. Research papers 1 and 2 provide guidance on 
appropriate assessment of balance, for overall populations and for subgroups of interest. 
To assist the applied researcher implement GM, sample code is provided in Appendix 
4.2.  
This thesis recommends that matching is followed by regression-adjustment, in order to 
reduce bias due to finite sample imbalance, and to increase efficiency. Research paper 3 
proposes a straightforward two-step approach for performing regression-adjustment on 
the matched data (for software code, see Appendix 5.2). This approach reduces the 
sensitivity of the estimates to the regression specification, by first improving covariate 
balance. 
As an alternative remedy for the challenge of model misspecification, research paper 4 
proposes machine learning techniques for estimating the PS and the endpoint 
regression. In particular, this paper proposes another implementation of regression-
adjusted matching, BCM, which can be used with machine-learning. Amongst the DR 
methods examined in this thesis, TMLE is recommended when coupled with machine 
learning estimation techniques.  I provide the applied researcher with guidance for 
implementing these methods in Appendix 6.1. 
One consideration for the choice of methods is the computing time and resources 
involved. TMLE and BCM run instantly when using fixed parametric approaches, 
however when coupled with machine learning, each approach can take more than 3 
hours with a standard PC. Therefore the use of high performance computing (HPC) is 
recommended, for example the LSHTM HPC cluster 
(http://wiki.lshtm.ac.uk/hpc/index.php5/Main_Page). GM exploits the parallel 
computing abilities of an HPC cluster, however depending on the dimensions of the 
dataset and the number of variables to balance on, can be computationally intensive. So 
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for example for the analysis of the case study in research paper 2, running GM on the 
HPC cluster took between 3 and 10 hours. 
3. To report structural uncertainty according to the choice or specification of the 
statistical method. 
This thesis also recommends that researchers acknowledge structural uncertainty from 
the choice or specification of the statistical approach used for addressing selection bias.  
The quality assessment tool provides suggestions on ways to account for this structural 
uncertainty (research paper 1, checklist question 5). For example, following the example 
of the case studies presented in this thesis, the applied researcher is advised to 
implement several statistical approaches which rely on different assumptions, and then 
present cost-effectiveness results after each approach, interpreting potential differences 
in the resulting point estimates, confidence intervals and CEACs.  
7.8 Implications for policy making 
Observational data can provide a valuable source of evidence for health care decision 
makers who aim to allocate scarce resources. Current methodological guidelines 
propagate the use of patient-level data for deriving parameters for CEA (NICE, 2008, 
Briggs et al., 2012). While developing methods for incorporating observational data was 
raised as a priority for methodological research in CEA (Longworth et al., 2009, Kearns 
et al., 2012), there is currently no detailed guidance for critical appraisal of CEA that 
use observational data. The checklist developed in this thesis (research paper 1) 
provides decision makers with a critical appraisal tool for evaluating an important 
aspect of the quality of CEA that use observational data: the statistical methods that are 
used to address selection bias.  
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While this thesis focused on statistical methods, it also provides some insights for the 
design of CEA that use observational data. With large investments in observational 
databases worldwide, it is desirable that observational studies are designed so as to help 
subsequent statistical analysis make more plausible assumptions (Rubin, 2010, Rubin, 
2008).  For the purposes of CEA, observational data collected on health care 
interventions should ideally include the potential confounders that are judged to be 
prognostic of either the effectiveness or the cost endpoint. If it is unlikely that all the 
confounders can be observed, the researcher is recommended to consider whether there 
are plausible IVs that could be measured (Grootendorst, 2007). 
7.9 Conclusion 
This thesis aimed to address the relative lack of methodological guidance on statistical 
methods for CEA that use patient-level observational data. The critical appraisal of 
applied CEA highlighted that studies using observational data did not appropriately 
assess the underlying assumptions their statistical methods make. The conceptual 
review drew on insights from the causal inference literature, and identified promising 
further methods for CEA.  
This thesis found that methods that can avoid assuming that the endpoint regression and 
the PS are correctly specified, can give less biased and more precise estimates of cost-
effectiveness than methods previously recommended for CEA. In particular, combining 
matching methods with regression is a robust, appropriate and accessible method that 
should be adopted in future studies. This thesis presents methods that can improve the 
quality of CEA that use patient-level observational data, to help future studies provide a 
sounder basis for policy making.  
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